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Drug resistance is a wide-spread phenomenon and affects medical fields from infection 
biology to oncology. In the protozoan parasite Trypanosoma brucei, the causative agent of 
sleeping sickness, a number of resistance mechanisms have been described so far, most of 
them affecting drug uptake. In the presented PhD study I have investigated resistance of 
trypanosomes against the drug suramin. Suramin is a very old drug but its mode of action in 
trypanosomes is not well understood. By investigation of suramin-resistant parasites on 
their genomic and transcriptomic level I aimed to gain new insights into the pathway by 
which trypanosomes take up suramin and the mode of action of suramin.  
I analyzed the transcriptome of a T. brucei rhodesiense line with a very quickly emerging in 
vitro suramin resistance. By combination of a mapping-based approach with a de novo 
transcriptome assembly, a new variant surface glycoprotein, VSGSur, was identified. 
Subsequent experiments showed that the expression of VSGSur is enough to cause ~100-fold 
suramin resistance in T. brucei. The phenotypic changes in these parasites were not limited 
to drug resistance; the uptake of a number of different substrates and nutrients was highly 
reduced. This suggests on the one hand that the VSGSur-mediated resistance phenotype is 
caused by lower levels of intracellular suramin due to a reduced suramin uptake, linked to a 
decreased uptake of transferrin and low density lipoprotein. On the other hand, these results 
demonstrate that VSGs have an impact on the cell biology of trypanosomes that is broader 
than previously believed and reaching beyond immune evasion. 
I further selected these trypanosomes for even higher levels of suramin resistance. Analysis 
of sequence variations revealed a non-synonymous mutation in the RuvB-like helicase. This 
mutation was absent in the sensitive parent clone, heterozygous after suramin selection for 
three months, and turned homozygous during the course of further selection. Even though 
this finding needs further experimental validation, we have strong indications that RuvB-
like helicase is a suramin target in trypanosomes, since (i) an unrelated suramin-resistant T. 
evansi isolate bears a mutation of the same residue, and (ii) suramin was shown to inhibit 
helicases in viruses. 
Taken together, the transcriptome analysis of suramin-resistant trypanosomes led to the 
identification of two new resistance mechanisms: A VSGSur-mediated resistance that causes 
a reduced suramin uptake; and a mutation in the RuvB-like helicase that might protect this 
potential drug target from suramin action. 
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1.1. The phenomenon of drug resistance 
Drug resistance is a widespread problem in many fields of modern medicine. It hampers the 
combat of all infectious diseases in the field: viral [1], bacterial [2], fungal [3] and parasitic 
[4] pathogens are all able to develop resistance against the respective drugs and to impede 
successful treatment. But drug resistance is not restricted to infection biology. In the field of 
oncology, it poses a major problem as cancer cells very often become resistant against 
cytostatic drugs during the course of treatment [5], which is the reason for the poor 
prognosis of many late-stage neoplastic diseases. Even healthy human cells can develop 
resistance or tolerance to certain drugs: neurons, for instance, can become tolerant to 
opioids during analgesic treatments of acute and chronic pain conditions [6,7]. Under the 
flagship “antibiotics crisis”, the topic of drug resistance has gained a lot of attention in the 
last two decades as antibiotic resistance has reached the levels of an epidemic [2]. This is 
reflected in the number of publications about the topic: both, the absolute and the relative 
(compared to the whole biomedical scientific literature) numbers of publications on drug 
resistance constantly rose since the '60s with a jump at the turn of the millennium (Fig 1). 




Figure 1: Number of publications about drug resistance on PubMed.  
The black line with the grey filling corresponds to the per-mil publications containing the string 
‘drug resistance’of all publications on PubMed. The coloured lines show the absolute numbers of 
publications per year using the search strings ‘drug resistance’ (blue); ‘"bacterial drug resistance" 
OR "antibiotic resistance" OR "antimicrobial drug resistance"’ (yellow); ‘"parasitic drug 
resistance" OR "parasite drug resistance"’ (orange); and ‘"drug resistance" AND (trypanosoma 
OR trypanosomes OR "sleeping sickness" OR trypanosomiasis)’ (red).  
Amongst different types of drug resistance, the mechanisms of antibiotic resistance have 
been studied most extensively and many different bacterial resistance mechanisms have 
been described on the cellular and biochemical levels. They can be divided into five main 
categories: decrease of drug uptake, increase of drug efflux, inactivation of the drug, lack of 
drug activation and alterations of the drug target (Fig 2). A decreased drug uptake can be 
caused by a reduced expression and/or modifications of drug transporters [8]. 
Complementary to a decreased drug uptake, an increased drug efflux can be conferred 
through overexpression of efflux pumps or modifications of the pumps that change their 
substrate specificity [9]. Notably, efflux pumps often confer resistance not only to one drug 
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but act on various drugs [10]. Once the drug has entered the cell, additional mechanisms can 
confer resistance. Drug-inactivating or drug-degrading enzymes can be overexpressed [11] 
or more active forms can evolve through modifications of less active enzymes [12]. In case 
the drug enters the cell as a pre-drug that needs to be activated enzymatically, these 
enzymes can be mutated [13] or downregulated [14] leading to a lack of activation. Finally, 
the resistance mechanism can act on the drug target itself. The target can be modified in a 
way that decreases drug binding affinity while maintaining the function of the protein [9]. 
Proteins that bind to and protect the target [15] or target protein homologues that are less 
sensitive to the drug [9] can be upregulated. Finally, overexpression of the target protein 
itself can confer resistance [16]. 
 
Figure 2: Mechanisms of drug resistance.  
On the left hand side, the action of the drug in drug sensitive cells is shown: The pro-drug is taken 
up through its transporter, activated and binds to and inactivates its target. On the right hand side, 
different resistance mechanisms are shown. 
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In comparison to antibiotic resistance, parasitic drug resistance seems to be a rather small 
field of research. Nevertheless, the very first observations and investigations of drug 
resistance were carried out in protozoan parasites, predominantly in trypanosomes, the 
causing agents of Human African Trypanosomiasis (HAT). Even before the first drugs 
against HAT were introduced in the field, Ehrlich described at the beginning of the 19th 
century, that trypanosomes can become resistant against different drugs such as against 
arsenic compounds, azo-dyes (trypan red and trypan blue) and basic triphenylmethane dyes 
(e.g. fuchsin) if infected mice were repeatedly treated with these compounds [17,18]. He 
observed that resistant parasites were cross-resistant to other compounds of the same class 
of molecules and suspected changes in the affinity of chemo-receptors on the surface of the 
parasites and consequently a reduced drug uptake to be responsible for the resistance [18]. 
In the following years this theory was heavily disputed [19], but was later-on solidified by 
Yorke, who observed in first in vitro tests that drug sensitive trypanosomes accumulated the 
arsenic tryparsamide intracellularly, whereas resistant parasites did not [20]. Even though, 
retrospectively this observation could have also been attributed to an increased drug efflux, 
a decreased drug uptake is still the predominant resistance mechanism in trypanosomes 
known nowadays. In the following, the most important resistance mechanisms against the 
drugs used for the treatment of HAT will be described starting with a brief overview about 
the disease and the drugs currently used in the field. 
1.1.1. Human African Trypanosomiasis and the drugs used for the treatment  
Human African trypanaosomiasis, also called sleeping sickness, is transmitted by the bite of 
the tsetse fly (genus Glossina) and therefore its occurrence depends on the geographic 
distribution of the fly. The disease is caused by two subspecies of the kinetoplastid 
Trypanosoma brucei: The East African T. b. rhodesiense causes an acute, and the Central 
and West African T. b. gambiense causes a chronic form of the disease. In both cases, the 
parasites first multiply in the blood and lymph system and cause the first stage of the 
disease, also called the haemolymphatic stage. After weeks to years they invade the central 
nervous system and lead to the second or neurological stage of the disease. The choice of 
the drug used for HAT treatment depends on the causal trypanosome species and the staging 
of the disease. The first stage of rhodesiense HAT is treated with suramin, the oldest drug 
currently used, introduced 100 years ago [21]. The first stage of gambiense HAT is treated 
with pentamidine, which was introduced in the forties of the 20th century [22]. The 
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treatment of second stage HAT relies on drugs that are able to cross the blood-brain barrier. 
This is not the case for suramin and pentamidine, therefore, highly toxic arsenic compounds 
were the only option to treat second stage HAT for a very long time. In the forties the 
arsenic melarsoprol was introduced [23], replacing its arsenic precursors [24]. Melarsoprol 
is still used to treat the second stage of rhodesiense HAT, even though it is less toxic than 
its precursors, its toxicity is still unacceptable and causes an encephalopathic syndrome in 
up to 10% of treated patients with case fatality rates of up to 50% [25]. In the '80s, a second 
drug that is able to cross the blood-brain barrier was introduced: eflornithine [26]. 
Eflornithine is much less toxic than melarsoprol but it is not active against the rhodesiense 
subspecies and therefore only used for the treatment of second stage gambiense HAT [27]. 
Since the turn of the century it is used in combination with nifurtimox [28].  
What all these drugs have in common is their parenteral administration requiring 
hospitalization, which complicates the treatment in the remote areas where HAT is 
prevalent. Even though African trypanosomes have been intensively used to study basic cell 
biology in the last few decades, the development of new drugs against HAT was neglected 
for long periods over the last century. Only in the last decades, fexinidazole [29,30], the 
first oral drug for the treatment of both stages of gambiense HAT, has been developed and 
tested in clinical trials. It recently received a positive opinion from the European Medicines 
Agency and will hopefully facilitate future treatment of the disease [31]. 
1.1.2. Melarsoprol and Pentamidine 
The mode of action of melarsoprol and pentamidine has been studied but is not completely 
understood. The highly trypanocidal action of melarsoprol is probably carried out through 
the formation of stable adducts with the kinetoplastid specific antioxidans trypanothione 
[32]. The diamidine pentamidine interacts electrostatically with polyanions such as the 
circular mitochondrial (kinetoplast) DNA. It leads to a loss of kinetoplast DNA and of the 
mitochondrial membrane potential [33,34].  
It had already been observed in the fifties that trypanosomes resistant to melarsen, a 
precursor of melarsoprol, are cross-resistant to pentamidine [35]. This melarsoprol-
pentamidine cross-resistance (MPXR) later-on became the first resistance mechanism 
extensively studied in trypanosomes. The reason for MPXR was found in a decreased drug 
uptake [36] and was attributed to a defective adenosine transporter P2 [37,38]. The gene 
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encoding P2 was identified as adenosine transporter 1 (TbAT1) by expression of a 
T. b. brucei cDNA library in yeast with deficient purine biosynthesis [39]. Mutations in 
TbAT1 were found in in vitro selected T. b. brucei with a MPXR phenotype [39] and in 
resistant T. b. rhodesiense and gambiense patient isolates [40]. Homozygous disruption of 
TbAT1 resulted in ~2-fold resistance to melarsoprol and pentamidine, even though 
resistance was much stronger to other diamidines [41]. A second gene involved in MPXR 
was identified by reverse genetics. In a genome-wide RNAi-library screen, knock-down of 
aquaglyceroporin 2 (TbAQP2) and aquaglyceroporin 3 (TbAQP3) expression caused 
MPXR [42]. Subsequent genetic knock-out of both genes increased the IC50 by two-fold 
for melarsoprol and 15-fold for pentamidine [42]. Subsequent experiments with inducible 
expression of TbAQP2 and TbAQP3 in a TbAQP2/3 knockout, showed that loss of the gene 
TbAQP2 was responsible for the resistance phenotype. In addition, mRNA and whole-
genome sequencing of two in vitro selected T. b. rhodesiense lines with a pronounced 
MPXR phenotype, revealed a deletion of TbAQP2 in addition to mutations and loss of 
TbAT1 [43]. It was furthermore shown, that mutations in TbAQP2 were also present in 
resistant field isolates and thus most probably confer drug resistance in the field [44]. It was 
somewhat surprising to find a channel that physiologically transports small, uncharged 
molecules to be involved in transport of positively charged molecules like pentamidine. 
Indeed, expression of a TbAQP2/3 chimera with the TbAQP2 selectivity filter sensitized the 
TbAQP2/3 null cells to melarsoprol but not to pentamidine [45]. Song et al. further showed 
that pentamidine binds to and inhibits TbAQP2 but does not permeate the channel, thus they 
hypothesized that AQP2 is a pentamidine receptor, and that the uptake is subsequently 
carried out through endocytosis [46]. The aforementioned in vitro selected T. b. rhodesiense 
lines [43] additionally had both acquired heterozygous mutations in the TbUBP1 gene 
encoding for an RNA-binding protein. However, follow-up experiments were not fully 
conclusive and did not support a role of UBP1 in MPXR (Appendix 2). 
1.1.3. Eflornithine and Nifurtimox 
Eflornithine is the only drug against HAT whose mode of action is well understood: It 
inhibits polyamine synthesis or more specifically the decarboxylation of ornithine to 
putrescine by the enzyme ornithine decarboxylase [47]. In a forward genetics approach, a T. 
b. brucei line was selected in vitro and developed resistance within only two months [48]. 
Eflornithine is an amino acid analogue and since the resistant cells showed a decreased drug 
Chapter 1: Trypanosomes, drugs and drug resistance 
9 
 
accumulation, the amino acid transporters were screened for mutations. Indeed the amino 
acid transporter 6 gene (TbAAT6) was found to be heterozygously deleted [48]. Subsequent 
reverse genetic experiments confirmed the involvement of TbAAT6 in drug resistance and 
thus its key role in elfornithine uptake [48–50]. Treatment failures of eflornithine 
monotherapy were reported from the field, but these were not further investigated, therefore 
it is unknown whether drug resistance was involved and whether TbAAT6 mutations play a 
role in the field [51]. The easy and fast selection for eflornithine resistance in vitro is 
alarming, but development of resistance in the field might be hindered through the 
combination of eflornithine with nifurtimox as used nowadays. In contrast to 
T. b. gambiense, the T. b. rhodesiense subspecies is innately less susceptible to eflornithine, 
which has been attributed to a faster turnover of ornithine decarboxylase in T. b. 
rhodesiense [52]. 
The nitroheterocyclic pro-drug nifurtimox probably enters T. brucei by passive diffusion 
through the plasma membrane as shown for the South American Trypanosoma cruzi [53]. 
Intracellularly, nifurtimox has to be activated in order to become cytotoxic. Cytotoxicity is 
probably mediated by free radicals and oxidative stress [54,55]. Studies on in vitro selected 
nifurtimox resistant T. cruzi showed a decrease of nifurtimox reducing activity and an 
abnormal karyotype with loss of a chromosome that contains a putative type I 
nitroreductase (NTR) [56]. Subsequent heterozygous and homozygous NTR deletion in T. 
cruzi and T. brucei [56] as well as RNAi library screens [49] confirmed the involvement of 
NTR in nifurtimox resistance. This is the only known resistance mechanism in 
trypanosomes that is conferred by a lack of intracellular drug activation.  
1.1.4. Suramin and suramin resistance 
Suramin is a highly anionic polysulphonated naphthylurea that inhibits different 
intracellular targets in trypanosomes [57] and whose mode of action is not well understood 
(Chapter 2). Given the large size of the molecule (compared to other drugs) and its 6-fold 
negative charge, suramin is likely taken up through receptor-mediated endocytosis [58,59]. 
The presence of different plasma proteins has a major impact on suramin uptake by 
trypanosomes as suramin shows very high levels of plasma-protein binding [59]. Suramin 
resistant trypanosomes have not been described in human patients, but suramin resistance is 
widely spread in animal pathogenic trypanosomes [60,61]. In a genome-wide RNAi screen, 
knock-down of the invariant surface glycoprotein 75 (TbISG75) and of a number of 
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lysosomal and endosomal genes was found to confer suramin resistance, substantiating the 
proposed uptake route through endocytosis [42]. Knock-down of TbISG75 further led to a 
decreased suramin binding, therefore TbISG75 was proposed to act as the suramin receptor 
in T. brucei [42]. 
1.1.5. Resistance mechanisms in T. brucei - a matter of drug uptake? 
It is striking that most identified drug resistance mechanisms in T. brucei affect drug uptake 
(Fig 3). In case of melarsoprol and eflornithine, the genes involved in resistance encode 
transporters that directly carry out drug uptake (TbAAT6, TbAT1 and TbAQP2). For 
pentamidine, the role of TbAQP2 is not completely understood and it was proposed to be a 
receptor rather than a channel, while the uptake might be mediated through endocytosis 
[46]. However, it is somewhat surprising that genome-wide RNAi screens for pentamidine 
resistance did not identify genes encoding for endosomal proteins as observed for suramin 
[42]. Suramin first binds to its receptor and is subsequently taken up through endocytosis, 
whereby it passes through the endosomal system until it reaches the lysosome. Thus, a large 
number of different proteins are involved in uptake and intracellular drug transport, which is 
reflected in the high number of hits detected in the genome-wide RNAi-library screen [42]. 
Nifurtimox is the only drug for which a resistance mechanism distinct from drug uptake has 
been identified. Do these results reflect a biological feature of T. brucei? Do trypanosomes 
acquire resistance mainly through reduction of drug uptake or are these findings one-sided 
due to the applied methodologies? 
We cannot answer these questions at the moment. But the applied methodologies are indeed 
predisposed to identify resistance mechanisms involving drug uptake. The older studies on 
drug resistance were usually carried out by selective investigation of candidate genes in 
drug selected resistant parasites. As the mode of action of most of the trypanocidal drugs are 
not well understood, the investigators have focused on transporter genes. The more recent 
studies usually used RNAi knock-down to generate resistance. As shown in Figure 2, 
downregulation of genes, and thus loss-of-function, predominantely leads to resistance if 
the protein encoded by the downregulated gene is involved in drug uptake or drug 
activation. For genes that encode proteins involved in drug efflux, drug inactivation, or the 
drug target itself, downregulation will usually not lead to resistance but instead sensitize the 
parasites. These genes could be identified through overexpression libraries or by whole 
genome or mRNA sequencing of resistant parasites rather than with RNAi. Furthermore, 
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one should keep in mind that not only the genes encoding proteins directly in contact with 
the drug can be modified, but their whole regulatory network can cause resistance. Loss or 
downregulation of certain repressors of drug target synthesis could for example lead to 
higher expression of the drug target and hence drug resistance. These regulators could very 
well be identified also by RNAi, and indeed such a mechanism wa s already described for 
suramin: Knock-down of de-ubiquitinating enzymes led to suramin resistance through a 
decrease of ISG75 abundance; thus suramin resistance was a secondary effect of the altered 
turnover of ISG75 [42,62]. In Figure 3 the described resistance mechanisms of T. brucei are 
summarized graphically. 
  





Figure 3: Mechanisms of drug resistance in T. brucei.  
T. brucei can become resistant to melarsoprol, pentamidine, suramin or eflornithine through 
alterations of the uptake systems, notably through reduced expression, gene loss or mutations of the 
involved receptors and transporters. Nifurtimox resistance in T. brucei is acquired through loss or 
knock-down of the drug-activator nitroreductase. The other resistance mechanisms known from 
bacteria and other organisms, such as an increased drug efflux, enzymatic drug inactivation or 
alterations of the drug targets, have not been identified in T. brucei. The finding that drug resistance 
in T. brucei is predominantly caused by loss-of-function is all the more suprising since the 
trypanosomes, in contrast to bacteria or malaria parasites, are diploid. 
 
  




The presented PhD thesis investigated drug resistance with a focus on suramin, aiming to 
better understand this elusive molecule, its uptake and mode of action in T. brucei.  
The work begins with a literature review about suramin, its broad clinical assessment for 
different diseases, and its potential biochemical targets (Chapter 2).  
The thesis continues with the experimental investigation of suramin resistance in T. brucei. 
Starting with forward genetics of resistant parasites (Chapter 3), the results obtained by 
bioinformatics and molecular biology were corroborated by reverse genetic experiments, 
establishing a new link between suramin resistance and antigenic variation (Chapter 3 
and 4).  
Further, cell biological consequences of suramin resistance were examined with a special 
focus on ISG75 and receptor-mediated endocytosis, opening up new questions about the 
basic cell biology of trypanosomes (Chapter 4).  
In the last chapter, high-level suramin-resistant parasites were generated and characterized 
by mRNA sequencing with the goal to find additional resistance mechanisms. This finally 
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Suramin is a hundred years old and still being used to treat the first stage of acute human 
sleeping sickness, caused by Trypanosoma brucei rhodesiense. Suramin is a multifunctional 
molecule with a wide array of potential applications, from parasitic and viral diseases to 
cancer, snakebite and autism. Suramin is also an enigmatic molecule: What are its targets? 
And how does it get into cells in the first place? Here we provide an overview on the many 
different candidate targets of suramin, discuss modes of action, and routes of cellular 
uptake. We reason that once the polypharmacology of suramin is understood at the 
molecular level, new, more specific, and less toxic molecules can be identified for the 
numerous potential applications of suramin. 
  




2.2 A versatile molecule 
2.2.1. Suramin, the fruit of the first medicinal chemistry program 
When suramin was introduced for the treatment of African sleeping sickness in 1922, it was 
one of the first anti-infective agents that had been developed in a medicinal chemistry 
program. Starting from the antitrypanosomal activity of the dye trypan blue, synthesized in 
1904 by Paul Ehrlich, Bayer made a series of colorless and more potent derivatives. 
Molecule 205 was suramin (Figure 1), synthesized by Oskar Dressel, Richard Kothe and 
Bernhard Heymann in 1916. Sleeping sickness (also known as human African 
trypanosomiasis, HAT) was at the forefront of research at that time, not a neglected disease 
as it is today, and the development of suramin was a breakthrough for the emerging field of 
chemotherapy. While the history of suramin has been reviewed elsewhere [21], we focus 




Figure 1. Suramin structure and medicinal chemistry parameters.  
Except for its good solubility in water, suramin lacks lead-like properties as defined/stipulated by 
Lipinsky's rule of 5. 




2.2.2. Suramin as an antiparasitic drug 
Suramin is still being used for the treatment of Trypanosoma brucei rhodesiense infections 
[63]. However, it does not cross the blood-brain barrier and therefore is administered only 
for the first, hemolymphatic stage of sleeping sickness, when the trypanosomes have not yet 
invaded the patient's CNS. The standard treatment regimen for suramin is an initial test dose 
of 4-5 mg/kg followed by five weekly doses of 20 mg/kg (but not more than 1 g) injected 
i.v. [64]. Suramin is also used for Surra (mal de caderas), caused by T. evansi, in particular 
for the treatment of camels [65]. The treatment regimen is a single injection i.v. of 10 mg/kg 
suramin, i.e. about 6-10 g [65]. In vitro, suramin also has some activity against T. cruzi [66]. 
However, it is not used for Chagas' disease, and studies in mice even suggested that suramin 
would exacerbate the disease [67]. In vitro activity of suramin against Leishmania major 
and L. donovani has recently been described [68]. Furthermore, suramin blocks host cell 
invasion by the malaria parasite Plasmodium falciparum. This was observed for both the 
invasion of erythrocytes by P. falciparum merozoites [69] and the invasion of HepG2 
hepatoma cells by P. falciparum sporozoites [70]. 
 Suramin had been in use for river blindness, caused by the filarial parasite 
Onchocerca volvulus [71]. It acts on both microfilariae and, to a larger extent, on adult 
worms [72,73]. However, suramin was subsequently replaced by the less toxic, and orally 
bioavailable, ivermectin [74,75]. The adverse effects of suramin are indeed manifold, 
including nephrotoxicity, hypersensitivity reactions, dermatitis, anemia, peripheral 
neuropathy and bone marrow toxicity [64,76]. But despite its potential toxicity, the lack of 
bioavailability, and absence of lead-like properties (Figure 1), suramin has found a 
surprising variety of repurposing applications. Table 1 provides an overview on the 
biological activities of suramin and Table 2 lists clinical trials performed with suramin. 
2.2.3. Suramin as an antiviral agent 
The antiviral and antibacteriophage activities of suramin are known since the mid-20th 
century [77,78]. Soon after the discovery of retroviruses, suramin was found to inhibit 
retroviral reverse transcriptase [79], which served as a rationale to test suramin against 
human immunodeficiency virus (HIV). Suramin protected T-cells from HIV infection in 
vitro [80], and in AIDS patients it reduced the viral burden in some of the study subjects; 
however, no improvement of the immunological features and clinical symptoms was 
achieved [81–83]. Later-on suramin was found to inhibit host cell attachment through 




binding to the HIV-1 envelope glycoprotein gp120, indicating that the in vitro protection 
against HIV infection is mediated through inhibition of viral entry [84]. 
 Suramin also inhibits the binding of Dengue virus to host cells through a direct 
effect on the viral envelope protein [85]. Inhibition of host cell attachment was also found 
for Herpes simplex [86] and Hepatitis C viruses [87], which explained the previously 
reported protective effects of suramin against in vitro herpes simplex infections [88] and in 
vivo infections of ducks with Duck Hepatitis B Virus [89]. Similar to the experience with 
HIV, suramin had initially been tested against Hepatitis viruses due to its inhibitory effect 
on the viral DNA polymerase [90,91]. But in a small clinical trial suramin was found to be 
ineffective and toxic in chronic active Hepatitis B patients [92]. Suramin neutralized 
enterovirus 71 (EV71) in cell culture and in a mouse model by binding to capsid proteins 
[93–95]. 
 Suramin also bears potential against emerging viruses. It was shown to inhibit both 
RNA synthesis and replication in Chikungunya virus [96]. In vitro suramin conferred 
protection if present at the time of infection, and this was attributed to a reduction of viral 
host cell binding and uptake [97]. In the murine model suramin led to a reduction of 
pathognomonic lesions if injected prior to Chikungunya infection [98]. Suramin also 
inhibited host cell invasion by Ebola virus [99] and Zika virus, even when added after viral 
exposure of the cell cultures [100]. 
2.2.4. Suramin against cancer 
The first studies on the effects of suramin on neoplasms in animals were carried out in the 
1940's; mice engrafted with lymphosarcoma developed significantly smaller tumors when 
simultaneously treated with suramin [101]. In the 1970's it was shown that suramin can 
enhance the action of cyclophosphamide and adriamycin in mice engrafted with Ehrlich 
carcinoma [102]. A first clinical trial with suramin was carried out in the 1980's in 
advanced-stage adrenal and renal cancer patients [103]. Around half of the patients showed 
either partial or minimal responses, none showed complete remission. Nevertheless, a 
number of subsequent clinical trials with suramin were carried out (Table 2). In particular, 
suramin was tested against prostate cancer [104–112], non-small cell lung cancer [113], 
breast cancer [113], bladder cancer [114,115] and brain tumors [116,117]. Most of these 
studies were based on the potential of suramin to act as an antagonist of growth factors 




[118–120], which are often overexpressed by tumors. In addition, suramin directly exhibits 
cytostatic activity on cultured tumor cells [121–123]. However, the initial clinical tests did 
not warrant the further development of suramin as an anticancer monotherapy. 
 Subsequent tests focused on suramin as a chemosensitizer, based on the findings that 
at sub-cytotoxic levels (<50 µM), it enhanced the efficacy of anticancer drugs such as 
mitomycin C, taxol or doxorubicin in ex vivo cultures and in animal models [124–126]. 
Suramin combined with taxol inhibited invasiveness and prevented metastasis in a 
xenograft mouse model [127]. Different explanations are conceivable for the 
chemosensitizing effects of suramin on tumor cells, including inhibition of telomerase [128] 
or inhibition of fibroblast growth factors and angiogenesis [129]. A phase II clinical study 
was performed in patients with advanced, drug-resistant, non-small cell lung cancer treated 
with taxol or carboplatin; supplementation with nontoxic doses of suramin did not 
overcome drug resistance [130]. Randomized controlled studies to validate the use of 
suramin as a chemosensitizer in chemotherapy-naive lung cancer patients remain to be 
performed. A combination of estramustine, docetaxel and suramin gave promising results in 
hormone-refractory prostate cancer patients [112]. 
2.2.5. Suramin as an antidote 
Three of the many biological activities of suramin support a potential use as a protective 
agent: the inhibition of thrombin, the inhibition of phospholipase A2, and the inhibition of 
purinergic signaling. Several vipers possess toxins that mimic thrombin [131], perfidiously 
triggering the coagulation cascade in the mammalian blood. Suramin not only inhibits 
thrombin itself [132] but also the thrombin-like proteases of snake venom [133], and was 
therefore proposed as an antidote for snakebite. Other common constituents of metazoan 
venoms are phospholipases A2 that convert phospholipids into lysophospholipids. Again, 
suramin inhibits mammalian phospholipase A2 [134] as well as the orthologs from snake 
venom [135–137] and bee venom [138], suggesting that it can act as an antidote. A certain 
degree of protection from venoms by suramin was confirmed in mouse models [138–140]. 
The potential use of suramin as an antidote is attractive given the high global burden of 
snakebites [141] and the current shortage of antivenom [142]. 
 Suramin's ability to block P2 purinergic, G protein-coupled receptors [143] may 
counteract the action of neurotoxins that trigger arachidonic acid signaling, e.g. via 




phospholipase A2 activity [144]. A possible explanation is that suramin prevents the 
activation of ATP receptors at the motor nerve ending, which otherwise would depress Ca2+ 
currents and reduce acetylcholine release at the presynaptic membrane [145]. Suramin was 
also proposed to serve as a neuroprotective agent [146,147], as an antidote for kidney 
toxicity during cancer chemotherapy [148] and, based on its antiapoptotic effect, to protect 
from liver failure [149]. Suramin also inhibits connexin channels of the tight junction, 
thereby suppressing ATP release and protecting cells from pore-forming bacterial toxins 
such as hemolysin [150]. The suramin analogs NF340 and NF546 were cardioprotective in a 
mouse model for heart graft rejection, presumably via inhibition of the purinergic G protein-
coupled receptor P2Y11 [151]. 
2.2.6. Further potential uses of suramin 
Suramin was found to have beneficial effects in a rat arthritis model [152] and to suppress 
fear responses in the rat [153]. It also promoted the expansion of T cells during 
immunization of mice and was therefore considered as a small molecule adjuvant for 
vaccination [154]. Based on the cell danger hypothesis, suramin has recently been tested for 
the treatment of autism spectrum disorders (ASD). The cell danger hypothesis suggests that 
a systemic stress response, which involves mitochondria and purinergic signaling, 
contributes to the development of psychopathologies like autism. Suramin had been shown 
to act as an inhibitor of purinergic signaling [155] and mitochondrial function [156], and was 
therefore proposed as a potential therapy for ASD [157]. First tests in mouse models showed 
correction of symptoms in juveniles [157] as well as in adults [158]. A first small human 


















Parasitic infections    
     T. b. rhodesiense HAT x x x 
     T. b. gambiense HAT x x x 
     Surra, T. evansi x x n.a. 
     River blindness, O. volvulus x x x 
     Trypanosoma cruzi x   
     Leishmania spp. x   
     Plasmodium falciparum x   
Viral infections    
     Hepatitis  x x x 
     AIDS, HIV x  x 
     Herpes simplex x x  
     Chikungunya x x  
     Enterovirus 71 x x  
     Dengue x   
     Zika x   
     Ebola x   
Neoplastic diseases    
     Non-small cell lung cancer x x  
     Breast cancer x x  
     Bladder cancer x x  
     Brain tumors x x  
     Prostate cancer x x x 
Other uses    
     Snake bite x x  
     Arthritis x x  
     Autism n.a. x x 
 




Table 2. Clinical trials with suramin. Trials with a registered NCT number are from 
ClinicalTrials.gov; others are from the literature. 
Registry ID Disease Phase Year 
NCT02508259 Autism spectrum disorders I, II 2015 
NCT01671332 Non-small cell lung cancer II 2012 
NCT01038752 Non-small cell lung cancer II 2010 
NCT00083109 Recurrent renal cell carcinoma I, II 2004 
NCT00066768 Recurrent non-small cell lung cancer I 2003 
NCT00054028 Recurrent breast cancer I, II 2002 
NCT00006929 Recurrent non-small cell lung cancer II 2000 
NCT00006476 Bladder cancer I 2000 
NCT00004073 Brain and central nervous system tumors II 1999 
NCT00002921 Adrenocortical carcinoma II 1997 
NCT00003038 Advanced solid tumors I 1997 
NCT00002723 Prostate cancer III 1996 
NCT00002881 Prostate cancer III 1996 
NCT00002652 Multiple myeloma and plasma cell neoplasm II 1995 
NCT00002639 Brain and central nervous system tumors II 1995 
NCT00001381 Bladder neoplasms, transitional cell carcinoma I 1994 
NCT00001266 Prostatic neoplasm II 1990 
NCT00001230 Filariasis observ. 1988 
[103] Solid tumors observ. 1987 
[82] AIDS observ. 1987 
[92] Hepatitis B observ. 1987 
 
2.2.7. (Too) many targets 
Suramin is a large molecule that carries six negative charges at physiological pH (Figure 1). 
It is likely to bind to, and thereby inhibit, various proteins [160]. Thus the many and diverse 
potential applications of suramin reflect the polypharmacology of suramin. Indeed, a large 
number of enzymes have been shown to be inhibited by suramin (Table 3). Suramin inhibits 
many glycolytic enzymes [161,162], enzymes involved in galactose catabolism (PubChem 




BioAssay: 493189) and enzymes of the Krebs cycle [163]. Suramin further decreases the 
activity of a large number of enzymes involved in DNA and RNA synthesis and 
modification: DNA polymerases [164,165], RNA polymerases [164,166,167], reverse 
transcriptase [79,164], telomerase [128], and enzymes involved in winding/unwinding of 
DNA [168,169] are inhibited by suramin, as well as histone- and chromatin modifying 
enzymes like chromobox proteins [170], methyltransferases [171] and sirtuin histone 
deacetylases [172]. Suramin is also an inhibitor of other sirtuins [173] and protein kinases 
[174,175], glutaminase (PubChem BioAssay: 624170), phospholipase A2 [176,177], protein 
tyrosine phosphatases [178], lysozyme [179] and different serine- and cysteine-
proteases [180–182]. For caspases, cysteine proteases involved in apoptosis, suramin was 
described to act as either inhibitor or activator [183,184]. Suramin further inhibits the 
Na+,K+-ATPase and other ATPases [185–187], certain classes of GABA receptors [188,189], 
and several G protein-coupled receptors [190] including P2 purinoceptors and follicle-
stimulating hormone receptor [191,192]. Suramin also showed inhibitory effects against 
components of the coagulation cascade [132,193] and the complement system [194–196], and 
against deubiquitinating enzymes (PubChem BioAssay: 504865; 463106). It also interacts 
with prion protein, inhibiting the conversion into the pathogenic form PrPSc [197]. Beside the 
many inhibitory activities, suramin also activates certain nuclear receptors that act as 












Table 3. Putative target proteins of suramin, biological processes and mechanisms. Suramin acts as 
an inhibitor or antagonist in all cases except for the pregnane X receptor and the ryanodine receptor. 
The mode of action against caspase is controversial. 
Putative target Reference 
Metabolism  
6-Phosphofructokinase [161] 
Fructose-l,6-bisphosphate aldolase [161] 
Glucose-6-phosphate isomerase [161] 
Glyceraldehyde-3-phosphate dehydrogenase [161] 
Glycerol-3-phosphate dehydrogenase [161,200] 
Glycerol kinase  [161] 
Hexokinase [161] 
Phosphoglycerate kinase [161] 
Pyruvate kinase [162] 
Triose-phosphate isomerase [161] 
Succinic dehydrogenase [163] 
Galactokinase 493189* 
Glutaminase 624170* 
Glycerophosphate oxidase [200] 
Nucleoside triphosphate diphosphohydrolase 1 & 2 [186,187,201–204] 
Nucleotide pyrophosphatase/phosphodiesterase 1 & 3 [205] 
Nucleic acids  
DNA polymerase alpha [164,165] 
DNA polymerase beta [164,165] 
DNA polymerase gamma [164] 
DNA polymerase delta [165] 
DNA polymerase I [164,165] 
Terminal deoxynucleotidyltransferase [164] 
DNA primase [164] 
DNA dependent RNA polymerase [164,167] 
RNA dependent RNA polymerase [166] 
Reverse transcriptase [79,164] 
Telomerase [128] 
RNAse H [206] 
Flavivirus RNA helicase [100,168,207] 
DNA Topoisomerase II [169] 
Tyrosyl-DNA phosphodiesterase 1 [208] 
Human antigen R [209] 
DNA-binding protein MCM10 [210] 
Epigenetics  
Chromobox protein homologue 1 beta 488953* 
Chromobox protein homologue 7 [170] 
Histone methyltransferases [171,211] 
Precorrin-4 C(11)-methyltransferase [212] 




Sirtuin 1, 2, 5 [172,173,213]  
Protease  
Kallikrein [182] 
Alpha Thrombin [132] 
Human neutrohphil cathepsing G [181] 
Human neutrophil elastase  [181] 
Human neutrophil proteinase 3 [181] 
Rhodesain [180] 
Caspases 1, 2, 8, 9, 10 [183,184,214,215] 
Falcipain-2 [216] 
Extracellular matrix  
Hyaluronidase [217,218] 
Iduronate sulfatase [218] 
-glucuronidase [218] 
Membrane channels and signaling  
Non-junctional connexin 43 hemichannels [150] 
Na+,K+-ATPase [185] 
Cystic fibrosis transmembrane regulator [219] 
Ryanodine receptor 1 [199] 
GABAA receptors [188,189] 
P2X Purinergic receptors [155] 
P2Y Purinergic receptors [155] 
N-methyl-D-aspartate receptor [220] 
DNA-dependent protein kinase [174] 
Protein kinase C [175] 
Protein tyrosine phosphatases [178] 
VIP receptor [190] 
Follicle-stimulating hormone receptor [192] 
Pregnane X receptor [198] 
Diadenosine tetraphosphate hydrolase [221] 
Other  
Prion (PrpC) [197] 
Complement factors [182,194–196] 
Phospholipase A2 [177,222] 
Lysozyme [179] 
Antimicrobial Peptide CM15 [223] 
Ubiquitin carboxyl-terminal hydrolases 1 & 2 504865; 463106* 
HSP 60 chaperonin system [224,225] 
GroEL chaperonin system [224,225] 
*PubChem BioAssay, last retrieved 29.04.2019 
  




2.2.8. Enigmatic mechanisms of action against African trypanosomes  
Somewhat ironically, much less appears to be known about the targets of suramin in 
African trypanosomes, where it has been in use for a century, than in tumor cells or viruses. 
Suramin was shown to inhibit glycolytic enzymes of T. brucei with selectivity over their 
mammalian orthologues, in particular hexokinase, aldolase, phosphoglycerate kinase and 
glycerol-3-phosphate dehydrogenase [161]. Intriguingly, the trypanosomal enzymes have 
higher isoelectric points (>9), which is due to extra arginines and lysines that are absent in 
the mammalian orthologues [226]. These residues form positively charged, surface exposed 
'hot spots' that were proposed to be bound by the negatively charged suramin [161]. 
Inhibition of trypanosomal glycolysis by suramin is in agreement with the dose-dependent 
inhibition of oxygen consumption and ATP production observed in trypanosomes isolated 
from suramin-treated rats [58]. However, the glycolytic enzymes of T. brucei are localized 
inside glycosomes [227], and it is unclear how suramin could penetrate the glycosomal 
membrane, or if suramin could bind to glycolytic enzymes in the cytosol, before they are 
imported into the glycosomes [57]. Alternative targets proposed for the trypanocidal effect 
of suramin are glycerophosphate oxidase [200,228], a serine oligopeptidase termed OP-Tb 
[229], and REL1 [230], the RNA-editing ligase of the trypanosome's kinetoplast. It is 
unclear how suramin would pass the inner mitochondrial membrane, but suramin inhibited 
oxidative phosphorylation in mitochondrial preparations of the trypanosomatid Crithidia 
fasciculate [231]. Suramin also appeared to inhibit cytokinesis in T. brucei, as indicated by 
the finding that suramin treatment resulted in an increased number of trypanosomes with 
two nuclei [232].  
2.2.9. Uptake routes of suramin into cells 
The negative charges of suramin (Figure 1) not only promote binding to various proteins, 
they also prevent diffusion across biological membranes. However, the majority of targets 
(Table 3) are intracellular, and radiolabeled suramin was shown to be taken up by human 
endothelial and carcinoma cells [233,234] and by T. brucei bloodstream forms [58,59]. 
Suramin is not a of P-glycoprotein substrate [235], nor of any other known transporter. 
Thus suramin must be imported by endocytosis. Mammalian cells can take up suramin in 
complex with serum albumin by receptor-mediated endocytosis [236]. This had originally 
also been thought to happen in T. brucei [58]. However, the trypanosomes do not take up 
albumin by receptor-mediated endocytosis [237], and LDL (low density lipoprotein) was 




proposed to act as the vehicle instead [59]. Suramin bound to LDL and inhibited the binding 
and uptake of LDL, while LDL enhanced the uptake of suramin in bloodstream-form T. 
brucei [59]. In contrast, overexpression in procyclic T. b. brucei of Rab4, a small GTPase 
involved in the recycling of endosomes, decreased suramin binding and uptake without 
affecting LDL binding or uptake [238]. In the same study, overexpression of a mutant Rab5, 
which was locked in the active, GTP-bound form, increased LDL uptake without affecting 
suramin uptake [238]. These findings indicated that, at least in the procyclic trypanosomes 
of the tsetse fly midgut, LDL and suramin are imported independently of each other. 
 The development of genome-wide RNAi screens in bloodstream-form T. brucei 
combined with next-generation sequencing offered new opportunities to address the 
genetics of drug resistance. This approach identified genes, silencing of which reduced the 
sensitivity to suramin [42]. These included a number of genes encoding for endosomal and 
lysosomal proteins, in agreement with uptake of suramin through endocytosis. The invariant 
surface glycoprotein ISG75 was identified as a likely receptor of suramin since knock-down 
of ISG75 in bloodstream-form T. brucei decreased suramin binding and suramin 
susceptibility [42]. ISG75 is a surface protein of unknown function whose abundance is 
controlled by ubiquitination [62]. Thus, there appear to be (at least) two pathways for 
receptor-mediated endocytosis of suramin in T. brucei bloodstream forms: either directly 








Table 4. Solved structures of suramin complexed to target proteins. 
PDB id Protein Reference 
6CE2 Myotoxin I from Bothrops moojeni [136] 
4YV5 Myotoxin II from Bothrops moojeni [135] 
1Y4L Myotoxin II from Bothrops asper [177] 
3BJW Ecarpholin S from Echis carinatus [137] 
1RML Acid fibroblast growth factor [239] 
n.a. Human epidermal growth factor (hEGF) [240] 
4X3U CBX7 chromodomain [170] 
3BF6, 2H9T Human thrombin [241] 
2NYR Human sirtuin homolog 5 [173] 
3PP7 Leishmania mexicana pyruvate kinase [162] 
3GAN Arabidopsis thaliana At3g22680 n.a. 
3UR0 Murine norovirus RNA-dependent RNA polymerase [166] 
4J4V Pentameric bunyavirus nucleocapsid protein [242] 
4J4R Hexameric bunyavirus nucleocapsid protein [242] 
  





Suramin remains controversial. Is its polypharmacology a liability or an asset? Is it toxic or 
protective? Dated or timeless? Whatever the verdict on suramin, there is hardly a molecule 
with as many biological activities. The list of potential targets is indeed impressive, and the 
publication stream on suramin is not stagnating. The large majority of papers is not about 
trypanosomes or trypanosomiasis (Figure 2). The list of potential targets has to be taken 
with a grain of salt, though, since the negative charges of suramin, and its promiscuity in 
protein binding, can cause all kinds of artefacts. Suramin can dissolve matrigel [243], 
resulting in a false positive signal in cell-based screening campaigns that use matrigel for 
support, e.g. for inhibitors of angiogenesis [243]. On the other hand, suramin's high affinity 
to albumin [244] may give false negative results in cell-based tests that contain mammalian 
serum. But in spite of the various confounders, a number of different drug-target 
interactions for suramin have been experimentally validated, and are directly supported by 
crystal structures (Table 4). 
 
Figure 2. Publications on suramin in PubMed. Cumulative numbers are shown for papers 
on suramin and trypanosomes or trypanosomiasis (black, search term "trypanosom*"), 
cancer (red, "cancer OR tumor"), viruses (yellow, "virus OR viral OR hiv OR aids"), and 
toxins (green, "toxin OR venom"). Other papers on suramin are shown in beige. There is 
no saturation yet. And it is surprising that only a minority of the publications on suramin 
actually deal with trypanosomes. 
 




 Several routes of investigation on the bioactivities of suramin have culminated in 
clinical trials with healthy volunteers (i.e. phase I) or patients (i.e. phases II and III; Table 
2). Yet, to our knowledge, none of these trials was a striking success, and it is unclear 
whether suramin will ever find medical applications outside the field of parasitology. 
However, molecules that act in a similar way than suramin may be identified via target-
based screening once the mode of action is understood – new molecules that are more 
specific, less toxic, and possess better pharmacological properties than suramin. Thus it will 
be important to dissect the polypharmacology of suramin at the molecular level. We hope 
that the compiled list of targets (Table 3) will serve this purpose. 
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Suramin is one of the first drugs developed in a medicinal chemistry program (Bayer, 
1916), and it is still the treatment of choice for the hemolymphatic stage of African sleeping 
sickness caused by Trypanosoma brucei rhodesiense. Cellular uptake of suramin occurs by 
endocytosis, and reverse genetic studies with T. b. brucei have linked downregulation of the 
endocytic pathway to suramin resistance. Here we show that forward selection for suramin 
resistance in T. brucei spp. cultures is fast, highly reproducible, and linked to antigenic 
variation. Bloodstream-form trypanosomes are covered by a dense coat of variant surface 
glycoprotein (VSG), which protects them from their mammalian hosts' immune defenses. 
Each T. brucei genome contains over 2000 different VSG genes, but only one is expressed 
at a time. An expression switch to one particular VSG, termed VSGSur, correlated with 
suramin resistance. Reintroduction of the originally expressed VSG gene in resistant T. 
brucei restored suramin susceptibility. This is the first report of a link between antigenic 
variation and drug resistance in African trypanosomes. 
3.1.1. Abbreviated summary 
Suramin is still in use to treat sleeping sickness caused by Trypanosoma brucei rhodesiense. 
Here we show that in culture, trypanosomes can quickly become suramin-resistant by 
expressing one particular variant surface glycoprotein (VSG) gene, and they revert to 
sensitive upon replacement of that VSG gene with the originally expressed VSG gene. This 
is the first reported link between antigenic variation and drug resistance in African 
trypanosomes. 




Sleeping sickness, also called human African trypanosomiasis (HAT), is still a prevalent 
disease in sub-saharan Africa. It is transmitted by the blood-feeding tsetse flies and caused 
by two subspecies of Trypanosoma brucei: T. b. gambiense causes the chronic form, T. b. 
rhodesiense the acute form of HAT. Untreated, both typically end with coma and death. 
Among the four currently available drug therapies, suramin is the oldest one and is used for 
the treatment of the first, hemolymphatic stage of T. b. rhodesiense HAT. Suramin is a big 
and highly charged molecule (Fig. S1) and therefore not able to passively diffuse through 
biological membranes. It is supposedly taken up by receptor-mediated endocytosis [58] with 
an involvement of low-densitiy lipoprotein [59]. More recent high-throughput RNAi-
screens [42] have shown a variety of endosomal and lysosomal genes to render 
trypanosomes less susceptible to suramin when knocked-down, which is in agreement with 
an uptake via endocytosis. Furthermore, knock-down of the invariant surface glycoprotein 
ISG75 led to a 50% reduction of suramin susceptibility. ISG75 was therefore proposed to be 
the binding partner of suramin on the cell surface [42,245]. The mode of action of suramin 
has been elusive since it was shown to have diverse intracellular targets [57]. 
Despite its use for about a hundred years now, there have been no reports of suramin 
resistance in human pathogenic trypanosomes. The cure-rates of first stage T. b. rhodesiense 
HAT are typically high. Suramin treatment failures were mainly observed in context of a 
miss-staging of the disease [246], since suramin has a low brain permeability and is 
ineffective once the trypanosomes have crossed the blood-brain barrier. However, suramin 
resistance is prevalent among animal pathogenic trypanosomes, for example in T. evansi 
isolates from Sudanese camels [60] and Chinese buffaloes and mules [61]. Selection for 
suramin resistance is feasible under laboratory conditions. After 550 days of in vitro 
selection T. evansi were 1800-fold less susceptible to suramin [247], and T. brucei showed a 
resistance factor of 20-140 after in vivo selection with subcurative doses [248]. The suramin 
resistance phenotype was lost after transformation of the trypanosomes to insect-stage, 
procyclic forms. 
 We have observed the appearance of strong drug resistance in T. brucei bloodstream 
forms after exposure to high suramin concentrations for only a few days. Here we use 
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transcriptomics and reverse genetics to elucidate the genetic mechanism behind this 
phenomenon. 
3.3. Results 
3.3.1. In vitro selection for suramin resistance monitored in real-time 
Isothermal microcalorimetry allows to monitor the growth of axenic T. brucei cultures in 
real-time based on the heat emitted by the cells' metabolism [249]. Here we use the 
technology to track the emergence of drug resistance. Incubated at presumably lethal 
concentrations of suramin, i.e. the 5-fold and 25-fold of the IC50, T. b. rhodesiense 
bloodstream-form cultures appeared to be dead after two days, started to regrow after three, 
and had fully recovered by day five (Fig. 1). This phenomenon was consistently observed: 
we have performed the same experiment with T. b. brucei, which also recovered from 
suramin pressure within one week. In all cases, the recovered trypanosomes were suramin-
resistant by factors between 30 and 100 as compared to the starting population. No such 
phenomenon was observed with other drugs: melarsoprol or pentamidine completely killed 
the T. brucei cultures at concentrations of 5- and 25-fold their IC50 [249] (Fig. 1).  
 
Figure 1. Bloodstream-form T. brucei incubated with presumably lethal concentrations of suramin 
rapidly became resistant and regrew. No such phenomenon was observed with the drugs melarsoprol 
or pentamidine. 
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3.3.2. Rapid emergence of resistance also in clonal populations 
The microcalorimetric experiment was performed with an inoculum of 105 cells. To rule out 
that a subpopulation of suramin-resistant trypanosomes had been present all along and was 
simply selected for under drug pressure, we repeated the experiment with fresh T. b. 
rhodesiense STIB900 clones. Incubated at concentrations between 500 and 1700 nM 
suramin (i.e. 5-80 fold their respective IC50), drug-resistant progeny was again obtained 
within one week for all tested clones [n=11]. Table 1 summarizes the results for one clone 
(named T. b. rhodesiense STIB900_c1) and four independent suramin-resistant derivatives 
thereof (named T. b. rhodesiense STIB900_c1_sur1 to _sur4), selected at 1050 nM suramin 
(80-fold the IC50). All four derivatives were at least 90-fold resistant to suramin as 
compared to the parent clone STIB900_c1 (p < 0.0001 by One Way Anova with Tukey's 
multiple comparisons test). While their sensitivity to melarsoprol and pentamidine was 
unchanged (Table 1), the suramin-resistant lines were cross-resistant to the structurally 
related trypanocidal dye trypan blue (p<0.001, Ehrlich, 1904; Fig. S1). 
Table 1. Drug sensitivities of the parental clone T. b. rhodesiense STIB900_c1 and four 
independently selected derivatives (sur1-4). Values are 50% inhibitory concentrations in nM ± 
standard deviation (n≥5). 
 Suramin Trypan Blue Melarsoprol Pentamidine 
STIB900_c1 13  ±4 2,700 ±900 22 ±1.2 1.1  ±0.4 
STIB900_c1_sur1 1,250 ±40 16,200 ±5,600 23 ±2.3 1.0 ±0.3 
STIB900_c1_sur2 1,240 ±10 16,300 ±5,300 24 ±1.9 1.5 ±1.1 
STIB900_c1_sur3 1,240 ±90 16,300 ±5,200 24 ±2.2 1.2 ±0.5 
STIB900_c1_sur4 1,270 ±100 16,600 ±5,700 26 ±3.3 1.5 ±1.2 
 




Figure S1. Suramin (Bayer & Co, 1916) is a colorless derivative of the azo-dye trypan blue 
(Ehrlich, 1904). 
The cross-resistance phenotype was stable in the absence of drug pressure for several 
weeks. After 80 days of cultivation, however, the resistance factor had decreased to 10- to 
50-fold in the four lines (Fig. 2). Cumulative growth curves (Fig. S2) demonstrate slightly 
longer population doubling times of the resistant derivatives (8.2 h for STIB900_c1_sur1 
and 8.3 h for STIB900_c1_sur4) as compared to the suramin sensitive parent clone (7.7 h). 
 
Figure 2. Stability of 
suramin resistance in the 
absence of selection.  
The resistance factor was 
defined as the IC50 of the 
derivatives of T. b. 
rhodesiense STIB900_c1 
divided by the IC50 of T. b. 
rhodesiense STIB900_c1 
itself, grown in parallel. 




Figure S2. Cumulative growth curves of suramin sensitive and resistant parasites.  
Growth rates are displayed as cumulative cell number of STIB900_c1 (red), STIB900_c1_sur1 
(green) and STIB900_c1_sur4 (blue), error bars represent the standard deviation. Cumulative 
cell counts were significantly different between resistant and sensitive parasites after four days 
(p-value = 0.00042 for STIB900_c1 versus STIB900_c1_sur1 and p-value = 0.00042 for 
STIB900_c1 versus STIB900_c1_sur4, n=6). 
3.3.3. VSGs are differentially expressed in resistant and sensitive parasites 
The finding that suramin resistance reproducibly developed even in cultures from freshly 
cloned trypanosomes, indicated that the underlying mutation – whatever its nature – had 
occurred during the selection period. However, the reproducible acquisition of a particular 
point mutation is unlikely to happen within days. We therefore reckoned the mechanism of 
suramin resistance more likely to be reflected at the level of gene expression than gene 
sequence. Total RNA from T. b. rhodesiense STIB900_c1 and the four selected lines, 
grown in the absence of suramin, was subjected to quantitative transcriptomics by mRNA-
Seq. Over 50 million high-quality reads were obtained for each line (European Nucleotide 
Archive accession PRJEB20650). As expected given the short interval between suramin-
sensitive parent and suramin-resistant derivatives, there were hardly any differences in 
transcript abundance (Fig. S3). Genes encoding proteins that had been shown to be involved 
in suramin resistance in T. brucei [42], i.e. the invariant surface glycoprotein ISG75, the 
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putative major facilitator superfamily transporter MFST or the lysosomal proteins CatL, 
CBP1 and GLP-1, were not differentially expressed in the suramin-resistant lines. The only 
hits that were differentially expressed mapped to VSG genes (Fig. S3). Thus all four 
selected lines had undergone an expression switch to a new VSG.  
 
Figure S3. Transcriptomics of suramin sensitive and resistant T. brucei.  
Analysis as described in figure legend 3, the data shows the original mapping to the TREU927 
reference genome complemented with the Lister 427 bloodstream expression sites prior to the 
identification of VSGSur and VSG900. A number of genes seem to be over- (red) or under-
expressed (blue); all of the significant hits are VSG genes. 
3.3.4. The suramin-resistant lines have all switched to the same VSG 
The sequence of this newly expressed VSG was reconstructed by de novo assembly from the 
Illumina reads. The reconstructed sequence was verified by reverse transcriptase PCR 
followed by direct sequencing, making use of the fact that all T. brucei mRNAs possess the 
same spliced leader sequence at the 5' end [250]. Three of the four resistant lines had 
switched to the identical VSG gene, which was termed VSGSur (GenBank accession 
MF093647). T. b. rhodesiense STIB900_c1_Sur2 expressed a gene that was almost 
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identical to VSGSur (GenBank accession MF093648), differing only in four SNPs (two of 
which were non-synonymous); and a different 3' UTR. The sequence of the VSG expressed 
in the parental clone STIB900_c1 was reconstructed in the same way and termed VSG900 
(GenBank accession MF093646). Re-mapping of the Illumina reads upon inclusion of these 
two VSG sequences resulted in more than 10% of reads mapping to VSG900 in the sensitive 
parent clone, and more than 10% of reads mapping to VSGSur in all the resistant derivatives 
(Fig. 3).  
 
 
Figure 3. Differential gene expression of resistant derivatives vs. suramin-sensitive parental 
T. b. rhodesiense STIB900 clone as analyzed with DESeq2. Illumina reads were mapped to the 
TREU927 reference genome supplemented with Lister 427 bloodstream expression sites and with 
the sequences of VSGSur and VSG900. The x-axis displays transcript abundance (mean read count over 
all samples normalized for library size) and the y-axis displays the logarithmic fold-change of 
transcript abundance (all four resistant derivatives vs. the sensitive parent clone). Genes with a 
significant (p<0.01) fold-change are colored in red if overexpressed, and in blue if underexpressed 
in the resistant derivatives. 
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Reverse-transcriptase qPCR confirmed the switch from VSG900 to VSGSur in the resistant 
lines as they all showed a more than 10,000-fold upregulation of VSGSur (Fig. 4). We also 
analyzed the suramin-selected derivatives of another clone of T. b. rhodesiense STIB900 
(STIB900_c2), and they had switched to VSGSur as well (Fig. 4). Moreover, the suramin-
resistant population derived from T. b. brucei strain BS221 had undergone a switch to a 
VSG with 97% nucleotide sequence identity (Needleman-Wunsch global alignment) to 
VSGSur (Fig. 4; GenBank accession MF093649).  
 
Figure 4. Expression of 
VSGSur and VSG900 as 
determined by qRT-
PCR in resistant T. b. 
rhodesiense and T. b. 
brucei, normalized to 
telomerase reverse 
transcriptase (TERT). 
3.3.5. Suramin resistance correlates with expression of VSGSur but not ESAG7 
VSGSur encodes a bona fide variant surface glycoprotein of 491 amino acids with an N-
terminal export signal and a C-terminal GPI-anchoring signal as predicted by SignalP [251] 
and GPI-SOM [252], respectively. Profile scans against the Procite and Pfam databases of 
sequence motifs did not return significant hits beside the entry for the T. brucei VSG 
conserved C-terminal domain (PF10659; E-value of 0.0002). A Blastp search with VSGSur 
as the query against the non-redundant protein sequence database at NCBI returned 
significant hits on variant surface glycoproteins, the best one on VSG 522 (GenBank: 
AGH61081.1) with a sequence identity of 72%. The same search against all organisms 
other than Trypanosoma spp. did not return a single hit. In the absence of any particular 
feature that would distinguish it from other VSGs, we initially presumed that it is not 
VSGSur itself that caused drug resistance but one of the expression site associated genes 
(ESAGs), which are polycistronically co-transcribed with each VSG and which could have 
Chapter 3: A variant surface glycoprotein causes suramin resistance in T. brucei 
45 
 
failed to correctly map due to sequence divergence between STIB900 and the reference 
sequence used. If an antigenic switch results from activation of a new VSG expression site, 
new alleles of ESAGs will be expressed as well. If the switch is due to replacement of the 
active VSG by gene conversion, the expressed ESAGs will remain the same. 
 ESAG7 encodes the non-anchored part of the heterodimeric transferrin receptor and 
differs in sequence among the T. brucei VSG expression sites [253,254]. For each of the 
five sequenced T. b. rhodesiense lines, the whole transcriptome was assembled de novo 
from the Illumina reads and the expressed ESAG7 was extracted using a blast search 
(Tb927.7.3260, 2175 nt). Three of the suramin-resistant lines expressed exactly the same 
ESAG7 gene as the parental T. b. rhodesiense STIB900_c1 (GenBank accession 
MF093650); the fourth expressed an ESAG7 that differed in five nucleotides, two of which 
were non-synonymous (GenBank accession MF093651). Thus in one of the suramin-
selected lines, the switch to VSGSur appears to have occurred by activation of a new 
expression site, while in the remaining three it happened by gene conversion, replacing the 
originally expressed VSG900 gene while maintaining the ESAGs. This strongly suggests that 
it is the expression of VSGSur itself, and not of the ESAGs, that causes suramin resistance. 
This hypothesis was corroborated by reverse genetic manipulation of VSG expression. 
3.3.6. Reversal of the VSG900-VSGSur switch restores suramin sensitivity  
We made a genetic construct (Fig. 5A) to target the active VSG expression site of the 
suramin-resistant T. b. rhodesiense STIB900_c1_sur1. In order to exchange the expressed 
VSGSur with VSG900, the construct was framed with the 5’ and 3’ UTR of VSGSur and 
contained the coding sequence of VSG900 together with a blasticidin resistance gene. 
Positive transfectants were selected with blasticidin and cloned by limiting dilution. The 
construct had integrated in the genomes of all the analyzed clones [n=6] as determined by 
PCR using primers binding to the 5’ and 3’ UTR of VSGSur as the adjacent genomic context 
was unknown. Reverse-transcriptase qPCR confirmed a high expression of the re-
introduced VSG900 (Fig. 5B). Subsequent drug sensitivity assays with three of the 
transfectants showed a complete loss of resistance in all of them, with IC50 values between 
10 and 12 nM (Fig. 5c).  
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Figure 5. Reverse genetic re-introduction of VSG900. A) Schematic illustration of VSGSur 
(top) and the construct (bottom) used for re-introduction of VSG900 into the active 
bloodstream expression site of the resistant derivative STIB900_c1_sur1. The construct is 
framed with the 5’ and 3’ untranslated region (UTR) of VSGSur, it contains a blasticidin 
resistance gene (BSD), an αβ tubulin splice site (αβ tub) and the coding sequence (cds) of 
VSG900. Binding sites of primers used for the verification of the genomic integration of the 
construct are indicated with black arrows. B) qRT-PCR, normalized with TERT. Expression 
of VSGSur (red) and VSG900 (blue) are shown for STIB900_c1_sur1 and six transfected clones 
thereof, with VSG900 introduced into the active bloodstream expression site. C) Suramin dose-
response curves for STIB900_c1_sur1 and three transfected clones expressing VSG900. 
 
One of the transfectants was once more subjected to suramin pressure. It quickly 
reestablished suramin resistance with a resistance level similar to STIB900_c1_sur1 (Fig 6). 
Since these re-selected parasites could have undergone either expression site switch or gene 
conversion in order to re-express VSGSur, we investigated three lines selected from one 
transfectant by PCR using primers binding to the 5’ and 3’ UTR of VSGSur. Two of them 
(c1_sur1_900a_sur1 and c1_sur1_900a_sur2) had lost the construct, thus had undergone a 
gene conversion in order to switch back to VSGSur. In the third line (c1_sur1_900a_sur3) the 
construct was still present, therefore it had undergone an expression site switch in order to 
express VSGSur. We subsequently exposed the three lines to blasticidin; as expected the two 
lines that had undergone gene conversion were killed. The line that had undergone an 
expression site switch recovered under blasticidine pressure and the obtained parasites 
(c1_sur1_900a_sur3_bl1, _bl2 and _bl3) had completely lost the suramin resistance (Fig 6). 




Figure 6. Ups and downs of suramin sensitivity in the course of the experiment. IC50 values are 
shown for the sensitive parent clone c1 before selection (dark blue), one of the resistant derivatives 
after suramin selection (dark red), a transfected clone thereof with VSG900 re-introduced into the 
active bloodstream expression site (blue), one suramin selected derivative of that clone (light red), 
and three blasticidine selected lines thereof (light blue). 
3.3.7. Binding and uptake of trypan blue 
We exploited the facts that the suramin-selected lines were cross-resistant to trypan blue, 
and that trypan blue becomes fluorescent when bound to protein [255], to further examine 
the observed phenomenon of drug resistance. The fluorescence of trypanosomes was 
quantified by flow cytometry after incubation for two hours with different concentrations of 
trypan blue (Fig 7). Since dead cells are strongly perfused by trypan blue, we first compared 
dead and living cells. The dead cells showed a much higher fluorescence and could be 
clearly separated from the living cells by setting the gate accordingly in a cell-size versus 
fluorescence plot (Fig. S4). Fluorescence of living cells incubated at physiological 
temperature is derived from both, surface bound and endocytosed trypan blue. At 37°C the 
two tested resistant derivatives (STIB900_c1_sur1 and STIB900_c1_sur4) showed 
significantly lower fluorescence levels when compared to the sensitive parent clone 
(STIB900_c1) over all concentrations (Fig. 7A). As endocytosis in trypanosomes is 
inactivated at low temperatures [256], we performed the same experiment at 4°C to quantify 
the fluorescence of surface-bound trypan blue (Fig 7B). The resistant parasites showed 
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similar levels of fluorescence as the sensitive clone at concentrations of 5 to 200 µg ml-1 but 
significantly differed at 390 µg ml-1, where the sensitive clone showed a strong increase in 
fluorescence. If the fluorescence at 37°C represents binding plus uptake, and the 
fluorescence at 4°C represents binding, then the curve obtained by subtraction (Fig. 7C) 
represents the trypan blue which had been endocytosed during the two hours of incubation. 
These values were lower for the resistant parasites than for the sensitive clone at 
concentrations up to 200 µg ml-1. There was no difference at 390 µg ml-1 trypan blue, 




Figure S4. Size (forward scatter, x-axis) versus fluorescence intensity (y-axis) of dead (left) and 
alive (right) cells after incubation with 5 µg ml-1 trypan blue for two hours. The dead cells had 
been incubated for 5 min at 56 °C beforehand. Cells in the gate defined for the living cells are 
labeled in red 
 
 




Figure 7. Fluorescence of suramin sensitive and resistant cells incubated at different concentrations 
of trypan blue for two hours. Significantly different fluorescence levels between the sensitive and 
the resistant lines are indicated (*, p<0.05; **, p<0.01; **, p<0.001; n≥5, pairwise t-test); there were 
no significant differences between the two resistant lines. (A) Cells incubated at 37°C: the 
fluorescence levels represent surface bound plus endocytosed trypan blue. (B) Cells incubated at 
4°C: the fluorescence levels represent surface-bound trypan blue. (C) The difference between the 
fluorescence at 37°C and 4°C therefore represents an estimate of the endocytosed trypan blue. 
  




The famous parasitologist Frank Hawking (father of the even more famous physicist 
Stephen Hawking) stated that "Strains of trypanosomes may be made suramin-resistant in 
the laboratory, but this resistance takes much longer to develop than with arsenicals" [257]. 
Here we show that >90-fold suramin resistance emerges in T. brucei spp. bloodstream 
forms after only few days of in vitro selection at high drug pressure. In contrast, it had taken 
us almost two years to select for melarsoprol-resistant derivatives of T. b. rhodesiense 
STIB900 with resistance factors of the same magnitude [258]. Comparative analysis of gene 
expression showed an association of a particular VSG with suramin resistance. Our first 
suspicion, that VSGSur was only a marker and the actual cause of resistance was one of the 
ESAGs, was rebuted by the finding that three of the four resistant lines had switched their 
VSG gene while maintaining the VSG expression site, as indicated by perfect conservation 
of expressed ESAG7. The finding that one of the resistant lines expressed a slightly different 
ESAG7 indicated that VSGSur in parental T. b. rhodesiense STIB900 localized to a (silent) 
telomeric VSG expression site rather than to the chromosome-internal or minichromosomal 
VSG repository [259]. The suramin resistance phenotype was slowly reversible over time, 
which might be explained by the slightly longer population doubling times of the resistant 
derivatives. 
 The causality between VSGSur expression and suramin resistance was confirmed by 
reverse genetic re-introduction of the originally expressed VSG into the resistant parasites, 
which completely restored susceptibility. The finding that the expression of VSGSur causes 
suramin resistance, explains the fast emergence of the resistance and the high 
reproducibility of the in vitro selection. It also explains the discrepancy with Hawking's 
observation cited above, because he was using subcurative treatment of infected mice to 
select for resistance (in vitro cultivation of T. brucei was not possible at the time).  
 In vivo, parasites that are bound to express a particular VSG under suramin pressure 
will be eliminated by host antibodies. This might be the reason why suramin, after one 
century of use, is still effective in the treatment of early-stage east-African sleeping 
sickness. The commonly used regimen is five injections of 20 mg/kg, leading to suramin 
plasma levels over 100 µg ml-1 for several weeks [25], which is clearly above the in vitro 
IC50 of trypanosomes expressing VSG
Sur. The situation would be different if lower doses of 
suramin were administered. One could speculate that such a mechanism could have 
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facilitated the emergence of suramin resistance in animal-pathogenic trypanosomes, as the 
usual treatment regimen in horses and camels is a single dose of 10 mg/kg suramin, and the 
disease typically leads to immunosuppression [65]. Thus if the trypanosomes escaped the 
effects of suramin in the short term by switching to a certain VSG, this would give them 
more time to develop other resistance mechanisms. It has been reported that a functional 
immune system is important for effective suramin treatment of animal 
trypanosomiasis [260]. 
 VSGs could be either directly or indirectly involved in binding and uptake of 
suramin, and VSGSur might be non-functional in this respect. Previous studies which 
proposed an uptake of suramin via endocytosis [58,59] are in accordance with this, as VSG 
in T. brucei bloodstream forms is endocytosed at a very high rate [261]. An involvement of 
VSG in suramin binding or uptake could also explain the insensitivity of procyclic 
trypanosomes to suramin [248] as they don’t express VSG genes. 
 Binding of trypan blue at 4°C to suramin-sensitive trypanosomes suggests a 
saturable high-affinity component plus a low affinity component that becomes apparent at 
390 µg ml-1 trypan blue (testing of higher concentrations was not possible because of 
toxicity and solubility problems). This implies the presence of more than one binding 
partner on the cell surface of the sensitive clone. The low affinity component appeared to be 
missing in the suramin-resistant clones (Fig. 7B). However, the uptake of trypan blue at 
37°C by the suramin-resistant lines was impaired at concentrations between 5 and 200 µg 
ml-1 (Fig. 7C), indicating that the low-affinity binding component may not be responsible 
for drug resistance. Thus while the genetic basis for fast suramin resistance in T. brucei is 
an expression switch to VSGSur, the biochemical basis remains to be elucidated.  
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3.5. Experimental Procedures 
T. brucei isolates and cultivation 
The T. b. rhodesiense strain STIB900 is a derivative of STIB704, which was originally 
isolated from a male patient at St. Francis Hospital in Ifakara, Tanzania in 1982. It was 
passaged several times in rodents and once in a tsetse fly (Glossina morsitans morsitans) 
before a cloned population was adapted to axenic in vitro culture. The T. b. brucei strain 
BS221 is a derivative of 427 (not to be confounded with Lister427), which was originally 
isolated in Uganda in 1960. Parasites were cultivated in Iscove’s Modified Dulbecco’s 
Medium supplemented according to Hirumi [262] with 15% of heat-inactivated horse-
serum. The parasites were grown at 37°C, 5% CO2 and diluted three times a week. 
Microcalorimetry with T. b. rhodesiense 
T. b. rhodesiense strain STIB900 were cultivated in Minimum Essential Medium with 
Earle's salts, supplemented according to Baltz et al. [263] with minor modifications: 0.2 
mM 2-mercaptoethanol, 1 mM sodium pyruvate, 0.5 mM hypoxanthine and 15% heat-
inactivated horse serum. Trypanosome cultures in the late exponential growth phase were 
diluted with fresh culture medium to a density of 105 cells ml-1. Ampoules were filled, in 
triplicate, with 3 ml cell suspension and supplemented with suramin, pentamidine or 
melarsoprol at concentrations corresponding to 5×IC50 or 25×IC50 in the identical 
medium [249]. Culture medium without trypanosomes served as baseline control. The heat 
flow was measured continuously over a period of 8 days at 37 °C in a TAM III isothermal 
microcalorimeter (thermal activity monitor, model 249; TA instruments, New Castle DE, 
USA). 
Cloning of T. b. rhodesiense 
A microdrop of a suspension with 104 cells ml-1 was made using a gilded paperclip and 
inspected by two persons under an inverted microscope. After confirmation of the presence 
of a single cell, the microdrop was supplemented with 50 µl of cloning medium. This 
consisted of 59% Iscove’s modified Dulbecco’s Medium, which had been supplemented 
according to Hirumi [262] for a total volume of 100%, 1% Mäser-mix [264], 20% 
inactivated horse-serum and 20% of pre-conditioned medium. The pre-conditioned medium 
was prepared by centrifugation of a dense trypanosome culture (10 min at 1840 g) and 
subsequent sterile filtering of the supernatant. After four days of incubation at 37°C, 5% 
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CO2, the plate was inspected under an inverted microscope and 50 µl of cloning medium 
was added to the wells with a growing clonal colony. After another 3 days the clones were 
passaged to new plates and cultivated as described above. 
In vitro selection for drug resistance and determination of growth rates 
A fresh clone of T. b. rhodesiense STIB900 in the exponential growth phase was selected 
with 1050 nM suramin in four wells each containing 1 ml medium with 5×104 cells. After 6 
days the parasites were removed from drug pressure by washing three times with fresh 
culture medium and cultured in drug-free medium as described above. For the BS221 strain 
105 cells were selected with 1070 nM (BS221_sur1) and 4270 nM (BS221_sur2) suramin 
and removed from drug pressure after 5 days. Cell growth was measured between day 15 
and day 26 after selection. Cumulative growth curves were determined by dilution of the 
cells to 105 ml-1, incubation for 24 h, and measurement of cell density with a CASY Cell 
Counter (OMNI Life Science, Bremen). This procedure was repeated for four days. 
Cumulative cell numbers and the population doubling times were calculated and statistically 
evaluated with t-tests applying Benjamini-Hochberg correction using R Studio (R version 
3.3.3). 
Alamar blue assay 
Suramin sodium salt and pentamidine isethionate were obtained from Sigma (S2671 and 
P0547 respectively), Trypan Blue from Fluka (93590) and melarsoprol from Sanofi-
Aventis/WHO. Alamar blue assays [265] for determination of in vitro drug sensitivities 
were carried out at least three times independently. Serial drug dilutions were prepared on a 
96 well plate in technical duplicates and cells were added to a concentration of 2×104. 
Parasite-free, drug-free wells were used for determination of background fluorescence. 
After an incubation time of 69 hours, plates were inspected microscopically and resazurin 
was added to a final concentration of 36 µM. Fluorescence intensity was measured after 3-4 
hours incubation using a SpectraMax (Molecular Devices) and SoftMax Pro 5.4.5 software. 
The 50% inhibitory concentrations (IC50) were calculated with GraphPad Prism 6.00 using a 
non-linear regression model to fit the dose-response curve (variable slope; four parameters, 
bottom value set to zero). Statistical analysis was performed with GraphPad Prism 6.00 
using an ordinary one-way Anova with Tukey's multiple comparisons test. 
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Extraction of RNA, mRNA-Seq and comparative transcriptomics 
Cultures in the exponential growth phase were centrifuged and washed once with PBS 
before total RNA was isolated using the RNeasy Mini Kit (Qiagen) including an on-column 
DNase treatment. RNA was shock-frozen in liquid nitrogen and stored at -80°C. Five 
microgram of RNA from two independent isolations were pooled for each sample. Library 
preparation and sequencing was performed at the Quantitative Genomics Facility (QGF) of 
the ETH Zurich in Basel. Sequencing libraries were prepared using the TruSeq Stranded 
mRNA Library preparation kit (Illumina). Single-end sequencing of 125 nucleotides was 
carried out on an illumina HiSeq 2500. The bioinformatic analysis was carried out on the 
sciCORE cluster of the University of Basel. Quality of the sequencing reads was controlled 
with fastqc software (Babraham Bioinformatics - FastQC A Quality Control tool for High 
Throughput Sequence Data. Available at: http://www.bioinformatics.babraham.ac.uk/ 
projects/fastqc/. Accessed: 6th April 2017). Illumina adaptors, low quality ends and reads 
with a length of fewer than 36 nucleotides were removed with trimmomatic [266]. 
Sequencing reads were mapped to the TREU927 reference genome (version TriTrypDB-28) 
complemented with bloodstream expression sites from Lister427 [254]. Mapping was 
performed with bwa [267] using the default parameters (seedlength of 19 nucleotides, 
matching score of 1, mismatch penalty of 4, gap open penalty of 6 and a gap extension 
penalty of 1). The alignment files in the SAM format were converted to binary files using 
samtools [268] and sorted and indexed using picard tools (Broad Institute. Available at: 
http://broadinstitute.github.io/picard/. Accessed: 6th April 2017). Read counts per transcript 
were determined with the Python package HTSeq [269] using a combined gff file from 
TREU927 (version TriTrypDB-28) and bloodstream expression sites from Lister427 [254], 
default parameters with a minimal mapping quality of 10 were used. Raw counts were 
analyzed with the R package DESeq2 [270] (version 1.14.1), independent filtering was 
disabled. 
 The de novo assembly of transcripts was carried out using trinity [271] with the 
default parameters. The de novo assembled transcripts were screened with blastn for 
ESAG7-like genes using the sequence of gene Tb927.7.3260 as query. 
Reverse transcription, PCR and quantitative PCR 
Complementary DNA (cDNA) was synthesized with SuperScript III Reverse Transcriptase 
(Invitrogen via Thermo Fisher Scientific, Waltham MA, USA) according to the 
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manufacturer’s protocol using oligo(dT) primer and 1-5 µg of total RNA. One microliter of 
the 1:100 diluted cDNA was used for PCR. Amplification of the VSGs was performed with 
one primer binding to the spliced leader sequence [250] at the 5’ UTR and the other primer 
binding to the 3’ end of the gene (Table S1). The sequences of the 3’ends were derived from 
the de novo assembly. For amplification of the VSG expressed in the BS221 strain, a primer 
binding unspecifically to the 3’ends of all VSGs [272] was used (Table S1). The PCR was 
carried out with Taq polymerase (Solis BioDyne, Estonia) or with KAPA HiFi HotStart 
DNA Polymerase (Kapa Biosystems, Cape Town, South Africa). PCR products were run on 
a 1% agarose gel, which was subsequently stained with GelRed Nucleic Acid Gel Stain 
(Biotium, Fremont CA, USA). The PCR products were purified with the Wizard® SV Gel 
and PCR Clean-Up System (Promega, Madison WI, USA) or the NucleoSpin® Gel and PCR 
Clean-up (Macherey-Nagel, Düren, Germany) and sent to Microsynth (Balgach, 
Switzerland) for sequencing. Primers for sequencing were the same as used for PCR, 
additional internal primers were designed for completion of the sequences. Quantitative 
PCR was carried out with Power SYBR® Green (Applied Biosystems via Thermo Fisher 
Scientific) on a StepOnePlus™ real-time PCR System (Applied Biosystems) in technical 
duplicates. StepOne Software v2.3 was used for analysis of the amplification plots and 
calculation of the CT values, which were normalized to the housekeeping gene telomerase 
reverse transcriptase [273] (TERT; ∆ CT). All primers (Table S1) were designed using the 
Primer3Plus software (Available at: http://primer3plus.com/cgi-bin/dev/primer3plus.cgi. 
Accessed: 6th April 2017) 
Table S1. Primers used for amplification of VSG and sequencing. 
Name Sequence Binding site Use 
SLT_F cgctattattagaacagtttctgtac 5’ UTR of all mRNA amplification of VSG 
vsg01 agcaaaagaggggcctttttaataa 3‘ end of VSGSur amplification of VSGSur 
vsg02 tcattcgtttggccatacgc internal VSGSur 
sequencing of VSGSur and qPCR of 
VSGSur 
vsg03 tctgggttcatatgcgctgc internal VSGSur sequencing of VSGSur 
vsg04 gcaagcaaaagaggagaagtt 3‘ end of VSG900 amplification of VSG900 
vsg05 caaggcaaaatccggctgtg internal VSG900 
sequencing of VSG900 and qPCR of 
VSG900 
vsg06 ttactgacagacgaaccggc internal VSGSur qPCR of VSGSur 
vsg07 gccgtagcagaatcagagct internal VSG900  qPCR of VSG900 
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vsg08 gtgttaaaatatatc 3' UTR of VSG (unspecific) Amplification of VSG in BS221 
vsg16 gaaccgaaaatagtcacgaaggc 5’ end of construct amplification of construct VSGSur to 
VSG900 for transfection vsg17 tttttcggtgaatttaaaggtgttaaa 3’ end of construct 
 
Reverse genetics with T. brucei rhodesiense 
For the gene exchange of VSGSur to VSG900 a construct was designed (Fig. 5A) containing 
the 3’ and 5’ UTRs of VSGSur, the coding sequence of VSG900, an αβ tubulin splice site and 
a blasticidin-resistance gene (BSD). The DNA was synthesized by GenScript (Piscataway 
Township NJ, USA) and integrated between the HindIII and the EcoRI-site of a pUC57 
vector. For amplification of the insert a PCR was performed using two flanking primers. 
Three µg of the purified PCR product were used for the transfection of 4×107 
STIB900_c1_sur1 cells in 100 µl Tb-BSF buffer [50] with an Amaxa Nucleofector using 
program Z-001. Positive transfected clones were obtained by limiting dilution in standard 
culture medium. After 24 hours of incubation, blasticidin was added to a total concentration 
of 5 µg ml-1. The construct integration was verified by PCR on genomic DNA: As the 
flanking genomic sequences upstream and downstream of VSGSur are unknown, primers 
binding to the 5’ and 3’ UTR of VSGSur were used for the PCR (Fig. 5), which resulted in a 
band of 1,624 nucleotides derived from the wildtype sequence of VSGSur and a second band 
of 2,356 nucleotides in the presence of the construct. Genomic DNA was isolated from 10 
ml dense culture in the following manner: The culture was centrifuged at 1800 g for 5 
minutes and washed with TE buffer (10 mM TrisHCl pH 8, 1 mM EDTA) once. Cells were 
eluted in 100 µl TE buffer and lysed by addition of 1 µl of 10% SDS and incubation for 10 
min at 55°C. Subsequently 30 µl of 5 M potassium acetate were added to the lysate and 
incubated on ice for 5 min to precipitate SDS and proteins. The lysate was spun down for 5 
min at full speed in a microcentrifuge and the supernatant transferred to a new tube. The 
DNA was precipitated with absolute ethanol, washed with 70% ethanol and eluted in 20 µl 
H2O. PCR was carried out as described above. The expression of VSG
Sur and VSG900 was 
measured by quantitative PCR as described above. 
Trypan blue binding and uptake  
A total of 2×105 parasites per sample was exposed to trypan blue (5, 20, 50, 200 or 390 µg 
ml-1) in 1 ml standard growth medium and incubated for two hours at 37°C or 4°C. After 
incubation, the parasites were centrifuged (5 min, 3000 g) and washed twice with 1 ml PBS 
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(Phosphate-buffered saline; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4) at room temperature or 4°C, respectively. The cells were resuspended in 
250 µl PBS followed by the addition of 250 µl 10% formalin for fixation. The fluorescence 
intensity of the fixed cells was measured with a BD FACSCaliburTM flow cytometer (BD 
Biosciences, San Jose, CA, USA) using the FL3 channel (670 nm long pass) upon 
excitation at 488 nm. Ten thousand events were acquired within the parasite gate based on 
size versus granularity (FSC x SSC). Dot plots and their fluorescence were evaluated in FL3 
histograms as trypan blue has its emission peak at 660 nm [255]. The measured 
fluorescence intensity was analyzed with Flowing Software (Version 2.5.1) by using a 
living parasite gate based on size versus fluorescence intensity (FSC x FL3) and statistically 
evaluated with R Studio, applying pairwise t-tests (Version 1.0.143, R version 3.3.3).  
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Suramin was introduced into the clinic a century ago and is still used to treat the first stage 
of acute human sleeping sickness. Due to its size and six-fold negative charge, uptake is 
mediated through endocytosis and the suramin receptor in trypanosomes is thought to be the 
invariant surface glycoprotein 75 (ISG75). Nevertheless, we recently identified a variant 
surface glycoprotein (VSGSur) that confers strong in vitro resistance to suramin in a 
Trypanosoma brucei rhodesiense line. In the present study we introduced VSGSur into the 
active bloodstream expression site of a T. b. brucei line. This caused suramin resistance and 
cross-resistance to trypan blue. We quantified the endocytosis of different substrates by 
flow cytometry and showed that expression of VSGSur strongly impairs the uptake of low 
density lipoprotein (LDL) and transferrin, both imported by receptor-mediated endocytosis. 
However, bulk endocytosis and endocytosis of the trypanolytic factor were not affected, and 
the VSGSur-expressors did not exhibit a growth phenotype in the absence of suramin. 
Knockdown of ISG75 was synergistic with VSGSur expression, indicating that these two 
proteins are mediating distinct suramin resistance pathways. In conclusion, VSGSur causes 
suramin resistance in T. brucei bloodstream forms by decreasing specific, receptor-mediated 
endocytosis pathways.  




Sleeping sickness, transmitted by the tsetse fly, is caused by two subspecies of the 
protozoan parasite Trypanosoma brucei: T. b. gambiense typically establishes a chronic 
infection, whereas T. b. rhodesiense causes a rather acute form of the disease. A third 
subspecies, T. b. brucei, is not infective to humans but, together with other trypanosome 
species, causes livestock trypanosomiasis. Trypanosomes are protected from the 
mammalian immune system by multiple mechanisms that confound both innate and 
acquired defenses. The surface coat consists of a dense layer of a single variant surface 
glycoprotein (VSG); with a reservoir of more than 2000 VSG genes and pseudogenes [274], 
trypanosomes evade their mammalian host's adaptive immune responses by antigenic 
variation. Thus there is no vaccine for sleeping sickness and chemotherapy relies on few 
available drugs, although more are entering the treatment pipeline [275]. Suramin is the 
oldest drug but remains used for the treatment of the first stage of T. b. rhodesiense 
infection. 
Despite the use of suramin for a hundred years, its mode of action against African 
trypanosomes is not completely understood. Suramin inhibits a number of different 
enzymes including many in the glycolytic pathway [57]. As a negatively charged molecule, 
suramin cannot cross membranes by diffusion and was proposed to be taken up through 
receptor-mediated endocytosis [58,59]. More recent RNAi target sequencing studies 
showed that knock-down of a number of endosomal and lysosomal genes leads to up to 
about 11-fold suramin resistance [42], substantiating an uptake route through endocytosis. 
Invariant surface glycoprotein 75 (ISG75) was proposed to act as the suramin receptor, 
since its knock-down led to a decrease in suramin sensitivity [42]. Suramin shows a high 
plasma protein binding with approximately 70% bound to albumin, 15% to low density 
lipoprotein (LDL) and 15% free [59]. Based on findings that trypanosomes took up >20-
fold more suramin in the presence of LDL than in the presence of plasma, while the binding 
and uptake of LDL were up to 70% reduced in the presence of high micromolar 
concentrations of suramin [59], suramin was proposed to be taken up in complex with LDL. 
However, procyclic trypanosomes overexpressing the trypanosome ortholog of Rab4 
showed a 50% decrease of suramin binding and almost no suramin uptake when compared 
to parental cells, while the uptake of LDL was unchanged [276]. The expression of a 
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constitutively activated version of Rab5 lead to increased LDL uptake without affecting 
suramin uptake, indicating that uptake of LDL and suramin are likely independent [276]. 
While resistance to suramin is widespread in the animal pathogen Trypanosoma evansi with 
50% inhibitory concentrations (IC50) of up to 40 µg/ml [60,61], there have not been any 
reports of suramin resistance in T. brucei spp. from the field. Nevertheless, resistance can be 
selected for under in vitro and in vivo conditions in the laboratory [248]. We recently 
described a variant surface glycoprotein, VSGSur, which is linked to suramin 
resistance [277]. VSGSur was identified by forward genetics. We had exposed 
T. b. rhodesiense STIB900 clones to high suramin concentrations (80-fold the IC50), and 
within only one week they became resistant. Transcriptome sequencing showed that all the 
resistant lines had switched to express VSGSur. This phenomenon was reproducible in 
multiple independent experiments. The VSGSur expressing parasites showed an increase in 
IC50 of almost 100-fold for suramin, and cross-resistance to trypan blue, a trypanocidal dye 
related to suramin. We quantified the amount of intracellular trypan blue and observed a 
reduced uptake by VSGSur expressing parasites [277]. In the present study we investigate the 
effects of enforced VSGSur expression in a suramin-sensitive T. b. brucei line, aiming to 
uncover the molecular mechanisms underlying the link between VSGSur expression and 
suramin resistance.  
4.3. Material and Methods 
Chemicals were purchased from Merck KGaA, Darmstadt, Germany, if not otherwise 
stated. 
T. brucei strains and cell culture 
The Lister 427 derived T. b. brucei 2T1 strain [278] was cultivated in Iscove’s Modified 
Dulbecco’s culture Medium complemented according to Hirumi [262] and supplemented 
with 10% heat-inactivated fetal calf serum. Cells were cultured at 37°C, 5% CO2. 
Introduction of VSGSur into 2T1 cells 
The plasmid previously described [277] was modified for the genomic replacement of the 
VSG221 by VSGSur in 2T1 cells. First the coding sequence of VSG900 within the plasmid was 
replaced by the coding sequence of VSGSur (GenBank accession MF093647), which was 
derived by PCR from cDNA of STIB900_c1_sur1 with primers containing XbaI and AscI 
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restriction sites (VSGsur_XbaI_F: taatctagaatgcaagccgtaacacgc, VSGsur_AscI_R: 
aatggcgcgccttaaaaaagcaaaaatgcaagc). The construct’s framing UTRs used for homologous 
recombination were replaced with the UTR-regions of VSG221. For the 5’ genomic UTR of 
VSG221 a PCR product amplified from 2T1 gDNA was cloned into the plasmid. Primer used 
for the amplification of the 5’ genomic UTR of VSG221 contained HindIII and NcoI sites 
(VSG221_5'UTR_HindIII_f: tagaagcttcaagcacaatttcatcctcct and VSG221_5'UTR_NcoI_r: 
catccatgggccgcgttcgtgtcg). Correct cloning was validated by sequencing. The 3’ UTR was 
replaced during the final PCR on plasmid DNA using a forward primer, which binds to the 
221 5’UTR sequence (VSG221_5'UTR_HindIII_f), and a reverse primer, which binds to the 
stop-codon of VSGSur and contains an overhang of 71 nucleotides from the VSG221 3’UTR 
sequence. The resulting PCR product was framed by the 3’ and 5’ UTRs of VSG221 and 
contained a blasticidine-resistance gene, an αβ tubulin trans-splice site and the coding 
sequence of VSGSur. Five micrograms of the purified PCR product were used for the 
transfection of 4 × 107 2T1 cells in 100 µl Tb-BSF buffer [50] with an Amaxa Nucleofector 
using program Z-001. Positive transfected clones were obtained by limiting dilution in 
standard culture medium and after 24 h of incubation, blasticidine was added to a total 
concentration of 10 and 20 µg/ml. Four positive transfected clones and the untransfected 
parent strain were analyzed by qPCR regarding the expression of VSGSur and VSG221.  
RNA isolation and quantitative PCR 
Parasites in the exponential growth phase were washed once with PBS and total RNA was 
isolated using the RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) including an on-
column DNase treatment. SuperScript III Reverse Transcriptase (Invitrogen via Thermo 
Fisher Scientific, Illkirch Cedex France) and an oligo(dT) primer was used to synthesize 
complementary DNA (cDNA) out of 1-5 µg total RNA according to the manufacturer’s 
protocol. Quantitative PCR was carried out in a Power SYBR Green Mix (Applied 
Biosystems via Thermo Fisher Scientific, Illkirch Cedex France) on a StepOnePlus real-
time PCR machine (Applied Biosystems) in technical duplicates. The primers used for 
qPCR were tcattcgtttggccatacgc and ttactgacagacgaaccggc for VSGSur and aaggccaagaaagcg 
and ttggtaacgcctgttttg for VSG221. The amplification plots were analyzed with StepOne 
Software v2.3. and the Ct values were normalized to the housekeeping gene telomerase 
reverse transcriptase using the ∆∆Ct method.  
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Drug and human serum sensitivity assays 
Suramin (sodium salt) (S2671) and pentamidine isethionate (P0547) were obtained from 
Sigma (now Merck), trypan blue (93590) from Fluka (now Merck) and melarsoprol from 
Sanofi-Aventis/WHO. In vitro drug sensitivities were determined with Alamar blue 
assays [265] using standard growth medium. Serial drug dilutions were prepared on a 96-
well plate and parasites were added to a final concentration of 1×104 cells/ml. After 
incubation for 69 hours, resazurin was added to a final concentration of 11.4 µg/ml. Cells 
were incubated for 2-4 more hours and fluorescence of viable cells was quantified using a 
SpectraMax reader (Molecular Devices, Wokingham, Berkshire, United Kingdom) and 
SoftMax Pro 5.4.5 Software. Dose-response curves were fitted with a non-linear regression 
model (variable slope; four parameters, lowest value set to zero) and IC50 values were 
calculated with GraphPad Prism 6.00. Human serum sensitivity was determined using 
Alamar blue assays as above. But, instead of drug addition, limited dilutions were prepared 
with human serum and the medium used was HMI-9 supplemented with 15% heat-
inactivated horse serum (i-horse). Human serum was obtained through centrifugation of 
whole blood of volunteers, heat inactivated at 56°C and stored at -20°C. Specific killing due 
to trypanolytic factor was checked by incubation of T. b. gambiense in 5% human serum of 
the same batch. T. b. gambiense cells were not lysed. 
Trypan Blue uptake 
Cells were harvested in the logarithmic growth phase and resuspended in standard growth 
medium at a concentration of 4×105 cells/ml. Trypan blue was added to the respective 
concentrations and cells incubated for 2 hours at 37°C. Subsequently, cells were centrifuged 
for 5 min at 3000 g at room temperature and washed twice with PBS. Cells were 
resuspended in 250 µl PBS and fixed in 5% formalin. Fluorescence intensities of the cells 
were measured with a BD FACSCaliburTM flow cytometer (BD Biosciences, San Jose, 
CA, USA). A total of 10 000 events were acquired within a gate of intact cells based on size 
versus granularity (FSC/SSC) and fluorescence of the gated cells was measured in the FL3 
filter. The measured fluorescence intensities were analyzed with Flowing Software (version 
2.5.1) using a refined FSCxSSC gate to exclude cell debris and an additional size versus 
fluorescence gate to exclude parasites that had already been dead during incubation with 
trypan blue and thus gave a much stronger signal. Fluorescence values were defined as the 
geometrical mean fluorescence of gated particles (>6000 per replicate).  
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ISG75 turnover  
For each cell line and each timepoint, 40 ml cell cultures were prepared the day before the 
experiment. The cell density was adjusted for each sample to reach 1.2 ×106 cells/ml. The 
next day, at the respective time points, cycloheximide (C7698 Sigma, now Merck) was 
added to the cultures to a concentration of 100 µg/ml. At timepoint zero, the cell densities 
were measured and the same number of cells was taken from each replicate. Cells were 
centrifuged for 10 min, 1000 g at room temperature. The supernatant was removed and the 
cell pellet resuspended in 1 ml PBS supplemented with protease inhibitor (cOmplete™, 
Mini, EDTA-free Protease Inhibitor Cocktail, Roche: 1 tab in 20ml) and centrifuged for 10 
min, 1000g at room temperature. The cells were washed one more time with PBS 
containing protease inhibitor, supernatant was removed and 10 µl of 3 × Laemmli buffer 
added. Cells were further diluted with Laemmli buffer to reach a density of 5×106 cells/ 10 
µl. Cells were sonicated and incubated at 70°C for 10 min. Samples were centrifuged at full 
speed in a microcentrifuge for 2 minutes and subsequently 10 µl of sample was loaded on a 
NuPAGE 4-12% Bis-Tris Protein Gel (Fisher Scientific - UK Ltd, Loughborough, United 
Kingdom) and run for 1 hour at 200 V in NuPAGE™ MOPS SDS Running Buffer (Fisher 
Scientific - UK Ltd, Loughborough, United Kingdom). Separated proteins were transferred 
to a polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore) in a TE22 wet 
transfer tank (GE healthcare) in SDS-Page running buffer supplemented with 20% 
methanol. The membrane was blocked with blocking buffer consisting of Tris-buffered 
saline with 0.01% Tween-20 (TBST) and 5% milk powder. Subsequently the membrane 
was incubated for 1 hour in blocking buffer containing the primary antibody. For ISG75 a 
1:2,500 diluted polyclonal rabbit antibody was used and for EF1α a monoclonal mouse 
antibody (clone CBP-KK1; Millipore) was used in a 1:20,000 dilution. Membranes were 
washed with TBST three times for 5 minutes and incubated for one hour with a secondary 
goat anti-rabbit peroxidase-conjugated IgG (A0545, Sigma, now Merck) at a 1:20,000 
dilution. Membranes were washed once with TBS and twice with PBS before addition of 
1 ml Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences, 
Buckinghamshire, UK). After two minutes of incubation, chemiluminescence was detected 
with a G:box imager (Syngene). Signals were quantified using ImageJ (Fiji) software [279]. 
 
 




A previously described pRPa plasmid for RNAi-mediated knockdown of ISG75 [42] was 
amplified in DH5α cells and digested with XhoI. A total of 6 µg purified digested plasmid 
was used to transfect 4×107 VSG221 respectively VSGSur expressing 2T1 cells. Transfection 
was carried out as described above and positive transfectants were selected with 10 µg/ml 
Hygromycin (Invivogen, Toulouse, France). Pseudoclones were picked after five days and 
RNAi-knockdown was induced by the addition of 1 µg/ml Tetracycline. To quantify the 
level of ISG75 knock-down, 72 hours after induction, RNA of induced and non-induced 
clones was isolated and qPCR was performed as described above [277] (chapter 3). Primers 
used for qPCR were ISG75qPCR_F (gcttgggttgcttgtgttct) and ISG75qPCR_R 
(tcgtatttttgcttttagcattagc). 
Suramin wash-out assay 
Serial drug dilutions were prepared on a 96-well v-shaped plate with the following media: 
HMI-9 with 15% inactivated horse serum, HMI-9 without serum, HMI-9 without serum but 
complemented with 10 µg/ml LDL and HMI-9 without serum but complemented with 0.5% 
bovine serum albumin (BSA, A7030). Parasites were washed twice with pre-warmed 
IMDM, eluted in the respective media and added to the assay plates to a final volume of 
100 µl/well and a concentration of 1×105 cells/ml for the HMI-9 medium with 15% 
inactivated horse serum. Since the cells in the media without serum were not dividing 
during the incubation time, higher inocula were used and parasites were added to a 
concentration of 2×105 cells/ml. Plates were incubated for 4 hours at 37°C, 5% CO2 and 
subsequently centrifuged at 1000 g for 3 minutes. 50 µl of the supernatant were removed 
and 150 µl pre-warmed IMDM was added to all the wells. Cells were washed 3 more times, 
each time 150 µl supernatant were removed and 150 µl IMDM or, in case of the last wash, 
150 µl HMI-9 with 15% i-horse were added. After the last centrifugation 150 µl supernatant 
were removed and 50 µl HMI-9 with 15% i-horse were added to elute the parasites. A new 
flat-bottom plate was prepared with 50 µl HMI-9 with 15% i-horse and 50 µl of the eluted 
parasites were transferred to the new plate. The flat-bottom plate was incubated for another 
64 hours before resazurin was added to a final concentration of 11.4 µg/ml. After another 4-
5 hours of incubation at 37°C, 5% CO2, fluorescence of viable cells was measured with a 
SpectraMax (Molecular Devices, Wokingham, Berkshire, United Kingdom) and SoftMax 
Pro 5.4.5 Software. Dose-response curves were fitted with a non-linear regression model 
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(variable slope; four parameters, lowest value set to zero) and IC50 values were calculated 
with GraphPad Prism 6.00. 
Uptake and binding of transferrin and low density lipoprotein 
To quantify the uptake of transferrin and LDL, cells in the logarithmic growth phase were 
washed once with serum-free medium supplemented with 1% BSA and resuspended in 
serum-free medium supplemented with 1% BSA at a concentration of 2×106 cells/ml. 392 
µl (for the transferrin uptake experiment) and 95 µl (for the LDL uptake experiment) of 
resuspended parasites were transferred to Eppendorf tubes. Cells were pre-incubated for 15 
minutes at 37°C to internalize surface bound transferrin and LDL. At the respective 
timepoints fluorescently labeled transferrin (Alexa Fluor™ 488 Conjugate, T13342, Fisher 
Scientific, Illkirch Cedex, France) was added to a concentration of 50 µg/ml or 
fluorescently labeled LDL (Bodipy FL, I34359, Fisher Scientific, Illkirch Cedex, France) to 
a concentration of 10 µg/ml. At time point zero, cells were quenched by putting them on ice 
and by addition of 1 ml ice-cold PBS. Cells were centrifuged for 5 minutes at 1000 g at 4°C 
and washed once with ice cold PBS. Cells were fixed and fluorescence quantified as 
described above.  
To quantify the impact of suramin on the uptake of transferrin and LDL, cells were washed 
once with IMDM and eluted in IMDM without BSA to a concentration of 2×106 cells/ml. 
The experiment was performed without BSA, since otherwise the majority of suramin 
would bind to BSA. Cells were pre-incubated for 15 minutes (transferrin) or for one hour 
(LDL) at 37°C. Suramin was added to concentrations between 0 and 1000 µM and 
subsequently transferrin or LDL were added to concentrations of 5 or 10 µg/ml 
respectively. Cells were incubated for 10 minutes (transferrin) or for 20 minutes (LDL) at 
37°C, quenched, washed and fixed as described above. 
For the quantification of transferrin and LDL binding to the cell surface, cells were washed 
with IMDM and eluted in IMDM to a concentration of 1×107 cells/ml. Cells were pre-
incubated for 15 minutes (transferrin) or for one hour (LDL) at 37°C and subsequently 
chilled on ice for 15 minutes. Either suramin or cold PBS was added and subsequently 
transferrin or LDL were added to a concentration of 800 or 100 µg/ml respectively. Cells 
were incubated for 10 minutes on ice, subsequently washed twice with ice-cold PBS and 
fixed as described above. 
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Concanavalin A uptake and binding 
Trypanosomes in the logarithmic growth phase were centrifuged at 1000 g for 5 minutes, 
the cell pellet was eluted in IMDM with 1% bovine serum albumin (BSA) to a 
concentration of 2×106 cells/ml. 498 µl of the eluted parasites were put in 1.5 ml Eppendorf 
tubes and pre-incubated at 37°C for 15 minutes. At the respective time points FITC 
conjugated Concanavalin A (C7642 Sigma, now Merck) was added to a concentration of 5 
µg/ml. After incubation at 37°C cells were quenched on ice by addition of ice-cold PBS. 
Subsequently cells were centrifuged for 5 minutes at 1000 g at 4°C and washed once with 
PBS. Cells were eluted in 250 µl PBS and fixed by addition of 250 µl 10% formalin.  
For the quantification of surface bound ConA, cells were centrifuged and eluted in IMDM 
with 1% BSA to a concentration of 2×106 cells/ml. These were pre-incubated on ice for 15 
minutes and subsequently the ConA was added to concentrations of 0, 5, 20 and 50 µg/ml. 
After incubation on ice for 10 minutes, ice-cold PBS was added, the cells centrifuged at 4°C 
(5 minutes, 1000 g) and subsequently washed one more time with ice-cold PBS, eluted in 
250 µl PBS and fixed by addition of 250 µl 10% formalin.  
Fluorescent intensities of the cells were measured as described above but using the FL1 
filter. Fluorescence values were defined as the geometrical mean fluorescence of >9000 
events. 
  




4.4.1. Expression of VSGSur renders T. b. brucei resistant to suramin  
To test the hypothesis that expression of VSGSur is sufficient to cause suramin resistance in 
T. brucei, we introduced the VSGSur gene into the active VSG expression site of T. b. brucei 
2T1, a well-established T. b. brucei bloodstream-form laboratory line [278]. 2T1 cells 
naturally express VSG221 [280], also called MITat1.2 (GenBank: X56762.1). To replace 
VSG221 with VSGSur we made a construct (Fig 1A) which contained the coding sequence of 
VSGSur together with a blasticidine resistance gene, framed by the sequence of the 5’and 3’ 
regions of VSG221. Four transfected clones were recovered, all of which showed no 
expression of VSG221 and expressed VSGSur at the same level as the parental line expressed 
VSG221 (determined by qPCR using telomerase reverse transcriptase (TERT) as a reference; 
Fig 1B). Two of the VSGSur expressing transfectants (2T1_sur1 and 2T1_sur4) were chosen 
for further analysis. Proliferation was essentially indistinguishable from the parent cell line 
when cultivated in standard medium without blasticidine (Fig 1C). The 50% inhibitory 
concentration (IC50) for suramin increased from 12 nM in the VSG
221 expressing parent to 
700 nM in the two VSGSur expressing transfectants (p = 0.0036, One-Way ANOVA; Fig 
1D). No alterations of drug sensitivities were observed for melarsoprol or pentamidine, 
excluding a non-specific drug resistance mechanism. However, the VSGSur expressing cells 
showed weak cross-resistance to trypan blue, with an elevation of the IC50 from 13 µM in 
the VSG221 expressing parent to 19 and 21 µM in the VSGSur expressing transfectants, but 
this was statistically non-significant. 




Figure 1: Introduction of VSGSur into the active bloodstream expression site renders 2T1 cells suramin-
resistant. (A) Schematic illustration of VSG221 within the active bloodstream expression site of 2T1 cells 
before transfection and of the construct used for the in situ replacement of VSG221 with VSGSur. The 
construct is framed with the 5’ region of VSG221 with adjacent sequence on one side and the 3’ region of 
VSG221on the other side; it contains a blasticidine resistance gene (BSD), an αβ tubulin splice site (αβ tub) 
and the coding sequence (cds) of VSGSur. Triangles indicate restriction-sites. (B) Expression of VSGSur and 
VSG221 as determined by qPCR in the parent 2T1 strain (2T1_wt) and in 4 transfected clones (2T1_sur1-
4). Values shown are derived from technical duplicates; they represent expression levels normalized to the 
housekeeping gene TERT. The transfected clones show a high expression level VSGSur, comparable to the 
expression level of VSG221 in the 2T1 parent cells. (C) Cumulative cell number as measured over four 
days, error bars represent standard deviations (n=3). (D) Dose-growth curves for suramin show an 58-fold 
decrease in suramin sensitivity after introduction of VSGSur (n = 3). 
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4.4.2. VSGSur expressing cells show a reduced uptake of trypan blue 
We exploited the fact that trypan blue becomes fluorescent when bound to proteins 
[255,281] to investigate drug uptake by T. b. brucei 2T1. Cells were incubated with 
different concentrations of trypan blue at 37°C and subsequently the fluorescence of cell-
associated trypan blue quantified by flow cytometry. In the cell size versus fluorescence 
scatters, gates were set to exclude dead cells, which give a much stronger signal than live 
cells [255]. VSGSur-expressors showed a 30-50% reduction of fluorescence when compared 
to their VSG221 expressing parent (Fig 2). This is consistent with the small increase in the 
IC50 towards this compound.  
 
Figure 2: Trypan blue uptake 
The trypan blue uptake of VSGSurand VSG221 expressing cells as determined by FACS after incubation for 2 
hours at 37°C. Error bars represent standard deviations of three independent experiments (*= p<0.05; **= 
p<0.01, paired t-test). 
4.4.3. VSGSur-mediated suramin resistance is not linked to ISG75 
Since some suramin resistance can be caused by ISG75 depletion [42], we investigated a 
possible effect of VSGSur on ISG75 turnover. Therefore, cells were incubated with 
cycloheximide to block protein synthesis, and the steady-state ISG75 levels were 
determined after 0, 2, 4 and 6 hours by Western blotting. The ISG75 half-life was around 3 
hours in both the VSG221 expressing and the VSGSur expressing trypanosomes (Fig 3A). We 
further investigated the effect of ISG75 depletion in VSGSur-expressors (2T1_sur1) and 
parental cells (2T1_wt) by introduction of a pRPA-based, tetracycline-inducible RNAi 
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knock-down construct. Induction of RNAi for 72 hours led to a 75-85% reduction of ISG75 
mRNA levels in 5 (2T1_wt_c1 and c3; 2T1_sur1_c1 to c3) out of 6 clones as determined by 
qPCR (Fig 3B). Growth was slightly faster under knock-down of ISG75 with an average 
population doubling time of 6.9 h in the presence of tetracycline compared to 7.2 h without 
tetracycline (p-value = 0.003, paired t-test including all clones, Fig 3C). Suramin sensitivity 
decreased in all the tested clones upon down-regulation of ISG75 (Fig 3D). The presence of 
ISG75-dependent suramin uptake also in the VSGSur-expressors indicates that this is not 
the pathway affected by VSGSur. Moreover, the effect of ISG75 silencing on suramin 
sensitivity was clearly stronger (p = 0.009, Welch Two Sample t-test) in the VSGSur-
expressors: the IC50 of suramin upon ISG75 knock-down increased 2.2 and 3.8 fold in 
parental 2T1 cells, and 7.9, 8.1 and 6.7 fold in VSGSur-expressors (Fig 3D). This is in 
agreement with the above hypothesis, that a pathway distinct from ISG75 is affected and 
hence, ISG75 confers a larger proportion of suramin uptake in the VSGSur expressing 
trypanosomes. 
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Figure 3: ISG75 expression and effect on suramin sensitivity (blue: parental, VSG221 expressing cells; 
red: VSGSur expressing cells). 
(A) ISG75 turnover as determined by western blot after inhibition of translation for different time spans. 
Plotted data points represent mean amounts of protein from two independent experiments, for each 
experiment two technical replicates (western blots) were made. (B) Reduction of ISG75 expression 
levels upon RNAi knockdown. Gene expression levels are normalized to the housekeeping gene TERT, 
values shown are derived from technical duplicates. (C) Cumulative growth curves of VSGSur and VSG221 
expressing cells +/- ISG75 knockdown. Values shown are the averaged growth curves for each group, 
including two biological replicates from each clone (2T1_wt_c1 and c3 for the VSG221-expressor and 
2T1_sur_c1, c2 and c3 for the VSGSur-expressor). The data points represent mean cell numbers plotted 
with the position_dodge function in R to allow visual distinction between the groups. Error bars 
represent standard deviation. (D) 50% inhibitory concentrations for suramin of VSGSur and VSG221 
expressing cells +/- ISG75 knockdown. ∆ represents the factor of increase upon ISG75 knockdown. 
4.4.4. Effects of serum proteins on suramin susceptibility 
Having excluded defects towards ISG75 turnover as a reason for the decreased suramin 
sensitivity of VSGSur expressing cells, we tested for the involvement of serum proteins in 
VSGSur-mediated suramin resistance. This had to be performed with wash-out assays since 
the trypanosomes cannot be cultivated without serum proteins over long periods. Parental, 
VSG221 expressing 2T1 cells and VSGSur-expressors were incubated for 4 hours with 
suramin in HMI-9 medium without serum proteins, in HMI-9 supplemented with albumin, 
with LDL or with serum respectively, washed, and incubated in standard growth medium 
(without suramin) for 3 days. As expected, the IC50 in these assays (Fig 4) were higher than 
in the standard 72 h assay, since suramin was only present for the first 4 hours. 
Nevertheless, cells incubated in medium without any serum proteins were highly sensitive 
to suramin: they showed a decrease in IC50 of 98% for VSG
221 and of 95% for VSGSur-
expressing cells when compared to the IC50 of cells incubated in medium with serum. This 
demonstrates that free suramin is taken up by trypanosomes. Addition of bovine serum 
albumin (BSA) counteracted suramin toxicity, indicating that suramin is sequestered by 
binding to albumin, which is in agreement with previous findings [59]. The same effect can 
also explain why the trypanosomes were less suramin sensitive in the presence of serum 
than without serum. Addition of LDL further increased suramin susceptibility of serum-free 
cultures (50% decrease of IC50; Fig. 4). However, this effect was only observed in parental, 
VSG221 expressing cells but not in the VSGSur expressing cells (p-value = 0.008, paired t-
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Figure 4: 50% inhibitory concentrations in presence of different serum proteins.  
Parasites were incubated either in standard growth medium with 15% inactivated horse serum (HMI-9), in 
HMI-medium without any serum (no serum), in HMI-medium without serum supplemented with albumin 
(BSA), or in HMI-medium without serum supplemented with LDL (LDL). Values that differed 
significantly (p<0.05, Tukey's multiple comparison test on logarithmic data) are labeled with different 
letters (a-g) (independent biological replicates: n = 3 for “HMI-9” and “BSA”; n = 4 for “no serum” and 
“LDL”; each biological replicate consisted of two technical replicates). 
4.4.5. The effect of VSGSur and suramin on LDL uptake 
To measure uptake of LDL, T. b. brucei 2T1 cells were incubated for different times with 
fluorescently labeled LDL at 37°C to allow endocytosis, and the internalized LDL was 
quantified using FACS. No plateau was reached within 120 minutes incubation time, 
neither for VSG221 nor for VSGSur expressing cells (Fig 5A). LDL uptake was highly reduced 
in VSGSur expressing cells with an 80-90% lower fluorescence than VSG221-expressors 
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throughout the 5 to 120 minute period (Fig 5A). The presence of suramin led to reduction of 
LDL uptake in wild type cells but not in VSGSur-expressors (Fig 5B). To differentiate 
whether the reduced LDL uptake is mediated through a reduced binding or endocytosis, we 
looked at the binding of LDL to the cell surface. LDL binding at 4°C was around 30 % 
reduced in VSGSur compared to VSG221 expressing cells (overall p-value = 0.0003, paired t-
test). Thus, the highly reduced LDL uptake cannot be explained by a reduction of the 
binding alone and a reduced endocytosis seems to play a major role. No effect on binding 
was observed in the presence of suramin (Fig 5C). 
 





Figure 5: Uptake and binding of fluorescently labeled low density lipoprotein and the effect of 
suramin 
(A) Uptake of low density lipoprotein over a period of 2 hours, error bars represent standard 
deviations (*= p<0.05; **= p<0.01; n=3 for timepoint 120 min; n=4 for timepoints 0-60 min; 
paired t-test). (B) Impact of suramin on the uptake of LDL during 20 minutes of incubation, 
asterisk represent significant p-values if fluorescence of VSG221 expressing cells under 
incubation with suramin is compared to the fluorescence of VSG221 expressing cells under 
incubation without suramin (*=p<0.05; **= p<0.01; ***=p<0.001; n=3, pairwise t-test with 
Bonferroni correction), error bars represent standard deviations. Dotted lines represent baseline, 
which was defined as fluorescence of cells which were incubated with the same amount of LDL 
but on ice to inhibit endocytosis. (C) Binding of LDL to the cell surface. Dotted lines represent 
background fluorescence of VSG221 expressing (blue) and VSGSur expressing (red) cells incubated 
without fluorescently labeled LDL. Error bars represent standard deviations of three 
measurements (two for 10 mM suramin). 
4.4.6. The effect of VSGSur and suramin on transferrin uptake 
We investigated uptake of transferrin as an additional substrate that is imported by receptor-
mediated endocytosis [282,283]. Again, trypanosomes were incubated for different periods 
with fluorescently labeled transferrin at 37°C and analyzed by FACS. In VSG221 expressing 
2T1 cells transferrin was quickly internalized, reaching a plateau of more than 4 times 
background fluorescence after ten minutes (Fig 6A). In contrast, VSGSur expressing 2T1 
cells incubated with labeled transferrin only showed a slight increase of fluorescence to 1.5 
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times background level (Fig 6A), which corresponds to an 80% lower fluorescence than 
observed in parental cells. Since transferrin uptake had been described to be reduced in the 
presence of suramin in HeLa cells [284], we investigated the effect of suramin on 
transferrin uptake in T. brucei. Cells were incubated with fluorescently labeled transferrin in 
different concentrations of suramin for 10 minutes (the incubation time was kept short to 
limit the toxic effects of suramin). At concentrations below 300 µM, suramin had no effect 
on transferrin uptake; only at very high suramin concentrations, reduced amounts of 
intracellular transferrin were measured in VSG221 expressing cells (Fig 6B, p-values of 0.04 
and 0.006 for concentrations of 300 and 1000 µM respectively, pairwise t-test with 
Benjamini Hochberg correction). To differentiate whether the reduced internalization of 
transferrin in VSGSur expressing cells was caused by reduced binding or reduced 
endocytosis, we quantified surface binding of transferrin to trypanosomes by incubating the 
cells on ice. The fluorescence of VSGSur expressing cells incubated without suramin was 
around 40% lower than the fluorescence of the VSG221 expressing cells (Fig 6). Thus again, 
the highly reduced transferrin uptake cannot be attributed to reduced binding. Upon addition 
of suramin at 1 mM and 10 mM, the difference between VSG221 and VSGSur-expressors 
became smaller (Fig 6C). However, at such high suramin concentrations we cannot exclude 
an ionic effect. The overall p-value of the difference between VSG221 and VSGSur-expressors 
was 0.03. 
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Figure 6: Uptake and binding of fluorescently labeled transferrin and the effect of suramin 
(A) Transferrin uptake of VSGSur and VSG221 expressing cells at 37°C over time. Error bars 
represent standard deviation of four independent experiments (*= p<0.05; **= p<0.01, paired t-
test). (B) Influence of suramin on transferrin uptake. Data of three independent experiments are 
shown, error bars represent standard deviations. Dotted lines represent baseline, which was 
defined as fluorescence of cells which were incubated with the same amount of transferrin but on 
ice to inhibit endocytosis. (C) Transferrin binding to the cell surface with and without suramin as 
determined after incubation of cells on ice. Dotted lines represent background fluorescence of 
VSG221 expressing (blue) and VSGSur expressing (red) cells incubated without fluorescently labeled 
transferrin. Error bars represent standard deviations of three measurements (two for 10 mM 
suramin). 
4.4.7. The effect of VSGSur on VSG endocytosis 
Variant surface glycoproteins are endocytosed at a very high rate with a turnover equivalent 
to the whole surface coat within 12 minutes [261]. To test whether VSGSur expression has a 
general impact on endocytosis, we investigated endocytosis of VSGSur and VSG221. 
Concanavalin A (ConA) is a lectin that binds to glycosylated surface proteins, in case of 
trypanosomes mainly to VSG [285]. It is endocytosed together with the VSG and can 
therefore be used to measure VSG endocytosis rates. Cells were incubated for time periods 
of 0 to 60 minutes at 37°C with 5 µg/ml fluorescently labeled ConA. Subsequently cells 
were fixed, and the fluorescence of cell-associated ConA was measured by flow cytometry. 
Up to an incubation period of 20 minutes fluorescence levels were in the same range or 
even higher for VSGSur than for VSG221-expressors. Thereafter VSGSur-expressors showed a 
slightly lower fluorescence than VSG221-expressors (Fig 7A). Since ConA does not bind 
equally well to all VSGs [285] we examined the ConA binding capacity of the two cell 
lines. The cells were incubated with different concentrations of ConA on ice to prevent 
endocytosis, and surface bound ConA was quantified by flow cytometry. VSGSur 
expressing cells showed a 22-34% higher fluorescence than VSG221-expressors (p-value = 
0.0097, paired t-test, Fig 7B). Taken together, the facts that VSGSur-expressors showed 
similar levels of internalized ConA as VSG221-expressors at 37°C but more surface bound 
ConA at 4 °C, indicate that endocytosis of VSG may be slightly reduced in VSGSur 
expressing cells. However, we observed no enlargement of the flagellar pocket, which is a 
hallmark for blocked endocytosis.  




Figure 7: Concanavalin A uptake and binding in VSGSur and VSG221 expressing cells. 
(A) Fluorescence of cells incubated with 5 µg/ml labeled ConA at 37°C, time point zero represents 
cells that were kept on ice before addition of ConA in order to allow binding but not uptake. Error 
bars represent standard deviations of five (for timepoint 60 only four) independent experiments. 
(B) Fluorescence of surface bound ConA of cells incubated with different ConA concentrations at 
4°C to prevent endocytosis. Error bars represent standard deviation of four independent 
experiments. 
Chapter 4: Impact of VSGSur on suramin sensitivity and endocytosis 
83 
 
4.4.8. The effect of VSGSur on sensitivity to human serum 
Most trypanosome species other than T. b. rhodesiense and T. b. gambiense are lysed by the 
two trypanolytic factors (TLF1 and TLF2) present in human serum. TLF1, a high density 
lipoprotein complex, and TLF2, a protein complex, both contain apolipoprotein L1 [286], 
which mediates trypanolysis [287]. TLF1 is much more active than TLF2 and kills T. b. 
brucei at very low concentrations in the absence of competing haptoprotein [288]. TLF1 
binds to the haptoglobin-haemoglobin receptor (TbHpHbR) in the flagellar pocket and is 
subsequently endocytosed [289]. To test whether the endocytosis of the TbHpHbR is 
affected by VSGSur expression, sensitivity to human serum was tested. However, 
bloodstream-form T. b. brucei 2T1 expressing VSGSur or VSG221 were equally sensitive (Fig 
8). This demonstrates that endocytosis of the trypanolytic factor of human serum, and the 
downstream mechanisms of cell lysis, are not affected by VSGSur.  
 
Figure 8: Sensitivity to normal human serum. 
  




We have originally identified VSGSur as the VSG expressed in bloodstream-form T. brucei 
spp. that had been selected in vitro for resistance to suramin [277]. The resistant cells had 
IC50 values to suramin of around 1.2 µM, which was almost 100-fold above the IC50 of the 
parental cells but still below the suramin plasma levels of 70 µM in the treated patients [25]. 
Thus expression of VSGSur is unlikely to cause suramin treatment failure in patients. 
Nevertheless, it is intriguing how a particular VSG can be linked to drug susceptibility. 
Here we show that transgenic expression of VSGSur is sufficient to cause suramin resistance 
in T. b. brucei, which is otherwise highly sensitive to the drug. Based on the reduced uptake 
of trypan blue by the cells that express VSGSur, our working hypothesis is that suramin 
resistance is mediated by a reduced drug uptake. Trypanosomes take up suramin through 
receptor-mediated endocytosis [58,59]. Endocytosis in trypanosomes takes place at the 
flagellar pocket and the most abundantly endocytosed protein is VSG itself. VSGs are 
endocytosed into Rab5a endosomes [290] at a very high rate [261]. Subsequently the VSG 
is recycled back to the trypanosome surface by exocytosis via Rab11 exocytic 
carriers [291].  
Concanavalin A, a lectin which binds to VSG, can be used as a marker to track VSG 
internalization [292]. We did not observe distinct alterations of ConA endocytosis in VSGSur 
expressing trypanosomes, neither by flow cytometry nor by fluorescence microscopy (not 
shown) and conclude that if there is an effect on VSG internalization at all, it is only 
marginal. Transferrin and low density lipoprotein (LDL) are important nutrients for African 
trypanosomes [293,294]. Transferrin binds to the transferrin receptor, which is a 
heterodimer of ESAG6 and ESAG7, and is subsequently endocytosed in Rab5a endosomes 
similar to the VSGs [290]. Once the ligand is removed, transferrin receptors are recycled to 
the cell membrane. Similar to VSG, this happens at a very high rate with a turnover of only 
11 minutes [295]. LDL is imported via receptor-mediated endocytosis as well. The LDL 
receptor is supposedly located at the flagellar pocket and on the flagellar membrane [296], 
but it has not been identified. As determined by flow cytometry, the VSGSur-expressors 
showed highly reduced intracellular levels of fluorescently labeled transferrin and 
fluorescently labeled LDL after incubation at 37°C. This suggests that VSGSur expression 
impairs endocytosis of the LDL receptor and the transferrin receptor. However, expression 
of VSGSur did not alter sensitivity to human serum, indicating that endocytosis of the 
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TbHpHb receptor is not affected. The HpHb receptor is a glycosylphosphatidylinositol 
(GPI) anchored, glycosylated surface protein located at the flagellar pocket [289]. Taken 
together, VSGSur-expressors showed a normal growth and no enlarged flagellar pockets, thus 
we assume that VSGSur has no effect on bulk endocytosis. Receptor-mediated endocytosis is 
affected by VSGSur, but only specific pathways. While endocytosis of transferrin is highly 
reduced, endocytosis of the VSG may be moderately reduced, and endocytosis of the HpHb 
receptor unaffected by VSGSur expression. Additionally, and most importantly for suramin 
susceptibility, endocytosis of the elusive LDL receptor is highly reduced. 
Suramin inhibited uptake of LDL by VSG221 expressing cells, in agreement with published 
results [59], but not in VSGSur expressing cells. Short-term suramin wash-out experiments in 
serum-free medium indicated that suramin uptake is lowest in the presence of albumin and 
intermediate in the presence of serum, which confirms the literature [59]. We further show 
for the first time that suramin is also taken up in the absence of serum. The addition of LDL 
appeared to increase suramin uptake in VSG221 expressing cells, which is in accordance with 
the literature [59], but not in VSGSur-expressors. On the other hand, knockdown of ISG75 
had a stronger effect on suramin sensitivity in VSGSur-expressors than in VSG221 expressing 
cells. 
Suramin remains an enigmatic molecule with polypharmacology and multiple potential 
uses. The effects of suramin on vesicular trafficking are likely to be complex, since suramin 
can interfere with vesicular transport and is imported via receptor-mediated endocytosis 
itself [58,59,276]. Our findings support a model of two independent pathways for 
endocytosis of suramin by trypanosomes: via the invariant surface glycoprotein ISG75 that 
directly binds suramin, and via the LDL receptor, a protein of unknown nature that binds 
suramin complexed to LDL. While the former is still active in cells expressing VSGSur, the 
latter is strongly impaired, causing suramin resistance in T. brucei. 
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The experiments were carried out as follows: 
The suramin selection (Figure 1) was done by me;  
the phenotypic characterization (Figure 2; Table 1), the reverse genetics experiment 
(Figure 4) and the mapping of sequencing reads and differential expression analysis (Figure 
5) were done by Silvan Hälg under my supervision; 
the analysis of sequence variants was carried out by me. 
  





Suramin is a fascinating molecule. In spite of the fact that it has successfully been used for 
the treatment of first-stage sleeping sickness for 100 years, very little is known about its 
mode of action against Trypanosoma brucei. The identification of the variant surface 
glycoprotein VSGSur as a determinant of suramin resistance in T. brucei has revealed a 
novel, surprising link between antigenic variation and drug resistance (Chapter 2). The 
subsequent characterization of VSGSur-mediated suramin resistance has identified LDL 
salvage as an uptake route for suramin that is affected in the resistant trypanosomes 
(Chapter 3). However, these studies have not revealed candidate targets of suramin. For this 
purpose, we have been further selecting a suramin-resistant, VSGSur-expressing 
T. b. rhodesiense line to obtain stable phenotypes of upto 1,100-fold resistance. 
Transcriptomics of these lines delivered three new pieces to the puzzle of suramin action: (i) 
the high-level suramin-resistant lines had acquired a set of point mutations in VSGSur that 
further increased suramin resistance; (ii) they over- and underexpress a larger number of 
genes including expression-site associated genes (ESAGs) and some of the previously 
known candidate genes for suramin resistance; (iii) amongst other mutations they have 
acquired a non-synonymous point mutation in the ATPase domain of a RuvB -like DNA 
helicase. Interestingly, exactly the same residue in RuvB -like helicase was found to be 
mutated in a suramin-resistant T. evansi field isolate. Thus we are confident that we have 
finally identified a primary candidate target for suramin in African trypanosomes. 





The drug suramin is a hundred years old and still being used to treat the first stage of acute 
human sleeping sickness, caused by Trypanosoma brucei rhodesiense. Suramin is a 
fascinating molecule with a wide array of potential applications, from parasitic and viral 
diseases to cancer and autism (Chapter 1). Despite its long term use against sleeping 
sickness, suramin remains an enigmatic molecule. In vitro it inhibits a number of T. brucei 
enzymes, among them many of the glycolytic pathway [57]. The 50% inhibitory 
concentrations for these enzymes are in the micromolar range, while T. brucei is killed by 
nanomolar concentrations and does not actively accumulate suramin [58]. This indicates the 
presence of additional or multiple targets in African trypanosomes. However, these targets 
together with the mode of action have remained elusive. Due to its large size and negative 
charge, suramin is likely imported via receptor-mediated endocytosis [58,59], and the 
receptor in T. brucei bloodstream forms is thought to be the invariant surface glycoprotein 
ISG75 [42]. 
 By selecting T. brucei bloodstream forms in vitro for suramin resistance, we have 
identified a variant surface glycoprotein, termed VSGSur, expression of which is sufficient to 
increase the IC50 to suramin by a factor of 100 [277]; (Chapter 3 & 4). While VSG
Sur-
mediated resistance is independent of ISG75, it is linked to the endocytosis of low density 
lipoprotein (Chapter 4). Expression of VSGSur in T. brucei affects selected membrane 
receptors, impairing the endocytosis of LDL and of transferrin, but not of the trypanolytic 
factor or of VSG itself (Chapter 4). These findings support the model of two independent 
pathways for suramin endocytosis, via ISG75 or via the LDL receptor, whereby the latter is 
impaired, via unknown interactions, by VSGSur. 
 While the investigation on VSGSur revealed a surprising link between antigenic 
variation and suramin resistance, it did not provide us with any new information about 
possible targets of suramin in trypanosomes. Therefore, we continued to expose the VSGSur 
expressing trypanosomes to increasing, sublethal concentrations of suramin, selecting for 
even higher resistance. Selection for high-level suramin resistance substantiated the role of 
VSGSur in suramin resistance and, finally, provided a candidate for the intracellular target of 
suramin. 
  





5.3.1. Further selection yields high-level suramin resistance 
While the initial selection that yielded 100-fold resistance to suramin had been extremely 
fast, it took a year to further select for enhanced resistance. By continuously increasing the 
selective pressure, we finally obtained a T. b. rhodesiense line of 1,100-fold suramin 
resistance. The course of selection is summarized in Figure 1.  
 
 
Figure 1. In vitro selection for suramin resistance in T. b. rhodesiense bloodstream form 
trypanosomes. Suramin concentration used for the selection is show as a line graph with gray 
filling. The mean 50% inhibitory concentrations of selected lines are shown as points, error bars 
represent standard deviations (n=4-6) 
5.3.2. Phenotypic profiling of the suramin-selected lines 
An increase in suramin concentration during the selection process typically abrogated, or 
strongly delayed, the growth of the trypanosomes. However, once the cultures had 
recovered in the absence of suramin, there was no apparent effect on the population 
doubling time in the selected lines (Figure 2A), indicating that there was no fitness cost 
associated with high-level suramin resistance (at least not in vitro; in vivo, trypanosomes 
depending on a particular VSG would be doomed). This is in agreement with the finding 




that the suramin resistance phenotypes were stable in the absence of drug pressure (Figure 
2B). The suramin-selected lines were moderately cross-resistant to trypan blue, but not to 






Figure 2. Phenotype of the suramin-resistant T. b. rhodesiense lines. (A) Growth curves of 
the sensitive and the resistant lines in the absence of drug pressure. Error bars represent standard 
deviations (n=1 for c1; n=2 for sur1; n=3 for s1b and s1e). (B) Stability of the suramin 
resistance in the s1e line after cultivation in absence of drug pressure, triangles represent 
individual drug assays. 




Table 1. Drug sensitivities (IC50 in nM) of the suramin-selected T. b. rhodesiense lines ± standard 
deviations (n = 4-5) 
5.3.3. Further selection with suramin affected VSGSur 
Aiming to test whether the highly suramin-resistant T. b. rhodesiense lines still expressed 
VSGSur, we performed quantitative PCR to measure the expression of VSGSurand VSG900. 
The s1b and s1e lines showed a very high expression of VSGSur, which was in the same 
range as for strain sur1 and >1000-fold higher than the expression of the housekeeping gene 
TERT. To investigate whether the VSGSur sequence remained identical in the higher resistant 
strains, we amplified the expressed VSG gene from cDNA by PCR with primers binding to 
the 5' spliced leader sequence and a conserved sequence (gatatattttaaca) in the 3' 
untranslated region of all VSG genes [272,274]. Sequencing of the PCR product revealed 
that VSGSur had acquired several point mutations in the strain s1e, which showed the highest 
resistance. The mutant gene was named VSGSupersur. It had acquired mutations both at the N- 
and C-terminus of the protein (Figure 3) and showed 98% amino acid sequence identity as 
compared to VSGSur. This surprising finding suggested that the mutations may have been 
selected for by the increasing suramin pressure. 
Line Suramin Trypan Blue Melarsoprol Pentamidine 
STIB900-c1 10 ± 4.4 3,300 ± 360 15 ± 3.2 4.4 ± 3.7 
STIB900-c1-sur1 1,100 ± 130 13,000 ± 4,400 15 ± 4.2 2.4 ± 2.5 
STIB900-c1-sur1-s1b 3,500 ± 580 19,000 ± 3,400 20 ± 5.9 2.9 ± 2.4 
STIB900-c1-sur1-s1e 11,000 ± 1,2 23,000 ± 5,200 19 ± 5.5 3.6 ± 3.4 





Figure 3. Variant surface 
glycoprotein expressed in 
higher suramin-resistant 
strains.  
Amino acid substitutions in 
VSGSupersur as compared to 
VSGSur modeled on the known 
structure of Mitat 1.1 (modeled 
with Phyre2[297]). 
 
5.3.4. Expression of VSGSupersur enhances suramin resistance 
To test the above hypothesis, we targeted the active VSG expression site of 
T. b. rhodesiense STIB900_sur1 with a VSGSupersur construct (Figure 4A). Successful 
replacement of VSGSur in line sur1 and expression of VSGSupersur was verified by 
amplification of the expressed VSG gene from cDNA by PCR and sequencing of the PCR 
product. Out of the four transfected clones two (sur1_tr1 and sur1_tr2) retained expression 
of VSGSur and two (sur1_tr3 and sur1_tr4) expressed VSGSupersur. The clones that expressed 
VSGSupersur exhibited an increased IC50 to suramin (Figure 4B), which was significant for 
clone sur1_tr4. This finding re-emphasizes the importance of VSGSur in suramin resistance, 
and it may provide useful information for identifying potential interaction partners. 
However, we still have not learned anything about the target(s) of suramin. 
 








Figure 4. Genetic exchange of VSGSur with VSGSupersur at the active expression site of T. b. 
rhodesiense STIB900_c1_sur1. (A) Construct used for the VSGSur replacement, deviations 
between VSGSupersur and VSGSur are shown in light red within the VSGSupersur sequence. Arrows 
represent primer binding sites for the amplification of the construct. The construct was framed 
with the 5’ and 3’ UTR of VSGSur used for the homologous recombination, it contains a 
blasticidine resistance gene (BSD), an αβ tubulin splice site (αβ tub) and the coding sequence of 
VSGSupersur. (B) 50% inhibitory concentrations of the transfected clones and the parent strain 
sur1. The pseudoclones sur1_tr1 and sur1_tr2 do still express VSGSur and the pseudoclones 
sur1_tr3 and sur1_tr4 express VSGSupersur. The boxplots represent median +/- quartiles, the mean 
is plotted as a black rectangle. Significant differences between the cell lines are indicated (* = p 
>0.05; ** = p>0.01; *** = p>0.001, Tukey multiple comparisons test). 




5.3.5. Transcriptomics identifies overexpressed genes in suramin-resistant lines 
The transfection experiments demonstrated that VSGSupersur, while contributing to enhanced 
suramin resistance, could not account for the resistance factor of 1000 observed in the most 
resistant T. b. rhodesiense line as compared to the sensitive c1 line (Table 1). Indeed 
replacement of VSGSur with VSGSupersur elevated the IC50 ~2.5-fold whereas the IC50 
increased ~9-fold from the sur1 to the s1e line. Furthermore the line s1b showed already an 
increase in IC50 as compared to the sur1 line, whereas the expressed VSG remained the 
same. Therefore there must be additional modifications of gene expression or mutations that 
alter suramin sensitivity. To obtain a global picture on differentially expressed genes 
between the T. b. rhodesiense lines, we performed RNA-Seq on mRNA from cultures in the 
absence of suramin. As control strains we included the c1 and sur1 lines. The experiment 
was performed in triplicates from independent cultures to increase sensitivity (as compared 
to the first study [277]; Chapter 3). 
A first comparison of the sensitive c1 line with the sur1 line confirmed the 
expression switch from VSG900 to VSGSur (Figure 5A). Four additional genes showed up as 
significant hits, all of them were VSGs with low expression levels. Inspection of the mapped 
data in the integrative genomics viewer revealed that only fragments of the genes were 
covered with mapped reads with a large number of mismatches. Both indicate that the reads 
derived from one or more VSG, not present in the database, and that they were expressed by 
a very small proportion of the trypanosomes. Three of the hits were expressed in the 
sensitive c1 strain with low expression levels. One hit was expressed by the resistant sur1 
line, but the expression level was negligibly low with 6-20 mapped reads. The genes that 
were not significantly differentially expressed despite a large fold-change, showed a high 
degree of variance in the sensitive c1 line.  
A comparison of the s1b with the sur1 line resulted in a larger number of 
significantly differentially expressed genes, most of them unregulated in the higher resistant 
s1b line (Figure 5B). Again all of them were VSGs, notably one putative VSG pseudogene, 
Tb927.9.1070, showed a high expression in the resistant s1b line. This indicates that further 
alterations of the VSG expression had taken place during the course of selection towards the 
higher resistant strains. But compared to the expression level of VSGSur the transcript 
abundance of all the differentially expressed VSGs was still much smaller.  
The largest number of differentially expressed genes was detected between line s1e 
and s1b (Figure 5C), which was to be exptected given the long selection period (Figure 1). 




The genes with a high expression and a large fold-change were all VSG genes or 
expression-site associated genes (ESAG). Additionally, a total of 85 genes not related to 
VSGs were significantly differentially expressed, out of which 45 were upregulated and 40 
were downregulated in the highly resistant s1e line as compared to the s1b line 















Figure 5. Alterations in gene expression associated with increased suramin resistance  
Pair-wise comparison of the gene expression between the four T. b. rhodesiense lines as analyzed 
with DESeq2[270]. The x-axis represents the number of reads mapped per transcript; the y-axis 
the log2-fold change in transcript abundance between the compared lines. Transcripts with an 
adjusted p-value<0.05 are plotted in colour: VSG genes and pseudogenes in red; expression-site 
associated genes in orange and other differentially expressed genes in blue. (A) comparison of the 
suramin sensitive c1 line with the resistant sur1 line; (B) comparison of the sur1 with the s1b line; 
(C) comparison of the s1b with the s1e line.  
 
Table S1A: Genes overexpressed in the highly suramin resistant s1e line as compared to the s1b 







FM162580_gene5 130 6.18 2.74E-36 ESAG2 
FM162580_gene7 105 6.16 1.46E-29 ESAG1 
Tb927.2.1380 1278 1.68 2.30E-13 leucine-rich repeat protein (LRRP), putative 
Tb927.9.11580 1511 0.75 8.18E-09 glycosomal membrane protein 
FM162567_gene11 49 1.97 6.55E-08 ESAG11 
Tb10.v4.0058 24 5.19 2.53E-07 Noncoding RNA, putative 
FM162576_gene1 31 2.38 3.48E-07 ESAG7 
FM162581_gene9 29 2.45 9.50E-07 ESAG2 




Tb927.11.16180 23 3.05 1.16E-06 hypothetical protein 
Tb927.9.3260 663 0.73 2.43E-06 hypothetical protein 
FM162577_gene3 18 5.17 6.10E-06 ESAG3 
FM162578_gene7 21 6.01 7.96E-06 ESAG1 
FM162567_gene6 61 1.30 7.05E-05 ESAG4 
Tb927.9.7770 1543 0.46 8.25E-05 spermidine synthase 
Tb11.v5.0495 149 1.54 0.0001 retrotransposon hot spot (RHS), putative 
Tb927.4.220 21 2.37 0.0002 
retrotransposon hot spot protein 2 (RHS2), 
interrupted, degenerate 
Tb927.2.960 61 1.41 0.0002 hypothetical protein 
Tb11.v5.0712 108 1.09 0.0003 calcium-transporting ATPase, putative 
Tb927.6.2200 1644 0.38 0.0007 DJ-1 family protein, putative 
FM162581_gene11 127 0.99 0.0007 ESAG1 
Tb927.6.210 95 1.14 0.0008 
leucine-rich repeat protein (LRRP, pseudogene), 
putative 
Tb927.1.3760 74 1.17 0.0010 hypothetical protein, conserved 
Tb927.2.5710 12 3.55 0.0011 hypothetical protein 
FM162577_gene4 10 4.36 0.0016 ESAG4 
Tb10.v4.0059 7 6.36 0.0017 chrX additional, unordered contig 
Tb927.2.4930 1096 0.36 0.0026 esterase, putative 
Tb927.7.2640 1382 0.35 0.0029 cytoskeleton associated protein, putative 
Tb927.11.12100 1154 0.41 0.0037 protein tyrosine phosphatase, putative 
FM162577_gene1 15 2.60 0.0041 ESAG6 
Tb927.2.1344 25 1.83 0.0043 
retrotransposon hot spot protein 1 (RHS1), 
interrupted 
FM162578_gene5 11 3.66 0.0045 ESAG2 
FM162576_gene2 14 2.98 0.0057 ESAG6 
Tb927.8.1990 4663 0.28 0.0066 peroxidoxin 
Tb927.8.5470 4175 0.42 0.0081 flagellar calcium-binding 24 kDa protein 
Tb927.2.1120 420 0.60 0.0085 
retrotransposon hot spot protein 4 (RHS4), point 
mutation 
Tb927.8.3530 11052 0.27 0.0087 
glycerol-3-phosphate dehydrogenase [NAD+], 
glycosomal 
Tb927.11.6210 1905 0.32 0.0132 Lanosterol 14-alpha demethylase 
Tb927.8.6110 2879 0.32 0.0132 
3-hydroxy-3-methylglutaryl-CoA synthase, 
putative 
FM162578_gene1 23 1.78 0.0143 ESAG6 
Tb927.8.2850 389 0.57 0.0146 Poly(A)-specific ribonuclease PARN-1 
Tb927.10.10220 65 0.95 0.0169 procyclin-associated gene 2 (PAG2) protein 
Tb927.8.5460 991 0.50 0.0169 Flagellar calcium-binding 44 kDa protein 
Tb927.3.4020 560 0.66 0.0184 phosphatidylinositol 4-kinase alpha, putative 
  




Tb927.4.5100 1173 0.36 0.0187 
Endoplasmic Reticulum-Golgi Intermediate 
Compartment (ERGIC)/Endoplasmic reticulum 
vesicle transporter, putative 
Tb927.7.1930 131 0.80 0.0188 nucleoside diphosphatase, putative 
Tb927.2.5040 668 0.39 0.0189 MORN repeat, putative 
Tb927.9.8450 1249 0.36 0.0250 UMP/CMP kinase 
Tb927.10.10610 2078 0.31 0.0284 protein tyrosine phosphatase, putative 
FM162577_gene0 32 1.91 0.0286 ESAG7 
Tb927.10.9550 37 1.32 0.0286 hypothetical protein 
Tb927.9.10650 688 0.42 0.0290 hypothetical protein 
Tb09.v4.0042 52 1.20 0.0309 
leucine-rich repeat protein (LRRP, pseudogene), 
putative 
Tb927.8.6390 2400 0.41 0.0309 lysophospholipase, putative 
Tb927.9.11230 1565 0.40 0.0309 calmodulin-like protein, putative 
FM162579_gene1 13 2.24 0.0325 ESAG6 
Tb927.4.230 236 0.57 0.0326 
DNA-directed RNA polymerase III subunit, 
pseudogene, putative 
Tb927.11.11410 983 0.57 0.0349 trans-sialidase, putative 
Tb927.3.2520 209 0.85 0.0349 ESAG1 protein, putative 
Tb927.4.1210 30 1.47 0.0392 hypothetical protein 
Tb927.7.7040 2802 0.51 0.0405 methylthioadenosine phosphorylase, putative 
Tb927.3.2530 248 0.76 0.0411 ESAG11, degenerate 
Tb927.8.5380 476 0.54 0.0426 ubiquitin fold modifier protein, putative 
Tb927.9.800 5 4.78 0.0438 
UDP-Gal or UDP-GlcNAc-dependent 
glycosyltransferase, putative 
 








Tb927.10.12360 1008 -1.03 1.18E-28 hypothetical protein, conserved 
Tb927.10.12520 1401 -1.16 2.05E-27 hypothetical protein, conserved 
Tb927.10.12470 1184 -1.08 9.16E-25 hypothetical protein, conserved 
Tb927.10.12380 1036 -0.91 3.63E-20 chaperone protein DnaJ, putative 
Tb927.10.12290 874 -0.91 1.01E-17 
UDP-Gal or UDP-GlcNAc-dependent 
glycosyltransferase, putative 
Tb927.10.12350 443 -1.06 2.66E-17 hypothetical protein, conserved 
Tb927.10.12310 1259 -1.08 1.18E-15 helicase-like protein 
Tb927.10.12490 1941 -1.09 1.26E-14 kinesin, putative 
Tb927.10.12440 718 -1.01 2.12E-13 kinesin, putative 
Tb927.10.12430 909 -1.03 4.19E-13 Noc2p family, putative 




Tb927.10.12370 1119 -1.07 9.27E-13 gamma-glutamylcysteine synthetase 
Tb927.10.12500 650 -1.02 4.08E-11 P-type H+-ATPase, putativ 
Tb927.10.12550 293 -0.94 2.45E-10 hypothetical protein, conserved 
Tb927.10.12320 522 -0.93 2.50E-10 hypothetical protein 
Tb927.10.12390 866 -0.97 1.35E-09 hypothetical protein, conserved 
Tb927.10.12530 234 -1.28 1.18E-08 chaperone protein DnaJ, putative 
Tb927.10.12300 462 -0.91 1.45E-08 hypothetical protein, conserved 
Tb927.10.12480 465 -0.92 1.58E-08 UAA transporter family, putative 
Tb927.10.12420 307 -0.88 8.80E-08 predicted S. cerevisiae Got1 homologue 
Tb927.10.12400 609 -0.95 1.17E-06 membrane transporter protein, putative 
Tb927.10.12540 535 -0.95 2.64E-06 
NADH-ubiquinone oxidoreductase complex I 
subunit, putative 
Tb927.10.12460 440 -0.84 3.12E-06 Zinc finger, C3HC4 type (RING finger), putative 
Tb927.10.12450 148 -1.03 3.74E-06 SNARE domain-containing protein, putative 
Tb927.10.12410 1162 -0.73 3.05E-05 hypothetical protein, conserved 
Tb927.10.12340 86 -1.22 4.15E-05 hypothetical protein 
Tb927.10.12330 294 -0.65 0.0008 zinc finger protein family member, putative 
Tb927.8.1870 13936 -0.33 0.0011 Golgi/lysosome glycoprotein 1 
Tb927.8.8290 3688 -0.46 0.0017 amino acid transporter AATP5 
Tb927.5.1950 2838 -0.36 0.0047 hypothetical protein, conserved 
Tb927.5.3240 2475 -0.32 0.0068 hypothetical protein, conserved 
Tb927.7.2660 11468 -0.38 0.0087 zinc finger protein family member, putative 
Tb927.9.13380 6871 -0.34 0.0127 Autophagy-related protein 24 
Tb927.4.4570 2772 -0.34 0.0160 hypothetical protein, conserved 
Tb927.9.10770 27571 -0.36 0.0203 polyadenylate-binding protein 2 
Tb927.6.1020 4171 -0.38 0.0217 
cysteine peptidase, Clan CA, family C1, 
Cathepsin L-like 
Tb927.10.8940 25000 -0.28 0.0232 flagellum targeting protein kharon1, putative 
Tb927.8.7780 5667 -0.28 0.0240 hypothetical protein, conserved 
Tb927.10.13720 2584 -0.29 0.0367 RNA-binding protein 29, putative 
Tb927.10.5810 12756 -0.34 0.0399 The ARF-like 2 binding protein BART, putative 
Tb927.5.2600 1453 -0.31 0.0474 








5.3.6. Genomics identifies mutated genes in suramin-resistant lines 
To identify mutations such as nucleotide polymorphisms or short indels that had occurred 
during the selection for high-level suramin resistance, the mapped illumina RNA-Seq reads 
were screened for deviation from the T. b. brucei TREU927 reference genome. The dataset 
was filtered for mutations only present in the highly suramin-resistant s1b and/or s1e lines 
but not in the 100-fold resistant T. b. rhodesiense STIB900_sur1 and the sensitive parent 
clone STIB900_c1. Stringent filtering for the presence of the mutation in the three replicates 
per line and the absence thereof in the three replicates of STIB900_sur1 and STIB900_c1 
returned 30 candidate variants. These were scrutinized by inspection of the aligned 
sequencing reads in a genome browser. Stringent criteria were used to exclude false 
positives: We excluded (1) variants which laid within highly diverse regions with a low 
quality of the alignment, (2) variants within VSG genes and pseudogenes and (3) variants 
that were wrongly called due to small differences in allele frequencies. This left five 
candidate variants for suramin resistance, summarized in Table 2. 
 
Table 2. Mutations identified. Variants that were present in the highly suramin-resistant s1b and/or s1e lines 
and absent in the c1 and sur1 lines. The variants in Tb927.11.760 and Tb427.BES129.12 were only present 
in <30% of the sequencing reads (*). 
Gene ID Gene Name Mutation Effect s1b s1e 










expression site-associated gene 11 
Haplotype of 7 SNPs 












Uncharacterised ACR, YagE family 











5.3.7. RuvB-like helicase is a candidate intracellular target of suramin 
Of the five identified mutations (Table 2), the A to G transition in ruvB-like helicase 
(Tb927.4.1270) was the most interesting for different reasons: (1) it was non-synonymous; 
(2) it was heterozygous in T. b. rhodesiense line s1b and homozygous in s1e, the line with 
the highest degree of suramin resistance; and (3) it is an essential gene in T. brucei 
bloodstream form parasites. The mutation is non-synonymous, changing isoleucine312 to 
valine (Figure 6). Position 312 lies within the AAA+ ATPase domain, four residues after 
the ATP-binding Walker-B motif of the helicase [298–300]. Homology-based 
modeling [301] resulted in the best Global Model Quality Estimation score for a model 
based on the RuvB-like helicase derived from cryo-electron microscopy structure of the 
evolutionarily conserved core of the INO80 complex from the fungus Chaetomium 
thermophilum [302] with a coverage of 98% and a sequence identity of 69% (Fig. 6A). The 
second best hit was a model based on the homo-hexamer crystal structure of human 
RuvBL1 [300] with a coverage of 96% and a sequence identity of 63% (Fig. 6B). The 
change from isoleucine to valine may seem inconspicuous. However, we have performed 
whole genome sequencing of a suramin-resistant T. evansi field isolates and in one of them 
(Westry 2, [60]) and found isoleucine312 of the T. evansi ruvB-like helicase 
(TevSTIB805.4.1310) to be heterozygously mutated as well, in this case to leucine 
(Figure 6C). The helicase sequences of the reference genomes, T. evansi STIB805 and T. b. 
brucei TREU927, are identical. The isoleucine at position 312 is conserved across 
kinetoplastidae as seen in a comparative blast search using 10 adjacent amino acids. Thus 
the RuvB -like helicase is a promising candidate for an intracellular target that is relevant 
for the susceptibility of African trypanosomes to suramin. 
 













Figure 6. Amino acid substitution at position 312 of the RuvB -like helicase Tb927.4.1270 
(A) Monomeric and (B) hexameric structures based on homology modeling. The mutated residue at position 312 is marked with 
black circles. (C) Amino acid alignment of RuvB –like helicases. The reference sequences of T. brucei (TREU 927) and T. 
evansi (STIB 805) are identical. However, the suramin-resistant T. b. rhodesiense STIB900 derivative s1e and the suramin-
resistant T. evansi field isolate Westry2 both have acquired a point mutation at position 312. The mutation is absent in T. b. 
rhodesiense STIB900_c1 parent. 
 
  





We have previously shown that expression of VSGSur in T. brucei bloodstream forms causes 
100-fold resistance to suramin [277]; (Chapter 3 & 4). The finding that VSGSur, after 
selection for high-level resistance, expressed a mutated version of VSGSur that further seem 
to enhance suramin resistance, substantiates the role of VSGSur in suramin susceptibility. 
However, the link between VSGSur expression and suramin resistance is unlikely to be 
relevant for the treatment of human African trypanosomiasis. In fact, it might be the 
explanation why there are no problems with suramin resistance in the treatment of HAT, 
since trypanosomes locked to VSGSur expression would be eliminated by the adaptive 
immune system. Nevertheless, the established link between VSGSur and suramin resistance 
is of fundamental interest to the biology of T. brucei, since this is the first link between two 
main research areas in African trypanosomes: antigenic variation and drug resistance. Our 
discovery of VSGSupersur affirms this link. While the predominantly expressed VSG remained 
VSGSur respectively VSGSupersur mRNA sequencing revealed ongoing dynamics of the VSG 
expression during the selection process. The expression level of these VSGs was negligibly 
low compared to the expression levels of VSGSur and VSGSupersur, but the fact that some of 
them remained expressed after several months of selection indicates that their expression at 
least does not bare any fitness costs under suramin pressure as compared to cells expressing 
VSGSur. The nature of these VSGs and their effect on suramin sensitivity still remains to be 
investigated. 
 The highest resistant line, T. b. rhodesiense STIB900 s1e, was the only line that 
showed significant changes in expression of genes other than VSGs. A total of 18 ESAGs 
were differentially expressed, all of them upregulated. This could be explained by the 
ongoing dynamics of VSG expression or an expression-site switch to VSGSupersur. Even 
though we do not know whether VSGSupersur evolved through mutations of VSGSur or 
whether VSGSupersur was already present in the genomic archive and subsequently activated 
through a VSG switch.  
Of the differentially expressed genes other than ESAGs, five had been previously identified 
in a RIT-Seq screen for suramin resistance [42]: a Golgi/lysosome glycoprotein 
(Tb927.8.1870), an amino acid transporter (Tb927.8.8290), an autophagy-related protein 
(Tb927.9.13380), a cysteine peptidase (Tb927.6.1020) and the ARF-like 2 binding protein 




BART (Tb927.10.5810). In agreement with the RIT-Seq data, these genes were slightly 
downregulated in the line s1e. 
 Analysis of nucleotide sequence variations in the mRNA sequencing data yielded a 
manageable number of variants that presumabely arose during the selection process. The 
most promising candidate was the non-synonymous point mutation in the ruvB-like DNA 
helicase. It was absent in the original T. b. rhodesiense line of resistance factor 100, 
heterozygous when the line had reached a resistance factor of 350, and homozygous at a 
resistance factor of 1,100. In contrast to the situation with human African trypanosomiasis, 
there are substantial problems with suramin resistance in animal trypanosomiases, in 
particular in T. evansi-infected camels and water buffalos [60,61]. We performed whole 
genome sequencing of suramin-resistant T. evansi field isolates and in one of them found 
the same residue in the ruvB-like DNA helicase to be mutated as well. The amino acid 
substitution from isoleucine to valine, respectively leucine, is not a dramatic change. But 
isoleucine312 is highly conserved, therefore more dramatic changes might interfere with the 
functionality of the protein. Since Tb927.4.1270 is essential in T. brucei bloodstream 
form [303] an impaired functionality would most probably reduce viability of the parasites. 
This was not the case in our highly suramin-resistant T. b. rhodesiense lines as indicated by 
the absence of a growth phenotype. Interestingly, DNA helicase is a known antiviral target 
of suramin: DNA helicases of Dengue virus, Chikungunya virus and Zika virus have been 
validated as suramin targets [100,168,207]. Thus, we are confident that the forward genetic 
approach finally provided a promising intracellular candidate target for suramin action in T. 
brucei bloodstream form parasites.  




5.5. Material and Methods 
Trypanosoma spp. strains 
The T. b. rhodesiense STIB900 strain originates from a patient isolate collected from a male 
patient at St. Francis Hospital in Ifakara, Tanzania in 1982.  
The T. evansi Westry2 strain was isolated in 1995 from a camel in Sudan [60].  
Cultivation, selection and determination of the growth rate 
The T. b. rhodesiense parasites were cultivated in Iscove’s Modified Dulbecco’s Medium 
(Sigma) supplemented according to Hirumi [262] with 15% of heat-inactivated horse-
serum, at 37°C, 5% CO2. Initial selection was carried out for six days at 1050 nM suramin 
(Sigma). Further selection was carried out as shown in Fig 1 by step-wise elevation of the 
suramin concentration. Cells were kept at the respective suramin concentrations until they 
showed a close-to-normal growth phenotype, subsequently the suramin concentration was 
increased. 
For the determination of the growth rate, cells were incubated in standard growth medium at 
a concentration of 105 cells/ml, after 24 hours the cell density was quantified and the cells 
diluted back to 105 cells/ml. This procedure was repeated during four consecutive days.  
Drug sensitivity testing 
Drug sensitivities for suramin sodium salt (S2671, Sigma, now Merck), pentamidine 
isethionate (P0547, Sigma, now Merck), trypan blue (93590, Fluka, now Merck) and 
melarsoprol (Sanofi-Aventis/WHO) were evaluated with Alamar blue assays [15]. Serial 
drug dilutions were prepared with standard growth medium in a 96-well plate. The parasites 
were added to a final concentration of 2×104 cells/ml and incubated for 68 hours. 
Subsequently, resazurin was added to a concentration of 11.4 µg/ml and the plates 
incubated for 3-4 more hours. The fluorescence of viable cells was measured with a 
SpectraMax reader (Molecular Devices) and SoftMax Pro 5.4.5 Software. Fitting of the 
dose-response curves (non-linear regression model, variable slope; four parameters, lowest 









The four parasite strains (STIB900_c1, STIB900_sur1, s1b and s1e) were grown in parallel 
in the absence of suramin and RNA was isolated from ~107 cells during the exponential 
growth phase using the RNAeasy Mini Kit (Qiagen). DNA was removed either with an on-
column DNase treatment during RNA isolation or after isolation using a DNA-freeTM kit 
(Ambion). RNA was isolated three times, resulting in three technical replicates per strain, 
and kept at -80°C. 
RT-PCR and sequencing of VSG 
Complementary DNA (cDNA) was synthetized from 1-2.5 µg RNA using oligo(dT) primer 
and the SuperScript III Reverse Transcriptase (Invitrogen via Thermo Fisher Scientific). To 
amplify the predominantly expressed VSG, PCR was carried out with a forward primer 
binding to the spliced leader sequence (cgctattattagaacagtttctgtac) and a reverse primer 
binding to the conserved 15 nucleotides in the 3’UTR of VSG (gtgttaaaatatatc). After 
purification, the PCR product was directly sequenced with VSGSur-specific primer 
(agcaaaagaggggcctttttaataa, tcattcgtttggccatacgc, tctgggttcatatgcgctgc and 
ttactgacagacgaaccggc). 
Plasmid and transfection of trypanosomes 
The coding sequence of VSGSupersur was PCR amplified from cDNA of strain s1e using 
primers that contained XbaI respectively AscI restriction site overhangs 
(taatctagaatgcaagccgtaacacgc and aatggcgcgccttaaaaaagcaaaaatgcaagc). The VSG sequence 
within the pUC57 plasmid described before [277]; (Chapter 3 & 4) was cut out with XbaI 
and AscI. And the VSGSupersur coding sequence was cloned into the plamid backbone using 
the LigaFast™ Rapid DNA Ligation System (Promega) according to the manufacturers’ 
protocol. The resulting plasmid contained a construct that was framed with the 3’ and 
5’UTR of VSGSur and that contained a blasticidine resistance marker, an αβ tubulin splice 
site and the coding sequence of VSGSupersur. The construct was amplified by PCR and after 
clean-up (Macherey-Nagel), the PCR product was directly used for the transfection of the 
trypanosomes. A total of 4×107 cells were transfected with 5µg PCR product in bloodstream 
form transfection buffer [50] using program Z-001 of an Amaxa Nucleofector (Lonza). The 
transfectants were cloned by limiting dilution and after 24 hours, blasticidine was added to a 




concentration of 5µg/ml. After one week, four blasticidine resistant clones were recovered, 
their expressed VSG was analyzed by PCR and Sanger sequencing as described above. 
RNA-Sequencing and mapping of reads 
Sequencing libraries were prepared individually for the three technical replicates per line, 
using the TruSeq Stranded mRNA Library preparation kit (illumina). 126 nucleotide single-
end sequencing was carried out on an illumina HiSeq 2500. A combination of the TREU927 
reference sequence (TryTrypDB-38) with the Lister427 bloodstream expression sites and 
the sequences of VSG900 (GenBank accession MF093646) and VSGSur (GenBank accession 
MF093647) was used as a reference sequence. The quality of the sequencing reads was 
determined with fastqc [304] and untrimmed reads were mapped to the reference sequence 
with the Burrows-Wheeler Aligner [267] using the default settings. The sam-files were 
converted to bam-files using samtools [268] and sorted and indexed with picard [305]. 
Reads mapped per transcript were quantified with HTSeq [269] based on a gff-file that 
consisted of a combination of the TREU927 reference annotation (TryTrypDB-38), the 
annotation of the Lister427 bloodstream expression sites and the sequences of VSG900 and 
VSGSur. Differential gene expression analysis was carried out with the DESeq2 [270] 
package in R (cooks-cutoff and independent filtering disabled). 
Detection of variants 
The sorted bam-files of the aligned mRNA-Seq (STIB900) reads were further processed for 
the analysis of genomic variants. Read duplicates were marked and read group identifiers 
were added using picard. Variants were called with the gatk (version 4.0.7.0) 
haplotypecaller in gvcf-mode [306]. The individual g.vcf-files were combined using gatk 
combinegvcfs and genotyped using gatk genotypegvcfs. Variant annotation was calculated 
using snpEff (version 4.3T) based on a gff file consisting of the TREU927 reference 
annotation (TryTrypDB-38), the annotation of the Lister427 bloodstream expression sites 
and the sequences of VSG900 and VSGSur [307].  
DNA isolation, sequencing and mapping 
The T. evansi strains were propagated in a mouse and after heart puncture at high 
parasitemia, the trypanosomes were separated from the blood with a diethylaminoethyl 
cellulose column. The genomic DNA was isolated by chloroform/phenol extraction. 
Sequencing libraries were prepared using illumina’s KAPA Hyper Prep Kit and paired-end 




126 nt sequencing was carried out on an illumina HiSeq 2500. Raw sequencing reads were 
trimmed with trimmomatic [266] (removal of low quality bases and illumina adaptors) and 
mapped to the T. evansi reference genome TevansiSTIB805 (TriTrypDB-9.0) using bwa 
[267]. The sam-file was converted to a bam-file using samtools [268] and sorted and 
indexed using picard [305]. The aligned genome was visualized with the integrative 
genomics viewer [308,309]. 
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6. General discussion 
6.1. VSGs – more than immune evasion 
VSGs are the most abundant proteins of bloodstream-form trypanosomes; densely packed 
on the cell membrane, they cover the whole surface of the cell [310]. Up to more than 2000 
VSG genes and pseudogenes can be found in the genomic archive of trypanosomes [274] 
but due to allelic exclusion only one specific VSG is expressed at a certain time [311]. 
Transcription of VSG genes is driven by RNA polymerase I and takes place at the active 
bloodstream expression site [312]. Sporadic switching of the expressed VSG leads to 
antigenic variation and confers protection against the hosts’ immune response by escaping 
the adaptive immune system [311]. Have VSGs ever been attributed any functions other 
than immune escape? Even though it is thought that a VSG gene gave rise to the serum 
resistance associated gene, which confers protection of T. b. rhodesiense from the human 
trypanolytic factor, the resulting protein is a truncated version of a VSG and has lost the 
typical characteristics of VSGs [313,314]. At some point a VSG was identified to be 
associated with in vitro generated TLF1 resistance in T. b. brucei [315] but follow-up 
studies excluded its direct involvement in TLF1 resistance [316]. Thus, with VSGSur we 
describe for the first time a gene, which based on its sequence and high expression levels 
clearly encodes a VSG, that has an impact on the cell that goes beyond immune escape. The 
link between expression of VSGSur and the phenotype of suramin resistance and reduced 
substrate uptake is surprising and opens up a number of questions: How does VSGSur confer 
resistance? Is the uptake machinery affected and if yes, which part? Does VSGSur interact 
with other surface proteins? And finally, what are the features that make VSGSur so special?  
In the following I will discuss different possible hypotheses on how VSGSur could act on the 
cell and mediate the observed phenotype. 
(1) Reduced binding of suramin to its receptor 
One possibility how VSGSur could confer suramin resistance is through inhibition of 
suramin binding to its receptor. An unusual structure or multimeric state of VSGSur could 
sterically occlude the suramin receptor; even electrostatic forces could be involved since 
suramin is highly negatively charged. Do our data support such a hypothesis? 
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(i) Trypan blue: binding of trypan blue to the cell surface was similar in VSGSur and 
VSG900 expressing cells for concentrations below 400 µg/ml, and elevated at a 
concentration of 400 µg/ml (Chapter 3). We speculated about the presence of a 
high-affinity and a low-affinity receptor with impact of VSGSur only on the low-
affinity receptor. But we have to bear in mind, that the uptake of trypan blue was 
reduced already at the lower concentrations in VSGSur expressors, thus the uptake 
data cannot be fully explained by a reduced binding to a potential low-affinity 
transporter. Furthermore, the concentration at which VSG900 expressing cells 
showed an increase of trypan blue binding was very high and led to toxicity, 
which could have biased the results and led to a higher fluorescence (since 
trypan blue permeates dead cells). A similar experiment in 2T1 with shorter 
incubation times did not show any difference in trypan blue binding between 
VSGSur and VSG221 expressing cells even at the highest concentration 
(Wiedemar, data not shown). Thus, I conclude that the reduced trypan blue 
uptake is not mediated by a reduced binding. Of course, experiments with trypan 
blue only give us a proxy for the situation with suramin; trypan blue is smaller 
than suramin and it bears four negative charges, in contrast to suramin with six 
negative charges. But the fact that VSGSur expressing cells showed cross-
resistance to trypan blue and a reduced uptake makes it likely, that the effect of 
VSGSur on trypan blue binding and uptake is comparable with the effects on 
binding and uptake of suramin. 
(ii) Transferrin and LDL: VSGSur did not only have an effect on the uptake of 
suramin but also on the uptake of LDL and transferrin. Is it possible that the 
changes of the VSGSur structure are that massive, that the VSG not only occludes 
the suramin receptor but also the transferrin and the elusive LDL receptor?  
The transferrin receptor is an ESAG6/7 heterodimer [317], and structural 
analysis showed that it does not extend above the densely packed VSG-layer 
[318]. If the VSG surmounts and mantels the transferrin receptor, it is 
conceivable that structural and/or electrostatic changes of the VSG could indeed 
have an effect on the binding of transferrin to its receptor. I did perform binding 
assays, which showed a certain decrease of cell associated LDL and transferrin 
in VSGSur expressing cells. But the decrease was not big enough to explain the 
reduced uptake of both substrates. Furthermore, the difference might as well 
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have been a technical bias: Endocytosis happens very fast [319], and thus the 
very high concentrations of substrates used in the binding assay would quickly 
lead to an increase of intracellular fluoresce of VSG221 expressing cells if just 
very little endocytosis had taken place. 
(iii) TLF1: There was no difference in TLF1 uptake between VSGSur and VSG221 
expressing cells. Under the above hypothesis this would mean, that VSGSur does 
not prevent binding of TLF1 to the HpHb receptor. Indeed structural analysis of 
the HpHb receptor showed, that the receptor surmounts the VSGs [320]; this 
makes it plausible, that a potential abnormal VSG has less of an effect on such a 
long protein. 
All in all, the hypothesis of a VSGSur mediated reduced receptor binding alone seems to be 
rather unlikely but it cannot be completely excluded based on our data. The one key 
experiment that once and for all clarifies this question would be a binding experiment with 
radiolabeled suramin, preferentially carried out in a cold-room to guarantee absence of any 
endocytosis. 
 (2) Altered movement and localization of surface proteins 
VSGs circulate very quickly; they move over the trypanosome surface to the flagellar 
pocket where they are endocytosed, sorted, and subsequently recycled to the cell surface via 
the flagellar pocket. This whole process happens within only 12 minutes [261]. The speed at 
which VSGs are able to diffuse over the cell surface depends on the size of the VSG [321] 
and its glycosylation [322]. Recently, it was shown that a flexible part between the C- and 
N-terminal domain of the 3D structure allows VSGs to adopt two different conformations 
that influence the speed of VSG movement [323]. It was even proposed that this flexibility 
allowed VSGs to slide over trans-membrane proteins [323]. Currently it is not known how 
the movement and localization of other surface proteins are regulated [324]. But one could 
speculate that their localization and transport to the flagellar pocket is driven or influenced 
by the fast movement of the dense VSG coat. Under such a scenario, it would be plausible 
that an atypical 3D structure, multimeric state, glycosylation or flexibility of VSGSur could 
influence the diffusion rate of the VSG itself. The movement and localization of other 
surface proteins could be influenced either indirectly through modified VSG kinetics or 
directly by changing VSG-protein interactions. 
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How is such a hypothesis to be assessed in view of our data? 
(i) ISG75: We did not observe any alterations in ISG75 turnover (half-life). But it is 
likely that ISG75 is recycled back to the cell surface after endocytosis [325], 
therefore we do not know whether the endocytosis rate correlates with the 
turnover rate. We cannot exclude that the movement of ISG75 from the cell 
surface [326] to the flagellar pocket is somehow hampered by VSGSur. 
(ii) Transferrin: The transferrin receptor is already located in the flagellar 
pocket [327] and does not have to be trafficked over the cell surface to the site of 
endocytosis. The VSG is not only endocytosed but also exocytosed at the 
flagellar pocket, and subsequently moves back to the external cell surface. With 
all this bidirectional movements of VSGs within the flagellar pocket, it is 
possible that a VSGSur with an unusual structure or kinetics has a secondary 
effect on location and micro-movement of the transferrin receptor as well. 
(iii) Concanavaline A: Measurement of the ConA uptake showed that VSGSur is 
endocytosed at a level not much lower than VSG221. Still there seems to be a 
small difference, especially if the increased ConA binding to VSGSur is taken 
into account. This could be derived from alterations of VSG kinetics.  
(iv) TLF1: The sensitivity to TLF1 was unchanged upon expression of VSGSur. This 
could be explained by a lack of interaction of the HpHb receptor with the VSGs 
due to the long and slender conformation of the HpHb receptor [320]. 
All in all, the suggested hypothesis is rather speculative, but based on our data it is a 
plausible scenario. Testing this hypothesis would be experimentally challenging. To have a 
first idea one could look at the surface localization of the transferrin receptor by 
fluorescence microscopy: Mislocalized ESAG6/7 outside of the flagellar pocket would 
indicate an influence of VSGSur on the movement and localization of surface proteins. But 
such conclusions have to be drawn with caution, as mislocalization of ESAG6/7 can also be 
a secondary effect of iron starvation (even though that was shown to be associated with 
ESAG6/7 overexpression, which was not the case in our RNA-Seq data) [328]. To 
comprehensively investigate the hypothesis one would have to monitor surface movements 
of the proteins in real time. This is highly challenging, but it is possible and has been done 
with VSGs [261]. Further, crystallography of the VSGSur structure could reveal potential 
alterations of the flexible part, which would suggest an effect on surface movement (or 
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possibly also endocytosis). A third way to find evidence for the suggested hypothesis would 
be to seek for binding partners of VSGSur and VSG221; if surface proteins indeed bind to one 
but not the other, this would be a strong indication for interactions on the cell surface. 
(3) Alteration of the endocytic system 
A third hypothesis is a specific defect of the endocytosis apparatus that only affects certain 
surface proteins. In bloodstream-form trypanosomes, surface proteins, notably VSG and the 
transferrin receptor, are endocytosed at a very high rate [261,319]. This not only allows the 
parasite to efficiently take up the required nutrients, but it supports evasion of the immune 
system, since antibodies bound to VSGs are intracellularly cleaved off and the VSG 
recycled to the cell membrane [261,329]. Endocytosis and exocytosis exclusively take place 
at the flagellar pocket, which is located at the posterior end of the trypanosomes. After 
endocytosis, the different surface proteins localize to different endosomal compartements: 
VSG and the transferrin receptor (both GPI-anchored proteins) are located in early Rab5A 
endosomes, while the transmembrane protein ISG100 localizes to Rab5B endosomes [330]. 
This led to the hypothesis that Rab5A confers endosomal traffic of GPI-anchored proteins. 
In the endosomal compartement, the proteins are sorted and either directed to the lysosome 
or recycled back to the flagellar pocket via Rab11 endosomes [329]. A VSG with an 
unusual structure could interfere with this system; if, for example, intracellular traffic and 
sorting were somehow hampered or modified by VSGSur, this could have an effect on the 
whole endocytosis apparatus and lead to miss-trafficking or mislocalization in the 
endosomal compartment. 
Do our results support this hypothesis? 
(i) General endocytosis: The VSGSur expressing cells did not show a big-eye 
phenotype (enlargement of flagellar pocket that is usually seen in trypanosomes 
with a general endocytosis-defect). Further, their viability and growth rate was 
comparable to VSG221 and VSG900 expressing parasites (even though, in certain 
media their growth was reduced to some extent; Wiedemar and Zwyer, 
unpublished). Based on these data we can exclude a general endocytosis defect, 
but not a defect that only affects certain parts of the endocytosis apparatus. 
(ii) The uptake of transferrin was highly reduced while the uptake of ConA was not 
strongly altered. Both, the transferrin receptor and the VSG (that mediates ConA 
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uptake) localize to Rab5A endosomes. Furthermore, the uptake of TLF1, and 
thus the endocytosis of the HpHb receptor, was not reduced. If the assumption 
were true that Rab5A endosomes confer trafficking of all GPI-anchored proteins, 
the HpHb receptor would also be localized to the Rab5A compartment. In this 
case, there would be at least three surface proteins located to the Rab5A, out of 
which some are affected by expression of VSGSur and others are not. Thus, we 
cannot narrow down the phenotype on a general defect of Rab5A-mediated 
transport. 
Even though our data does not prove a specific endocytosis defect, it is a plausible scenario 
that an altered endocytosis apparatus, leading to mislocalization of proteins within the 
endosomal compartement, would cause such an endocytosis defect. To experimentally 
address this hypothesis, immune fluorescence microscopy could be useful: co-staining of 
different parts of the endosomal compartment (Rab5A, Rab5B, Rab11) with different 
substrates (transferrin, ConA, LDL) and receptors (ISG75) could identify alterations and 
mislocalizations in the endocytic system. 
Conclusion 
In summary, I propose three main hypotheses on how VSGSur could lead to suramin 
resistance and the uptake defect. VSGSur could act on the level of binding, on surface 
transport, or on the endocytic system. It might also be a combination of the hypothesized 
mechanisms that leads to the observed phenotype. Based on our data we can conclude that 
VSGs can indeed influence processes beyond the well-studied topic of immune evasion, and 
that they might interact with other surface proteins and/or influence the endocytic system. 
This brings us to the next question: What are the special features of VSGSur allowing such 
an impact on the cells? 
Structural peculiarities of VSGSur 
Even if we presently cannot name them, there must be some unusual structural features in 
VSGSur. VSGs, which usually form homodimers [331], have their N-terminal domain 
exposed to the surface and their C-terminal domain attached to the cell membrane through a 
GPI-anchor [332,333]. They can bear different numbers of C- and N-glycosylation 
sites [334]. Based on the cysteine residues in the N- and C-termini, VSGs can be classified 
in different groups [335]. The number and positions of cysteines implies that VSGSur is a 
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typical A2 type VSG, and preliminary computational models have not shown any 
abnormalities of the 3D structure compared to other VSGs (Wiedemar & Zoltner, 
unpublished). But even if they are subtle, there must be some peculiar structural features 
within the 3D structure, glycosylation and/or multimeric state of VSGSur. A recently 
discovered additional O-glycosylation site on top of certain VSGs was associated with 
alterations of the 3D structure and the multimeric state [336]. Similar changes of VSGSur 
could possibly carry out the observed phenotype. Indeed, VSGSur contains a cysteine-
flanked loop with a threonine at position 164 similar to what was described by Pinger et al 
[336]. Interestingly, preliminary investigations of the multimeric state using blue-native gels 
indicate that VSGSur indeed forms a higher multimeric state than the classical dimer 
(Wiedemar & Zoltner, unpublished). Thus, hopefully, we will be able to identify the 
structure of VSGSur by further experiments like crystallography and size-exclusion 
chromatography. Another way to narrow down the parts of the VSGSur that are causal for 
the phenotype would be to investigate mutant and chimeric VSGs. The VSGSupersur mutant is 
a first step in that direction; if the enhancement of resistance in VSGSupersur expressing cells 
can be confirmed, this could depict structural key positions mediating the alterations. 
Additionally, one could systematically produce chimeras of VSGSur and VSG221, starting 
with a pair of chimeras that bear the VSGSur N-terminal domain and the VSG221 C-terminal 
domain and vice versa. 
6.2. What do we learn about suramin uptake? 
Based on the observation that ISG75 knock-down led to suramin resistance and reduced 
binding of suramin to the cell surface [42], it was proposed that ISG75 acts as the suramin 
receptor in T. brucei. But failure to show direct binding of suramin to ISG75 in vitro 
(unpublished data Martin Zoltner [337]) indicates the presence of additional factors 
involved in suramin binding. Our data are in agreement with a suramin uptake model that 
involves ISG75: The ISG75 knock-down experiments with VSG221 expressing cells showed 
a similar decrease in suramin susceptibility as observed by Alsford et al [42] and an even 
larger effect in VSGSur expressors. Even though the ISG75 turnover (half-live) was 
unchanged, a VSGSur-mediated defect of suramin binding, trafficking and/or endocytosis via 
ISG75 is basically possible. Concurrently we have made the following observations that 
indicate the presence of additional factors:  
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a) ISG75 knock-down had as stronger effect on VSGSur expressing cells than on the 
VSG221 expressing parent. Thus, ISG75 is even more important for suramin 
uptake in VSGSur expressing cells while for VSG221 expressing cells there might 
be an additional receptor or pathway involved. 
b) Suramin sensitivity (and thus suramin uptake) was enhanced in the presence of 
LDL in VSG221 but not in VSGSur expressing cells (similar results in VSGSur and 
VSG900 expressing T. b. rhodesiense STIB900 cells confirmed this finding; 
Wiedemar & Cal, data not shown). 
c) Suramin reduced LDL uptake in VSG221 but not in VSGSur expressing cells. This 
observation at first glance seems to contradict b), but it is in agreement with the 
literature [59] and points out the presence of an interdependence of suramin and 
LDL uptake. 
Together, these three observations indicate the presence of two suramin receptors. One 
receptor (RSur) binds free suramin; it is or it involves ISG75. The other receptor binds 
suramin in complex with LDL (RLDL_Sur). LDL was proposed to bind to two receptors; a 
high affinity and a low-affinity receptor [296]. I suggest that RLDL_Sur is one of these LDL 
receptors. If the uptake of suramin-LDL by RLDL_Sur is less efficient than the uptake of LDL 
alone, this would explain the inhibitory effect of suramin on LDL uptake. If we assume that 
VSGSur completely abrogates the function of RLDL_Sur, while having only a minor effect on 
RSur (through the above suggested reduced binding, traffic or uptake), we could also explain 
observations a) and b). Based on this model, suramin uptake in VSGSur expressing cells 
would then only take place through the ISG75 involving RSur and be independent of LDL. 
Of course there are critical points challenging this model: upon addition of LDL to serum-
free medium we did not see any shift in IC50 of the VSGSur expressors. But should they not 
take up less suramin if part of the suramin is bound to LDL? Possibly, but not necessarily: 
the LDL levels used in the assay were rather low and might just confer a small decrease of 
the unbound suramin pool.  
What about other models; could VSG itself act as a suramin receptor? In the course of my 
studies this was actually the first hypothesis we had. It could go in both directions: (i) All 
VSG confer suramin binding except for VSGSur; or (ii) VSGSur is the only VSG that confers 
suramin binding. In scenario (ii) one could further speculate that due to a binding of 
suramin to VSGSur, it does not bind to its usual receptor and is, after endocytosis, 
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exocytosed together with VSGSur. In my opinion, such models seem rather unlikely in the 
meantime because they do not provide any explanation of the highly reduced uptake of 
transferrin and LDL. 
Taken together, the effects of VSGSur are not simple and cannot easily be explained. VSGSur 
has a direct or indirect influence on different surface proteins. For suramin uptake itself, I 
propose a new model that includes two receptors: RSur involves ISG75 and confers uptake 
of unbound suramin; RLDL_Sur is one of the LDL receptors and confers uptake of suramin in 
complex with LDL. 
6.3. Helicase – a potential target of suramin in T. brucei 
In light of the many enzymes that can be inhibited by suramin (Chapter 2), it is likely that 
the cytotoxic action in T. brucei cannot be narrowed down to one single target but is carried 
out through a combination of different inhibitory effects. Nevertheless, we can assume that 
these various targets are not equally suramin sensitive, and that their inhibition is not 
equally harmful to the trypanosome. Thus, it is likely that there is a major target, mutation 
or upregulation of which can confer a certain degree of suramin resistance. With the RuvB-
like helicase (Tb927.4.1270) we might have identified this target. The fact that the 
isoleucin312 to valine (I312V) mutation in the RuvB-like helicase was absent in the 
T. b. rhodesiense line STIB900 before suramin selection, then at first appeared 
heterozygously, and later-on turned homozygous while the parasites were selected for 
higher and higher suramin resistance, is a strong indication that the mutation confers 
resistance. Theoretically, such a shift from wildtype to heterozygous to homozygous could 
as well be a hitchhiking effect and the real cause of resistance genetically linked to the 
mutated RuvB-like helicase. But, for the following reasons, we have strong indications that 
the mutation itself causes suramin resistance: 
a) There were no other mutations on that chromosome or elsewhere in the 
transcriptome that showed such a shift from wildtype to heterozygous to 
homozygous. 
b) The very same residue of RuvB-like helicase was found to be mutated in a 
completely independent parasite, which even belongs to another subspecies: a 
suramin-resistant field isolate of T. evansi.  
c) The mutated residue is highly conserved among kinetoplastids and beyond. 
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d) Suramin inhibits viral helicases already at nanomolar to low micromolar 
concentrations [100,168,207].  
RuvB-like helicases are involved in transcription activation via chromatin remodeling and 
removal of histone modifications, in DNA damage repair, oncogenesis and production of 
small nuclear ribonucleoproteins [299]. They also affect mitosis as they act on the 
replication fork and the spindle apparatus through interactions with microtubules [299] with 
an impact on chromosomal alignment and segregation [338]. They were further shown to 
bind to Holliday junctions [339] and might thus catalyze branch migration at the sites of 
homologous recombination, as do their bacterial orthologues [340]. RuvB-like helicases are 
also involved in telomere maintenance through interactions with telomere reverse 
transcriptase [341]. The activity of RuvB-like helicase is dose-sensitive, and heterozygous 
gene loss leads to haploinsufficiency in yeast [339]. Could an inhibition of the RuvB-like 
helicase confer the cytotoxic activity of suramin in T. brucei?  
In sight of the above described functions of RuvB-like helicases, an inhibition of the 
enzyme might lead to problems in transcription, replication and mitosis, with an onset of 
drug action within the first cell cycle, thus within a couple of hours in the quickly dividing 
T. brucei. Indeed, if T. brucei is exposed to suramin, onset of action can be seen after five 
hours [249]. Recent studies showed an elevated proportion of T. brucei cells with more than 
two nuclei after suramin exposure for 24 hours, which indicates a cytokinesis defect with 
maintained mitosis [34]. One could speculate that such a phenotype is mediated through an 
inhibitory effect of suramin on the interaction of RuvB-like helicase with microtubules, 
which play a role in cytokinesis [342].  
If the RuvB-like helicase is indeed a target, how could the identified mutations I312V in the 
lab-selected T. b. rhodesiense and I312L in the resistant T. evansi field isolate confer 
protection from suramin? 
The T. brucei RuvB-like helicase is an essential enzyme in bloodstream-form T. brucei 
[303], thus any nonsynonymous SNP must preserve helicase function. RuvB-like helicases 
can be present as monomers or as hexameric rings [299]. They contain three different 
domains: Domain I confers ATP binding, domain III, which is in close proximity to domain 
I, caps the ATP binding site, and domain II mediates binding to nucleic acids [300]. The 
mutated isoleucine is located within the second subunit of domain I, four residues after the 
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Walker B motif, which is thought to be responsible for ATP hydrolysis [300]. For the Zika 
virus helicase, 3D modeling indicated binding of suramin either to the ATP binding site or 
the RNA binding site [100]. If suramin binds to the ATP binding site in the T. brucei RuvB-
like helicase, the I312V substitution could protect from suramin action by an impairment of 
suramin binding. If suramin binds to and inhibits the nucleic acid binding site, the I312V 
amino acid exchange might not interfere with suramin binding directly as it is located 
elsewhere, in domain I close to the ATP binding site. But it might increase the activity of 
RuvB-like helicase and even out the inhibitory suramin action to some extent. This would 
not completely antagonize the action of suramin, but might lead to some degree of 
resistance as observed in the T. b. rhodesiense cells with the mutated RuvB-like helicase. 
To sum up, we have strong indications that the identified RuvB-like helicase is an 
intracellular target for suramin in T. brucei. To challenge this hypothesis I am currently 
performing reverse genetic experiments and introducing the mutated allele in wildtype and 
heterozygously mutated T. brucei cells. The outcome of these experiments will hopefully 
provide a clear answer and show whether I312V in T. brucei RuvB-like helicase indeed 
confers suramin resistance.  
6.4. Final conclusion 
Through analysis of the transcriptome of suramin-resistant T. b. rhodesiense cells, I have 
discovered a new variant surface glycoprotein, VSGSur, expression of which causes suramin 
resistance and a reduced uptake of different substrates. Even though the exact impact of 
VSGSur on suramin uptake is not yet fully understood, these results revealed a new 
mechanism, which is the first link between antigenic variation and drug resistance. The 
discovery of VSGSur even raises questions that go beyond the research area of drug 
resistance and affect fundamental biology of trypanosomes and the function of VSGs in 
general. 
With the RuvB-like helicase, I further identified a previously unknown candidate target for 
suramin action in T. brucei. If the described mutation in the RuvB-like helicase indeed leads 
to resistance, this will be the first observation of drug resistance mediated by an altered drug 
target in T. brucei. 
All in all, the results of this PhD thesis increase our knowledge on drug resistance in 
T. brucei by adding two new potential resistance mechanisms (Fig 1). I hope that this new 
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knowledge will provide a better understanding of drug uptake and drug action, which will 




Figure 1: Mechanisms of drug resistance in T. brucei. Two new resistance mechanisms against 
suramin are added compared to Figure 3 of Chapter 1: The VSGSur-mediated resistance, which is an 
alteration of the uptake system; and the mutation in RuvB-like helicase, which could potentially be a 





1.  Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug 
resistance. Viruses. 2014;6: 4095–4139. doi:10.3390/v6104095 
2.  Gross M. Antibiotics in crisis. Curr Biol CB. 2013;23: R1063-1065.  
3.  Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of 
antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 
2017;17: e383–e392. doi:10.1016/S1473-3099(17)30316-X 
4.  Vanaerschot M, Huijben S, Van den Broeck F, Dujardin J-C. Drug resistance in 
vectorborne parasites: multiple actors and scenarios for an evolutionary arms race. 
FEMS Microbiol Rev. 2014;38: 41–55. doi:10.1111/1574-6976.12032 
5.  Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and 
drug resistance. Breast Cancer Res BCR. 2014;16: 209. doi:10.1186/bcr3621 
6.  Morrone LA, Scuteri D, Rombolà L, Mizoguchi H, Bagetta G. Opioids Resistance in 
Chronic Pain Management. Curr Neuropharmacol. 2017;15: 444–456. 
doi:10.2174/1570159X14666161101092822 
7.  Allouche S, Noble F, Marie N. Opioid receptor desensitization: mechanisms and its 
link to tolerance. Front Pharmacol. 2014;5: 280. doi:10.3389/fphar.2014.00280 
8.  Wozniak A, Villagra NA, Undabarrena A, Gallardo N, Keller N, Moraga M, et al. 
Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with 
high and intermediate levels of carbapenem resistance in Chile. J Med Microbiol. 
2012;61: 1270–1279. doi:10.1099/jmm.0.045799-0 
9.  Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular 
mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13: 42–51. 
doi:10.1038/nrmicro3380 
10.  Alibert S, N’gompaza Diarra J, Hernandez J, Stutzmann A, Fouad M, Boyer G, et al. 
Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a 
pharmacodynamic perspective. Expert Opin Drug Metab Toxicol. 2017;13: 301–309. 
doi:10.1080/17425255.2017.1251581 
11.  Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22: 161–182, Table of 
Contents. doi:10.1128/CMR.00036-08 
12.  Gniadkowski M. Evolution of extended-spectrum beta-lactamases by mutation. Clin 
Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2008;14 Suppl 1: 11–
32. doi:10.1111/j.1469-0691.2007.01854.x 
13.  Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of 
isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol J 
Mol Epidemiol Evol Genet Infect Dis. 2016;45: 474–492. 
doi:10.1016/j.meegid.2016.09.004 
14.  Ando H, Kitao T, Miyoshi-Akiyama T, Kato S, Mori T, Kirikae T. Downregulation 




tuberculosis. Mol Microbiol. 2011;79: 1615–1628. doi:10.1111/j.1365-
2958.2011.07547.x 
15.  Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, Robicsek A, et al. qnrB, 
another plasmid-mediated gene for quinolone resistance. Antimicrob Agents 
Chemother. 2006;50: 1178–1182. doi:10.1128/AAC.50.4.1178-1182.2006 
16.  Palmer AC, Kishony R. Opposing effects of target overexpression reveal drug 
mechanisms. Nat Commun. 2014;5: 4296. doi:10.1038/ncomms5296 
17.  Ehrlich P. Chemotherapeutische Trypanosomen-Studien. Berliner klinische 
Wochenschrift. 1907;44: 310–314.  
18.  Ehrlich P. Address in Pathology, ON CHEMIOTHERAPY: Delivered before the 
Seventeenth International Congress of Medicine. Br Med J. 1913;2: 353–359.  
19.  Voegtlin C, Dyer HA, Miller DW. On Drug-Resistance of Trypanosomes with 
Particular Reference to Arsenic. J Pharmacol Exp Ther. 1924;23: 55–36.  
20.  Yorke W. DRUG-RESISTANCE. Br J Vener Dis. 1933;9: 83–97.  
21.  Wainwright M. Dyes, trypanosomiasis and DNA: a historical and critical review. 
Biotech Histochem Off Publ Biol Stain Comm. 2010;85: 341–354. 
doi:10.3109/10520290903297528 
22.  Lawson TL. Trypanosomiasis treated with “Pentamidine.” The Lancet. 1942;240: 
480–483. doi:https://doi.org/10.1016/S0140-6736(00)58164-1 
23.  Friedheim E a. H. Mel B in the treatment of human trypanosomiasis. Am J Trop Med 
Hyg. 1949;29: 173–180.  
24.  Steverding D. The development of drugs for treatment of sleeping sickness: a 
historical review. Parasit Vectors. 2010;3: 15. doi:10.1186/1756-3305-3-15 
25.  Burri C, Stich A, Brun R. Current Chemotherapy of Human African 
Trypanosomiasis. In: Maudlin I, Holmes PH, Miles MA, editors. The 
Trypanosomiases. CABI Publishing; 2004. p. 403.  
26.  Taelman H, Schechter PJ, Marcelis L, Sonnet J, Kazyumba G, Dasnoy J, et al. 
Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. 
Results in five patients. Am J Med. 1987;82: 607–614.  
27.  Iten M, Matovu E, Brun R, Kaminsky R. Innate lack of susceptibility of Ugandan 
Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). 
Trop Med Parasitol Off Organ Dtsch Tropenmedizinische Ges Dtsch Ges Tech 
Zusammenarbeit GTZ. 1995;46: 190–194.  
28.  Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus 
Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl 
Trop Dis. 2007;1: e64. doi:10.1371/journal.pntd.0000064 
29.  Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazué G, et al. 
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development 
for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4: e923. 
doi:10.1371/journal.pntd.0000923 
30.  Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R. Antitrypanosomal 




sleeping sickness. Antimicrob Agents Chemother. 2011;55: 5602–5608. 
doi:10.1128/AAC.00246-11 
31.  Deeks ED. Fexinidazole: First Global Approval. Drugs. 2019. doi:10.1007/s40265-
019-1051-6 
32.  Fairlamb AH, Henderson GB, Cerami A. Trypanothione is the primary target for 
arsenical drugs against African trypanosomes. Proc Natl Acad Sci U S A. 1989;86: 
2607–2611.  
33.  Worthen C, Jensen BC, Parsons M. Diverse effects on mitochondrial and nuclear 
functions elicited by drugs and genetic knockdowns in bloodstream stage 
Trypanosoma brucei. PLoS Negl Trop Dis. 2010;4: e678. 
doi:10.1371/journal.pntd.0000678 
34.  Thomas JA, Baker N, Hutchinson S, Dominicus C, Trenaman A, Glover L, et al. 
Insights into antitrypanosomal drug mode-of-action from cytology-based profiling. 
PLoS Negl Trop Dis. 2018;12: e0006980. doi:10.1371/journal.pntd.0006980 
35.  Rollo IM, Williamson J. Acquired resistance to “Melarsen”, tryparsamide and 
amidines in pathogenic trypanosomes after treatment with “Melarsen” alone. Nature. 
1951;167: 147–148.  
36.  Frommel TO, Balber AE. Flow cytofluorimetric analysis of drug accumulation by 
multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol Biochem 
Parasitol. 1987;26: 183–191.  
37.  Carter NS, Fairlamb AH. Arsenical-resistant trypanosomes lack an unusual adenosine 
transporter. Nature. 1993;361: 173–176. doi:10.1038/361173a0 
38.  Carter NS, Berger BJ, Fairlamb AH. Uptake of diamidine drugs by the P2 nucleoside 
transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol 
Chem. 1995;270: 28153–28157.  
39.  Mäser P, Sütterlin C, Kralli A, Kaminsky R. A nucleoside transporter from 
Trypanosoma brucei involved in drug resistance. Science. 1999;285: 242–244.  
40.  Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JC, Kaminsky R, et al. Genetic 
variants of the TbAT1 adenosine transporter from African trypanosomes in relapse 
infections following melarsoprol therapy. Mol Biochem Parasitol. 2001;117: 73–81.  
41.  Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, Wallace LJM, et al. Mechanisms 
of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot 
Cell. 2003;2: 1003–1008.  
42.  Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, et al. High-
throughput decoding of antitrypanosomal drug efficacy and resistance. Nature. 
2012;482: 232–236. doi:10.1038/nature10771 
43.  Graf FE, Ludin P, Arquint C, Schmidt RS, Schaub N, Kunz Renggli C, et al. 
Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. Cell 
Mol Life Sci CMLS. 2016;73: 3387–3400. doi:10.1007/s00018-016-2173-6 
44.  Graf FE, Ludin P, Wenzler T, Kaiser M, Brun R, Pyana PP, et al. Aquaporin 2 
mutations in Trypanosoma brucei gambiense field isolates correlate with decreased 





45.  Munday JC, Eze AA, Baker N, Glover L, Clucas C, Aguinaga Andrés D, et al. 
Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine 
and melaminophenyl arsenic drugs and the main genetic determinant of resistance to 
these drugs. J Antimicrob Chemother. 2014;69: 651–663. doi:10.1093/jac/dkt442 
46.  Song J, Baker N, Rothert M, Henke B, Jeacock L, Horn D, et al. Pentamidine Is Not a 
Permeant but a Nanomolar Inhibitor of the Trypanosoma brucei Aquaglyceroporin-2. 
PLoS Pathog. 2016;12: e1005436. doi:10.1371/journal.ppat.1005436 
47.  Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. Polyamine 
metabolism: a potential therapeutic target in trypanosomes. Science. 1980;210: 332–
334.  
48.  Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, Wong PE, et al. A 
molecular mechanism for eflornithine resistance in African trypanosomes. PLoS 
Pathog. 2010;6: e1001204. doi:10.1371/journal.ppat.1001204 
49.  Baker N, Alsford S, Horn D. Genome-wide RNAi screens in African trypanosomes 
identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol 
Biochem Parasitol. 2011;176: 55–57. doi:10.1016/j.molbiopara.2010.11.010 
50.  Schumann Burkard G, Jutzi P, Roditi I. Genome-wide RNAi screens in bloodstream 
form trypanosomes identify drug transporters. Mol Biochem Parasitol. 2011;175: 91–
94. doi:10.1016/j.molbiopara.2010.09.002 
51.  Pépin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course 
eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. 
Bull World Health Organ. 2000;78: 1284–1295.  
52.  Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R. Alterations in ornithine 
decarboxylase characteristics account for tolerance of Trypanosoma brucei 
rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother. 
1997;41: 1922–1925.  
53.  Tsuhako MH, Alves MJ, Colli W, Filardi LS, Brener Z, Augusto O. Comparative 
studies of nifurtimox uptake and metabolism by drug-resistant and susceptible strains 
of Trypanosoma cruzi. Comp Biochem Physiol C. 1991;99: 317–321.  
54.  Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. 
Chem Biol Interact. 1990;73: 1–27.  
55.  Boiani M, Piacenza L, Hernández P, Boiani L, Cerecetto H, González M, et al. Mode 
of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma 
cruzi: is oxidative stress involved? Biochem Pharmacol. 2010;79: 1736–1745. 
doi:10.1016/j.bcp.2010.02.009 
56.  Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-
resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S 
A. 2008;105: 5022–5027. doi:10.1073/pnas.0711014105 
57.  Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of 





58.  Fairlamb AH, Bowman IB. Uptake of the trypanocidal drug suramin by bloodstream 
forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. 
Mol Biochem Parasitol. 1980;1: 315–333.  
59.  Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, Fischer MJ, Janssen LH, et al. 
The uptake of the trypanocidal drug suramin in combination with low-density 
lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop. 
1993;54: 237–250.  
60.  El Rayah IE, Kaminsky R, Schmid C, El Malik KH. Drug resistance in Sudanese 
Trypanosoma evansi. Vet Parasitol. 1999;80: 281–287.  
61.  Zhou J, Shen J, Liao D, Zhou Y, Lin J. Resistance to drug by different isolates 
Trypanosoma evansi in China. Acta Trop. 2004;90: 271–275. 
doi:10.1016/j.actatropica.2004.02.002 
62.  Zoltner M, Leung KF, Alsford S, Horn D, Field MC. Modulation of the Surface 
Proteome through Multiple Ubiquitylation Pathways in African Trypanosomes. PLoS 
Pathog. 2015;11: e1005236. doi:10.1371/journal.ppat.1005236 
63.  Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet Lond 
Engl. 2010;375: 148–159. doi:10.1016/S0140-6736(09)60829-1 
64.  Burri C, Chappuis F, Brun R. Human African Trypanosomiasis. 23rd ed. Manson’s 
Tropical Diseases. 23rd ed. Saunders Ltd.; 2014. pp. 606–691.  
65.  Giordani F, Morrison LJ, Rowan TG, DE Koning HP, Barrett MP. The animal 
trypanosomiases and their chemotherapy: a review. Parasitology. 2016;143: 1862–
1889. doi:10.1017/S0031182016001268 
66.  Bisaggio DFR, Adade CM, Souto-Padrón T. In vitro effects of suramin on 
Trypanosoma cruzi. Int J Antimicrob Agents. 2008;31: 282–286. 
doi:10.1016/j.ijantimicag.2007.11.001 
67.  Santos EC, Novaes RD, Cupertino MC, Bastos DSS, Klein RC, Silva EAM, et al. 
Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a 
Virulent Strain of Trypanosoma cruzi. Antimicrob Agents Chemother. 2015;59: 
5999–6006. doi:10.1128/AAC.00779-15 
68.  Khanra S, Kumar YP, Dash J, Banerjee R. In vitro screening of known drugs 
identified by scaffold hopping techniques shows promising leishmanicidal activity 
for suramin and netilmicin. BMC Res Notes. 2018;11: 319. doi:10.1186/s13104-018-
3446-y 
69.  Fleck SL, Birdsall B, Babon J, Dluzewski AR, Martin SR, Morgan WD, et al. 
Suramin and suramin analogues inhibit merozoite surface protein-1 secondary 
processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum. 
J Biol Chem. 2003;278: 47670–47677. doi:10.1074/jbc.M306603200 
70.  Müller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. 
Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum 
binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells 
suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 




71.  Hawking F. Chemotherapy of onchocerciasis. Trans R Soc Trop Med Hyg. 1958;52: 
109–111.  
72.  Ashburn LL, Burch TA, Brady FJ. Pathologic effects of suramin, hetrazan and 
arsenamide on adult Onchocerca volvulus. Boletin Oficina Sanit Panam Pan Am 
Sanit Bur. 1949;28: 1107–1117.  
73.  Burch TA, Ashburn LL. Experimental therapy of onchocerciasis with suramin and 
hetrazan; results of a three-year study. Am J Trop Med Hyg. 1951;31: 617–623.  
74.  Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin 
Ophthalmol Auckl NZ. 2011;5: 1479–1491. doi:10.2147/OPTH.S8372 
75.  Coyne PE, Maxwell C. Suramin and therapy of onchocerciasis. Arch Dermatol. 
1992;128: 698.  
76.  Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the 
biological activity of suramin. Pharmacol Rev. 1993;45: 177–203.  
77.  Reiter B, Oram JD. Inhibition of streptococcal bacteriophage by suramin. Nature. 
1962;193: 651–652.  
78.  Herrmann-Erlee MP, Wolff L. Inhibition of mumps virus reproduction by congored 
and suramine. Arch Int Pharmacodyn Ther. 1957;110: 340–341.  
79.  De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor 
viruses. Cancer Lett. 1979;8: 9–22.  
80.  Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin 
protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. 
Science. 1984;226: 172–174.  
81.  Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, et al. 
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or 
AIDS-related complex: clinical pharmacology and suppression of virus replication in 
vivo. Lancet Lond Engl. 1985;2: 627–630.  
82.  Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams DI, et al. Lack 
of response to suramin in patients with AIDS and AIDS-related complex. Am J Med. 
1987;82: 615–620.  
83.  Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, et al. Suramin 
therapy in AIDS and related disorders. Report of the US Suramin Working Group. 
JAMA. 1987;258: 1347–1351.  
84.  Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J. Suramin 
inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to 
galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J 
Biol Chem. 1994;269: 24349–24353.  
85.  Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, et al. Dengue 
virus infectivity depends on envelope protein binding to target cell heparan sulfate. 
Nat Med. 1997;3: 866–871.  
86.  Aguilar JS, Rice M, Wagner EK. The polysulfonated compound suramin blocks 
adsorption and lateral difusion of herpes simplex virus type-1 in vero cells. Virology. 




87.  Garson JA, Lubach D, Passas J, Whitby K, Grant PR. Suramin blocks hepatitis C 
binding to human hepatoma cells in vitro. J Med Virol. 1999;57: 238–242.  
88.  Alarcón B, Lacal JC, Fernández-Sousa JM, Carrasco L. Screening for new 
compounds with antiherpes activity. Antiviral Res. 1984;4: 231–244.  
89.  Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Suramin prevents 
duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 1993;37: 
1539–1542.  
90.  Tsiquaye K, Zuckerman A. Suramin inhibits duck hepatitis B virus DNA polymerase 
activity. J Hepatol. 1985;1: 663–669.  
91.  Tsiquaye KN, Collins P, Zuckerman AJ. Antiviral activity of the polybasic anion, 
suramin and acyclovir in Hepadna virus infection. J Antimicrob Chemother. 1986;18 
Suppl B: 223–228.  
92.  Loke RH, Anderson MG, Coleman JC, Tsiquaye KN, Zuckerman AJ, Murray-Lyon 
IM. Suramin treatment for chronic active hepatitis B--toxic and ineffective. J Med 
Virol. 1987;21: 97–99.  
93.  Wang Y, Qing J, Sun Y, Rao Z. Suramin inhibits EV71 infection. Antiviral Res. 
2014;103: 1–6. doi:10.1016/j.antiviral.2013.12.008 
94.  Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, et al. The approved pediatric drug 
suramin identified as a clinical candidate for the treatment of EV71 infection-suramin 
inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect. 2014;3: e62. 
doi:10.1038/emi.2014.60 
95.  Ren P, Zheng Y, Wang W, Hong L, Delpeyroux F, Arenzana-Seisdedos F, et al. 
Suramin interacts with the positively charged region surrounding the 5-fold axis of 
the EV-A71 capsid and inhibits multiple enterovirus A. Sci Rep. 2017;7: 42902. 
doi:10.1038/srep42902 
96.  Albulescu IC, van Hoolwerff M, Wolters LA, Bottaro E, Nastruzzi C, Yang SC, et al. 
Suramin inhibits chikungunya virus replication through multiple mechanisms. 
Antiviral Res. 2015;121: 39–46. doi:10.1016/j.antiviral.2015.06.013 
97.  Ho Y-J, Wang Y-M, Lu J, Wu T-Y, Lin L-I, Kuo S-C, et al. Suramin Inhibits 
Chikungunya Virus Entry and Transmission. PloS One. 2015;10: e0133511. 
doi:10.1371/journal.pone.0133511 
98.  Kuo S-C, Wang Y-M, Ho Y-J, Chang T-Y, Lai Z-Z, Tsui P-Y, et al. Suramin 
treatment reduces chikungunya pathogenesis in mice. Antiviral Res. 2016;134: 89–
96. doi:10.1016/j.antiviral.2016.07.025 
99.  Henß L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, et al. Suramin is a 
potent inhibitor of Chikungunya and Ebola virus cell entry. Virol J. 2016;13: 149. 
doi:10.1186/s12985-016-0607-2 
100.  Tan CW, Sam I-C, Chong WL, Lee VS, Chan YF. Polysulfonate suramin inhibits 
Zika virus infection. Antiviral Res. 2017;143: 186–194. 
doi:10.1016/j.antiviral.2017.04.017 
101.  Williams WL. The Effects of Suramin (Germanin), Azo Dyes, and Vasodilators on 




102.  Osswald H, Youssef M. Suramin enhancement of the chemotherapeutic actions of 
cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich carcinoma. 
Cancer Lett. 1979;6: 337–343.  
103.  Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer 
drug with a unique mechanism of action. J Clin Oncol Off J Am Soc Clin Oncol. 
1989;7: 499–508. doi:10.1200/JCO.1989.7.4.499 
104.  Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, et al. A 
phase I/II study of continuous infusion suramin in patients with hormone-refractory 
prostate cancer: toxicity and response. Cancer Chemother Pharmacol. 1996;39: 1–8.  
105.  Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, et al. 
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited 
efficacy. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14: 1626–1636. 
doi:10.1200/JCO.1996.14.5.1626 
106.  Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, et al. 
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic 
prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15: 1470–1477. 
doi:10.1200/JCO.1997.15.4.1470 
107.  Hussain M, Fisher EI, Petrylak DP, O’Connor J, Wood DP, Small EJ, et al. Androgen 
deprivation and four courses of fixed-schedule suramin treatment in patients with 
newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. J 
Clin Oncol Off J Am Soc Clin Oncol. 2000;18: 1043–1049. 
doi:10.1200/JCO.2000.18.5.1043 
108.  Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, et al. Suramin 
therapy for patients with symptomatic hormone-refractory prostate cancer: results of 
a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus 
hydrocortisone. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18: 1440–1450. 
doi:10.1200/JCO.2000.18.7.1440 
109.  Calvo E, Cortés J, Rodríguez J, Sureda M, Beltrán C, Rebollo J, et al. Fixed higher 
dose schedule of suramin plus hydrocortisone in patients with hormone refractory 
prostate carcinoma a multicenter Phase II study. Cancer. 2001;92: 2435–2443.  
110.  Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, et al. Randomized 
study of three different doses of suramin administered with a fixed dosing schedule in 
patients with advanced prostate cancer: results of intergroup 0159, cancer and 
leukemia group B 9480. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20: 3369–
3375. doi:10.1200/JCO.2002.10.022 
111.  Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, et al. A Phase II 
trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 
2004;100: 65–71. doi:10.1002/cncr.11867 
112.  Safarinejad MR. Combination chemotherapy with docetaxel, estramustine and 
suramin for hormone refractory prostate cancer. Urol Oncol. 2005;23: 93–101. 
doi:10.1016/j.urolonc.2004.10.003 
113.  Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Suramin in 
non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. 




114.  Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, et al. Phase I trial of 
intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J 
Cancer. 2005;92: 2140–2147. doi:10.1038/sj.bjc.6602650 
115.  Uchio EM, Linehan WM, Figg WD, Walther MM. A phase I study of intravesical 
suramin for the treatment of superficial transitional cell carcinoma of the bladder. J 
Urol. 2003;169: 357–360. doi:10.1097/01.ju.0000032745.90528.dc 
116.  Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J, et al. 
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade 
gliomas. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19: 3260–3266. 
doi:10.1200/JCO.2001.19.13.3260 
117.  Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR, et al. 
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS 
Consortium study. Neuro-Oncol. 2004;6: 15–20. doi:10.1215/S1152851703000127 
118.  Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological 
activity. J Cell Biochem. 1985;29: 265–273. doi:10.1002/jcb.240290310 
119.  Coffey RJ, Leof EB, Shipley GD, Moses HL. Suramin inhibition of growth factor 
receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987;132: 143–
148. doi:10.1002/jcp.1041320120 
120.  Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated 
proliferation of human osteosarcoma cells. J Natl Cancer Inst. 1990;82: 1349–1352.  
121.  Spigelman Z, Dowers A, Kennedy S, DiSorbo D, O’Brien M, Barr R, et al. 
Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 1987;47: 4694–
4698.  
122.  Takano S, Gately S, Engelhard H, Tsanaclis AM, Brem S. Suramin inhibits glioma 
cell proliferation in vitro and in the brain. J Neurooncol. 1994;21: 189–201.  
123.  Guo XJ, Fantini J, Roubin R, Marvaldi J, Rougon G. Evaluation of the effect of 
suramin on neural cell growth and N-CAM expression. Cancer Res. 1990;50: 5164–
5170.  
124.  Song S, Yu B, Wei Y, Wientjes MG, Au JL-S. Low-dose suramin enhanced 
paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast 
xenograft tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10: 6058–
6065. doi:10.1158/1078-0432.CCR-04-0595 
125.  Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL-S. Low dose suramin as a 
chemosensitizer of bladder cancer to mitomycin C. J Urol. 2005;174: 322–327. 
doi:10.1097/01.ju.0000161594.86931.ea 
126.  Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JLS, et al. Phase I 
evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with 
naturally occurring cancers. J Vet Intern Med. 2006;20: 1172–1177.  
127.  Singla AK, Bondareva A, Jirik FR. Combined treatment with paclitaxel and suramin 
prevents the development of metastasis by inhibiting metastatic colonization of 





128.  Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL-S. Pharmacodynamics of 
telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J. 
2015;17: 268–276. doi:10.1208/s12248-014-9703-7 
129.  Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, et 
al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced 
non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9: 
3303–3311.  
130.  Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young 
D, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-
small-cell lung cancer: a phase II study. Ann Oncol Off J Eur Soc Med Oncol. 
2008;19: 1903–1909. doi:10.1093/annonc/mdn412 
131.  Stocker K, Fischer H, Meier J. Thrombin-like snake venom proteinases. Toxicon Off 
J Int Soc Toxinology. 1982;20: 265–273.  
132.  Monteiro RQ, Campana PT, Melo PA, Bianconi ML. Suramin interaction with 
human alpha-thrombin: inhibitory effects and binding studies. Int J Biochem Cell 
Biol. 2004;36: 2077–2085. doi:10.1016/j.biocel.2004.03.007 
133.  Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Eliás S, Tomaz MA, et al. 
Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-
trypanosomal drug suramin. J Mol Biol. 2005;350: 416–426. 
doi:10.1016/j.jmb.2005.04.072 
134.  Aragão EA, Vieira DS, Chioato L, Ferreira TL, Lourenzoni MR, Silva SR, et al. 
Characterization of suramin binding sites on the human group IIA secreted 
phospholipase A2 by site-directed mutagenesis and molecular dynamics simulation. 
Arch Biochem Biophys. 2012;519: 17–22. doi:10.1016/j.abb.2012.01.002 
135.  Salvador GHM, Dreyer TR, Cavalcante WLG, Matioli FF, Dos Santos JI, Velazquez-
Campoy A, et al. Structural and functional evidence for membrane docking and 
disruption sites on phospholipase A2-like proteins revealed by complexation with the 
inhibitor suramin. Acta Crystallogr D Biol Crystallogr. 2015;71: 2066–2078. 
doi:10.1107/S1399004715014443 
136.  Salvador GHM, Dreyer TR, Gomes AAS, Cavalcante WLG, Dos Santos JI, Gandin 
CA, et al. Structural and functional characterization of suramin-bound MjTX-I from 
Bothrops moojeni suggests a particular myotoxic mechanism. Sci Rep. 2018;8: 
10317. doi:10.1038/s41598-018-28584-7 
137.  Zhou X, Tan T-C, Valiyaveettil S, Go ML, Kini RM, Velazquez-Campoy A, et al. 
Structural characterization of myotoxic ecarpholin S from Echis carinatus venom. 
Biophys J. 2008;95: 3366–3380. doi:10.1529/biophysj.107.117747 
138.  El-Kik CZ, Fernandes FFA, Tomaz MA, Gaban GA, Fonseca TF, Calil-Elias S, et al. 
Neutralization of Apis mellifera bee venom activities by suramin. Toxicon Off J Int 
Soc Toxinology. 2013;67: 55–62. doi:10.1016/j.toxicon.2013.02.007 
139.  Arruda EZ, Silva NMV, Moraes R a. M, Melo PA. Effect of suramin on myotoxicity 
of some crotalid snake venoms. Braz J Med Biol Res Rev Bras Pesqui Medicas E 




140.  Fathi B, Amani F, Jami-al-ahmadi A, Zare A. Antagonistc effect of suramin against 
the venom of the Iranian snake Echis carinatus in mice. Iranian J Vet Sci Technol. 
2010;2: 19–15.  
141.  The Lancet, Editorial. Snake-bite envenoming: a priority neglected tropical disease. 
Lancet Lond Engl. 2017;390: 2. doi:10.1016/S0140-6736(17)31751-8 
142.  Arnold C. Vipers, mambas and taipans: the escalating health crisis over snakebites. 
Nature. 2016;537: 26–28. doi:10.1038/537026a 
143.  den Hertog A, Nelemans A, Van den Akker J. The inhibitory action of suramin on the 
P2-purinoceptor response in smooth muscle cells of guinea-pig taenia caeci. Eur J 
Pharmacol. 1989;166: 531–534.  
144.  Kuruppu S, Chaisakul J, Smith AI, Hodgson WC. Inhibition of presynaptic 
neurotoxins in taipan venom by suramin. Neurotox Res. 2014;25: 305–310. 
doi:10.1007/s12640-013-9426-z 
145.  Grishin S, Shakirzyanova A, Giniatullin A, Afzalov R, Giniatullin R. Mechanisms of 
ATP action on motor nerve terminals at the frog neuromuscular junction. Eur J 
Neurosci. 2005;21: 1271–1279. doi:10.1111/j.1460-9568.2005.03976.x 
146.  Ong WY, Motin LG, Hansen MA, Dias LS, Ayrout C, Bennett MR, et al. P2 
purinoceptor blocker suramin antagonises NMDA receptors and protects against 
excitatory behaviour caused by NMDA receptor agonist (RS)-(tetrazol-5-yl)-glycine 
in rats. J Neurosci Res. 1997;49: 627–638. doi:10.1002/(SICI)1097-
4547(19970901)49:5<627::AID-JNR13>3.0.CO;2-S 
147.  Kharlamov A, Jones SC, Kim DK. Suramin reduces infarct volume in a model of 
focal brain ischemia in rats. Exp Brain Res. 2002;147: 353–359. doi:10.1007/s00221-
002-1251-1 
148.  Dupre TV, Doll MA, Shah PP, Sharp CN, Kiefer A, Scherzer MT, et al. Suramin 
protects from cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 
2016;310: F248-258. doi:10.1152/ajprenal.00433.2015 
149.  Doggrell SA. Suramin: potential in acute liver failure. Expert Opin Investig Drugs. 
2004;13: 1361–1363. doi:10.1517/13543784.13.10.1361 
150.  Chi Y, Gao K, Zhang H, Takeda M, Yao J. Suppression of cell membrane 
permeability by suramin: involvement of its inhibitory actions on connexin 43 
hemichannels. Br J Pharmacol. 2014;171: 3448–3462. doi:10.1111/bph.12693 
151.  Bourguignon T, Benoist L, Chadet S, Miquelestorena-Standley E, Fromont G, Ivanes 
F, et al. Stimulation of murine P2Y11-like purinoreceptor protects against 
hypoxia/reoxygenation injury and decreases heart graft rejection lesions. J Thorac 
Cardiovasc Surg. 2019;158: 780–790.e1. doi:10.1016/j.jtcvs.2018.12.014 
152.  Sahu D, Saroha A, Roy S, Das S, Srivastava PS, Das HR. Suramin ameliorates 
collagen induced arthritis. Int Immunopharmacol. 2012;12: 288–293. 
doi:10.1016/j.intimp.2011.12.003 
153.  Zou CJ, Onaka TO, Yagi K. Effects of suramin on neuroendocrine and behavioural 




154.  Denkinger M, Shive CL, Pantenburg B, Forsthuber TG. Suramin has adjuvant 
properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo. Int 
Immunopharmacol. 2004;4: 15–24. doi:10.1016/j.intimp.2003.09.004 
155.  Dunn PM, Blakeley AG. Suramin: a reversible P2-purinoceptor antagonist in the 
mouse vas deferens. Br J Pharmacol. 1988;93: 243–245.  
156.  Bernardes CF, Fagian MM, Meyer-Fernandes JR, Castilho RF, Vercesi AE. Suramin 
inhibits respiration and induces membrane permeability transition in isolated rat liver 
mitochondria. Toxicology. 2001;169: 17–23.  
157.  Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, et al. 
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. 
PloS One. 2013;8: e57380. doi:10.1371/journal.pone.0057380 
158.  Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, et al. 
Reversal of autism-like behaviors and metabolism in adult mice with single-dose 
antipurinergic therapy. Transl Psychiatry. 2014;4: e400. doi:10.1038/tp.2014.33 
159.  Naviaux RK, Curtis B, Li K, Naviaux JC, Bright AT, Reiner GE, et al. Low-dose 
suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. 
Ann Clin Transl Neurol. 2017;4: 491–505. doi:10.1002/acn3.424 
160.  Town BW, Wills ED, Wilson EJ, Wormall A. Studies on suramin; the action of the 
drug on enzymes and some other proteins. General considerations. Biochem J. 
1950;47: 149–158. doi:10.1042/bj0470149 
161.  Willson M, Callens M, Kuntz DA, Perié J, Opperdoes FR. Synthesis and activity of 
inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Mol 
Biochem Parasitol. 1993;59: 201–210.  
162.  Morgan HP, McNae IW, Nowicki MW, Zhong W, Michels PAM, Auld DS, et al. 
The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of 
pyruvate kinases and bind to the adenosine site. J Biol Chem. 2011;286: 31232–
31240. doi:10.1074/jbc.M110.212613 
163.  Stoppani AO, Brignone JA. Inhibition of succinic dehydrogenase by polysulfonated 
compounds. Arch Biochem Biophys. 1957;68: 432–451.  
164.  Ono K, Nakane H, Fukushima M. Differential inhibition of various deoxyribonucleic 
and ribonucleic acid polymerases by suramin. Eur J Biochem. 1988;172: 349–353.  
165.  Jindal HK, Anderson CW, Davis RG, Vishwanatha JK. Suramin affects DNA 
synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990;50: 
7754–7757.  
166.  Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, et al. 
Structure-based inhibition of Norovirus RNA-dependent RNA polymerases. J Mol 
Biol. 2012;419: 198–210. doi:10.1016/j.jmb.2012.03.008 
167.  Waring MJ. The effects of antimicrobial agents on ribonucleic acid polymerase. Mol 
Pharmacol. 1965;1: 1–13.  
168.  Basavannacharya C, Vasudevan SG. Suramin inhibits helicase activity of NS3 
protein of dengue virus in a fluorescence-based high throughput assay format. 




169.  Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. 
Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster 
fibrosarcoma cells. Proc Natl Acad Sci U S A. 1992;89: 3025–3029.  
170.  Ren C, Morohashi K, Plotnikov AN, Jakoncic J, Smith SG, Li J, et al. Small-
molecule modulators of methyl-lysine binding for the CBX7 chromodomain. Chem 
Biol. 2015;22: 161–168. doi:10.1016/j.chembiol.2014.11.021 
171.  Feng Y, Li M, Wang B, Zheng YG. Discovery and mechanistic study of a class of 
protein arginine methylation inhibitors. J Med Chem. 2010;53: 6028–6039. 
doi:10.1021/jm100416n 
172.  Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity 
studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases 
(sirtuins). ChemMedChem. 2007;2: 1419–1431. doi:10.1002/cmdc.200700003 
173.  Schuetz A, Min J, Antoshenko T, Wang C-L, Allali-Hassani A, Dong A, et al. 
Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by 
suramin. Struct Lond Engl 1993. 2007;15: 377–389. doi:10.1016/j.str.2007.02.002 
174.  Hosoi Y, Matsumoto Y, Tomita M, Enomoto A, Morita A, Sakai K, et al. 
Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent 
protein kinase activity. Br J Cancer. 2002;86: 1143–1149. doi:10.1038/sj.bjc.6600191 
175.  Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein 
kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 
1989;258: 156–158.  
176.  El-Kik CZ, Fernandes FFA, Tomaz MA, Gaban GA, Fonseca TF, Calil-Elias S, et al. 
Neutralization of Apis mellifera bee venom activities by suramin. Toxicon Off J Int 
Soc Toxinology. 2013;67: 55–62. doi:10.1016/j.toxicon.2013.02.007 
177.  Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Eliás S, Tomaz MA, et al. 
Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-
trypanosomal drug suramin. J Mol Biol. 2005;350: 416–426. 
doi:10.1016/j.jmb.2005.04.072 
178.  Zhang YL, Keng YF, Zhao Y, Wu L, Zhang ZY. Suramin is an active site-directed, 
reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem. 
1998;273: 12281–12287.  
179.  Lominski I, Gray S. Inhibition of lysozyme by “Suramin.” Nature. 1961;192: 683.  
180.  Vicik R, Hoerr V, Glaser M, Schultheis M, Hansell E, McKerrow JH, et al. 
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of 
Trypanosoma brucei as lead trypanocidal agents. Bioorg Med Chem Lett. 2006;16: 
2753–2757. doi:10.1016/j.bmcl.2006.02.026 
181.  Cadène M, Duranton J, North A, Si-Tahar M, Chignard M, Bieth JG. Inhibition of 
neutrophil serine proteinases by suramin. J Biol Chem. 1997;272: 9950–9955.  
182.  Eisen V, Loveday C. Effects of suramin on complement, blood clotting, fibrinolysis 
and kinin formation. Br J Pharmacol. 1973;49: 678–687.  
183.  Eichhorst ST, Krueger A, Müerköster S, Fas SC, Golks A, Gruetzner U, et al. 
Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic 




184.  Tayel A, Ebrahim MA, Ibrahim AS, El-Gayar AM, Al-Gayyar MM. Cytotoxic 
effects of suramin against HepG2 cells through activation of intrinsic apoptotic 
pathway. J BUON Off J Balk Union Oncol. 2014;19: 1048–1054.  
185.  Fortes PA, Ellory JC, Lew VL. Suramin: a potent ATPase inhibitor which acts on the 
inside surface of the sodium pump. Biochim Biophys Acta. 1973;318: 262–272.  
186.  Demenis MA, Furriel RPM, Leone FA. Characterization of an ectonucleoside 
triphosphate diphosphohydrolase 1 activity in alkaline phosphatase-depleted rat 
osseous plate membranes: possible functional involvement in the calcification 
process. Biochim Biophys Acta. 2003;1646: 216–225.  
187.  Magalhães L, de Oliveira AHC, de Souza Vasconcellos R, Mariotini-Moura C, de 
Cássia Firmino R, Fietto JLR, et al. Label-free assay based on immobilized capillary 
enzyme reactor of Leishmania infantum nucleoside triphosphate diphosphohydrolase 
(LicNTPDase-2-ICER-LC/UV). J Chromatogr B Analyt Technol Biomed Life Sci. 
2016;1008: 98–107. doi:10.1016/j.jchromb.2015.11.028 
188.  Luo H, Wood K, Shi F-D, Gao F, Chang Y. Suramin is a novel competitive 
antagonist selective to α1β2γ2 GABAA over ρ1 GABAC receptors. 
Neuropharmacology. 2018;141: 148–157. doi:10.1016/j.neuropharm.2018.08.036 
189.  Nakazawa K, Inoue K, Ito K, Koizumi S, Inoue K. Inhibition by suramin and reactive 
blue 2 of GABA and glutamate receptor channels in rat hippocampal neurons. 
Naunyn Schmiedebergs Arch Pharmacol. 1995;351: 202–208.  
190.  Chung W-C, Kermode JC. Suramin disrupts receptor-G protein coupling by blocking 
association of G protein alpha and betagamma subunits. J Pharmacol Exp Ther. 
2005;313: 191–198. doi:10.1124/jpet.104.078311 
191.  El-Ajouz S, Ray D, Allsopp RC, Evans RJ. Molecular basis of selective antagonism 
of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino 
acids in the cysteine-rich loop. Br J Pharmacol. 2012;165: 390–400. 
doi:10.1111/j.1476-5381.2011.01534.x 
192.  Stevis PE, Deecher DC, Lopez FJ, Frail DE. Pharmacological characterization of 
soluble human FSH receptor extracellular domain: facilitated secretion by 
coexpression with FSH. Endocrine. 1999;10: 153–160. doi:10.1385/ENDO:10:2:153 
193.  La Rocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE. A pilot study 
of suramin in the treatment of metastatic renal cell carcinoma. Cancer. 1991;67: 
1509–1513.  
194.  Fong JS, Good RA. Suramin--a potent reversible and competitive inhibitor of 
complement systems. Clin Exp Immunol. 1972;10: 127–138.  
195.  Tsiftsoglou SA, Sim RB. Human complement factor I does not require cofactors for 
cleavage of synthetic substrates. J Immunol Baltim Md 1950. 2004;173: 367–375. 
doi:10.4049/jimmunol.173.1.367 
196.  Tsiftsoglou SA, Willis AC, Li P, Chen X, Mitchell DA, Rao Z, et al. The catalytically 
active serine protease domain of human complement factor I. Biochemistry (Mosc). 
2005;44: 6239–6249. doi:10.1021/bi047680t 
197.  Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schätzl HM. Charged 




and inhibit PrPSc replication. J Cell Sci. 2005;118: 4959–4973. 
doi:10.1242/jcs.02609 
198.  Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, et al. 
Identification of clinically used drugs that activate pregnane X receptors. Drug Metab 
Dispos Biol Fate Chem. 2011;39: 151–159. doi:10.1124/dmd.110.035105 
199.  Klinger M, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J, et 
al. Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a 
calmodulin binding site. Mol Pharmacol. 1999;55: 462–472.  
200.  Fairlamb AH, Bowman IB. Trypanosoma brucei: suramin and other trypanocidal 
compounds’ effects on sn-glycerol-3-phosphate oxidase. Exp Parasitol. 1977;43: 
353–361.  
201.  Dias DA, de Barros Penteado B, Dos Santos LD, Dos Santos PM, Arruda CCP, 
Schetinger MRC, et al. Characterization of ectonucleoside triphosphate 
diphosphohydrolase (E-NTPDase; EC 3.6.1.5) activity in mouse peritoneal cavity 
cells. Cell Biochem Funct. 2017;35: 358–363. doi:10.1002/cbf.3281 
202.  Oses JP, Cardoso CM, Germano RA, Kirst IB, Rücker B, Fürstenau CR, et al. 
Soluble NTPDase: An additional system of nucleotide hydrolysis in rat blood serum. 
Life Sci. 2004;74: 3275–3284. doi:10.1016/j.lfs.2003.11.020 
203.  Vasconcellos RDS, Mariotini-Moura C, Gomes RS, Serafim TD, Firmino R de C, 
Silva E Bastos M, et al. Leishmania infantum ecto-nucleoside triphosphate 
diphosphohydrolase-2 is an apyrase involved in macrophage infection and expressed 
in infected dogs. PLoS Negl Trop Dis. 2014;8: e3309. 
doi:10.1371/journal.pntd.0003309 
204.  Santos RF, Pôssa MAS, Bastos MS, Guedes PMM, Almeida MR, Demarco R, et al. 
Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on 
Trypanosoma cruzi infectivity and virulence. PLoS Negl Trop Dis. 2009;3: e387. 
doi:10.1371/journal.pntd.0000387 
205.  Iqbal J, Lévesque SA, Sévigny J, Müller CE. A highly sensitive CE-UV method with 
dynamic coating of silica-fused capillaries for monitoring of nucleotide 
pyrophosphatase/phosphodiesterase reactions. Electrophoresis. 2008;29: 3685–3693. 
doi:10.1002/elps.200800013 
206.  Andréola ML, Tharaud D, Litvak S, Tarrago-Litvak L. The ribonuclease H activity of 
HIV-1 reverse transcriptase: further biochemical characterization and search of 
inhibitors. Biochimie. 1993;75: 127–134.  
207.  Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ, et 
al. Identification and analysis of hepatitis C virus NS3 helicase inhibitors using 
nucleic acid binding assays. Nucleic Acids Res. 2012;40: 8607–8621. 
doi:10.1093/nar/gks623 
208.  Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, Inglese J, et al. 
Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA 
phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol Cancer 




209.  Kakuguchi W, Nomura T, Kitamura T, Otsuguro S, Matsushita K, Sakaitani M, et al. 
Suramin, screened from an approved drug library, inhibits HuR functions and 
attenuates malignant phenotype of oral cancer cells. Cancer Med. 2018;7: 6269–
6280. doi:10.1002/cam4.1877 
210.  Paulson CN, John K, Baxley RM, Kurniawan F, Orellana K, Francis R, et al. The 
anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA 
binding protein Mcm10. Open Biol. 2019;9: 190117. doi:10.1098/rsob.190117 
211.  Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF, et al. Assay 
development for histone methyltransferases. Assay Drug Dev Technol. 2013;11: 
227–236. doi:10.1089/adt.2012.480 
212.  Peinado RDS, Olivier DS, Eberle RJ, de Moraes FR, Amaral MS, Arni RK, et al. 
Binding studies of a putative C. pseudotuberculosis target protein from Vitamin B12 
Metabolism. Sci Rep. 2019;9: 6350. doi:10.1038/s41598-019-42935-y 
213.  Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small 
molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 
2003;425: 191–196. doi:10.1038/nature01960 
214.  Trueblood KE, Mohr S, Dubyak GR. Purinergic regulation of high-glucose-induced 
caspase-1 activation in the rat retinal Müller cell line rMC-1. Am J Physiol Cell 
Physiol. 2011;301: C1213-1223. doi:10.1152/ajpcell.00265.2011 
215.  Stark S, Schuller A, Sifringer M, Gerstner B, Brehmer F, Weber S, et al. Suramin 
induces and enhances apoptosis in a model of hyperoxia-induced oligodendrocyte 
injury. Neurotox Res. 2008;13: 197–207.  
216.  Marques AF, Esser D, Rosenthal PJ, Kassack MU, Lima LMTR. Falcipain-2 
inhibition by suramin and suramin analogues. Bioorg Med Chem. 2013;21: 3667–
3673. doi:10.1016/j.bmc.2013.04.047 
217.  Beiler JM, Martin GJ. Inhibition of hyaluronidase action by derivatives of hesperidin. 
J Biol Chem. 1948;174: 31–35.  
218.  Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. Experimental 
animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and 
sphingolipid accumulation in the rat. Proc Natl Acad Sci U S A. 1980;77: 3700–
3704. doi:10.1073/pnas.77.6.3700 
219.  Bachmann A, Russ U, Quast U. Potent inhibition of the CFTR chloride channel by 
suramin. Naunyn Schmiedebergs Arch Pharmacol. 1999;360: 473–476.  
220.  Peoples RW, Li C. Inhibition of NMDA-gated ion channels by the P2 purinoceptor 
antagonists suramin and reactive blue 2 in mouse hippocampal neurones. Br J 
Pharmacol. 1998;124: 400–408. doi:10.1038/sj.bjp.0701842 
221.  Sharma A, Yogavel M, Sharma A. Structural and functional attributes of malaria 
parasite diadenosine tetraphosphate hydrolase. Sci Rep. 2016;6: 19981. 
doi:10.1038/srep19981 
222.  Vieira DS, Aragão EA, Lourenzoni MR, Ward RJ. Mapping of suramin binding sites 





223.  Quemé-Peña M, Juhász T, Mihály J, Cs Szigyártó I, Horváti K, Bősze S, et al. 
Manipulating Active Structure and Function of Cationic Antimicrobial Peptide CM15 
with the Polysulfonated Drug Suramin: A Step Closer to in Vivo Complexity. 
Chembiochem Eur J Chem Biol. 2019. doi:10.1002/cbic.201800801 
224.  Abdeen S, Salim N, Mammadova N, Summers CM, Goldsmith-Pestana K, 
McMahon-Pratt D, et al. Targeting the HSP60/10 chaperonin systems of 
Trypanosoma brucei as a strategy for treating African sleeping sickness. Bioorg Med 
Chem Lett. 2016;26: 5247–5253. doi:10.1016/j.bmcl.2016.09.051 
225.  Stevens M, Abdeen S, Salim N, Ray A-M, Washburn A, Chitre S, et al. HSP60/10 
chaperonin systems are inhibited by a variety of approved drugs, natural products, 
and known bioactive molecules. Bioorg Med Chem Lett. 2019;29: 1106–1112. 
doi:10.1016/j.bmcl.2019.02.028 
226.  Wierenga RK, Swinkels B, Michels PA, Osinga K, Misset O, Van Beeumen J, et al. 
Common elements on the surface of glycolytic enzymes from Trypanosoma brucei 
may serve as topogenic signals for import into glycosomes. EMBO J. 1987;6: 215–
221.  
227.  Opperdoes FR, Borst P. Localization of nine glycolytic enzymes in a microbody-like 
organelle in Trypanosoma brucei: the glycosome. FEBS Lett. 1977;80: 360–364.  
228.  Fairlamb A. A study of glycerophosphate oxidase in Trypanosoma brucei. Ph.D. 
Thesis, University of Edinburgh. 1975.  
229.  Morty RE, Troeberg L, Pike RN, Jones R, Nickel P, Lonsdale-Eccles JD, et al. A 
trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, 
diminazene and suramin. FEBS Lett. 1998;433: 251–256.  
230.  Zimmermann S, Hall L, Riley S, Sørensen J, Amaro RE, Schnaufer A. A novel high-
throughput activity assay for the Trypanosoma brucei editosome enzyme REL1 and 
other RNA ligases. Nucleic Acids Res. 2016;44: e24. doi:10.1093/nar/gkv938 
231.  Roveri OA, Franke de Cazzulo BM, Cazzulo JJ. Inhibition by suramin of oxidative 
phosphorylation in Crithidia fasciculata. Comp Biochem Physiol B. 1982;71: 611–
616.  
232.  Thomas JA, Baker N, Hutchinson S, Dominicus C, Trenaman A, Glover L, et al. 
Insights into antitrypanosomal drug mode-of-action from cytology-based profiling. 
PLoS Negl Trop Dis. 2018;12: e0006980. doi:10.1371/journal.pntd.0006980 
233.  Gagliardi AR, Taylor MF, Collins DC. Uptake of suramin by human microvascular 
endothelial cells. Cancer Lett. 1998;125: 97–102.  
234.  Baghdiguian S, Boudier JL, Boudier JA, Fantini J. Intracellular localisation of 
suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by 
quantitative autoradiography. Eur J Cancer Oxf Engl 1990. 1996;32A: 525–532.  
235.  Sanderson L, Khan A, Thomas S. Distribution of suramin, an antitrypanosomal drug, 
across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-





236.  Baghdiguian S, Boudier JL, Boudier JA, Fantini J. Intracellular localisation of 
suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by 
quantitative autoradiography. Eur J Cancer Oxf Engl 1990. 1996;32A: 525–532.  
237.  Coppens I, Opperdoes FR, Courtoy PJ, Baudhuin P. Receptor-mediated endocytosis 
in the bloodstream form of Trypanosoma brucei. J Protozool. 1987;34: 465–473.  
238.  Pal A, Hall BS, Field MC. Evidence for a non-LDL-mediated entry route for the 
trypanocidal drug suramin in Trypanosoma brucei. Mol Biochem Parasitol. 
2002;122: 217–221.  
239.  Lozano RM, Jiménez M, Santoro J, Rico M, Giménez-Gallego G. Solution structure 
of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal 
model for the anti-tumoral action of suramins and suradistas. J Mol Biol. 1998;281: 
899–915.  
240.  Huang H-W, Mohan SK, Yu C. The NMR solution structure of human epidermal 
growth factor (hEGF) at physiological pH and its interactions with suramin. Biochem 
Biophys Res Commun. 2010;402: 705–710. doi:10.1016/j.bbrc.2010.10.089 
241.  Lima LMTR, Becker CF, Giesel GM, Marques AF, Cargnelutti MT, de Oliveira Neto 
M, et al. Structural and thermodynamic analysis of thrombin:suramin interaction in 
solution and crystal phases. Biochim Biophys Acta. 2009;1794: 873–881. 
doi:10.1016/j.bbapap.2009.03.011 
242.  Jiao L, Ouyang S, Liang M, Niu F, Shaw N, Wu W, et al. Structure of severe fever 
with thrombocytopenia syndrome virus nucleocapsid protein in complex with 
suramin reveals therapeutic potential. J Virol. 2013;87: 6829–6839. 
doi:10.1128/JVI.00672-13 
243.  Prigozhina NL, Heisel AJ, Seldeen JR, Cosford NDP, Price JH. Amphiphilic suramin 
dissolves Matrigel, causing an “inhibition” artefact within in vitro angiogenesis 
assays. Int J Exp Pathol. 2013;94: 412–417. doi:10.1111/iep.12043 
244.  Vansterkenburg EL, Wilting J, Janssen LH. Influence of pH on the binding of 
suramin to human serum albumin. Biochem Pharmacol. 1989;38: 3029–3035.  
245.  Alsford S, Field MC, Horn D. Receptor-mediated endocytosis for drug delivery in 
African trypanosomes: fulfilling Paul Ehrlich’s vision of chemotherapy. Trends 
Parasitol. 2013;29: 207–212. doi:10.1016/j.pt.2013.03.004 
246.  Pépin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 
1994;33: 1–47.  
247.  Fang Y, Ye WX, Nei HY, Wang YL. In vitro development of suramin-resistant 
clones of Trypanosoma evansi. Acta Trop. 1994;58: 79–83.  
248.  Scott AG, Tait A, Turner CM. Characterisation of cloned lines of Trypanosoma 
brucei expressing stable resistance to MelCy and suramin. Acta Trop. 1996;60: 251–
262.  
249.  Wenzler T, Steinhuber A, Wittlin S, Scheurer C, Brun R, Trampuz A. Isothermal 
microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and 





250.  Parsons M, Nelson RG, Watkins KP, Agabian N. Trypanosome mRNAs share a 
common 5’ spliced leader sequence. Cell. 1984;38: 309–316.  
251.  Nielsen H, Engelbrecht J, Brunak S, von Heijne G. A neural network method for 
identification of prokaryotic and eukaryotic signal peptides and prediction of their 
cleavage sites. Int J Neural Syst. 1997;8: 581–599.  
252.  Fankhauser N, Mäser P. Identification of GPI anchor attachment signals by a 
Kohonen self-organizing map. Bioinforma Oxf Engl. 2005;21: 1846–1852. 
doi:10.1093/bioinformatics/bti299 
253.  van Luenen HGAM, Kieft R, Mussmann R, Engstler M, ter Riet B, Borst P. 
Trypanosomes change their transferrin receptor expression to allow effective uptake 
of host transferrin. Mol Microbiol. 2005;58: 151–165. doi:10.1111/j.1365-
2958.2005.04831.x 
254.  Hertz-Fowler C, Figueiredo LM, Quail MA, Becker M, Jackson A, Bason N, et al. 
Telomeric expression sites are highly conserved in Trypanosoma brucei. PloS One. 
2008;3: e3527. doi:10.1371/journal.pone.0003527 
255.  Avelar-Freitas BA, Almeida VG, Pinto MCX, Mourão F a. G, Massensini AR, 
Martins-Filho OA, et al. Trypan blue exclusion assay by flow cytometry. Braz J Med 
Biol Res Rev Bras Pesqui Medicas E Biol. 2014;47: 307–315. doi:10.1590/1414-
431X20143437 
256.  Brickman MJ, Cook JM, Balber AE. Low temperature reversibly inhibits transport 
from tubular endosomes to a perinuclear, acidic compartment in African 
trypanosomes. J Cell Sci. 1995;108 ( Pt 11): 3611–3621.  
257.  Hawking F. Chemotherapy of Trypanosomiasis. In: Schnitzer RJ, Hawking F, 
editors. Experimental Chemotherapy. Academic Press; 1963.  
258.  Bernhard SC, Nerima B, Mäser P, Brun R. Melarsoprol- and pentamidine-resistant 
Trypanosoma brucei rhodesiense populations and their cross-resistance. Int J 
Parasitol. 2007;37: 1443–1448. doi:10.1016/j.ijpara.2007.05.007 
259.  El-Sayed NM, Hegde P, Quackenbush J, Melville SE, Donelson JE. The African 
trypanosome genome. Int J Parasitol. 2000;30: 329–345.  
260.  Leach TM, Roberts CJ. Present status of chemotherapy and chemoprophylaxis of 
animal trypanosomiasis in the Eastern hemisphere. Pharmacol Ther. 1981;13: 91–
147.  
261.  Engstler M, Thilo L, Weise F, Grünfelder CG, Schwarz H, Boshart M, et al. Kinetics 
of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in 
Trypanosoma brucei. J Cell Sci. 2004;117: 1105–1115. doi:10.1242/jcs.00938 
262.  Hirumi H, Hirumi K. Continuous cultivation of Trypanosoma brucei blood stream 
forms in a medium containing a low concentration of serum protein without feeder 
cell layers. J Parasitol. 1989;75: 985–989.  
263.  Baltz T, Baltz D, Giroud C, Crockett J. Cultivation in a semi-defined medium of 
animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. 




264.  Mäser P, Grether-Bühler Y, Kaminsky R, Brun R. An anti-contamination cocktail for 
the in vitro isolation and cultivation of parasitic protozoa. Parasitol Res. 2002;88: 
172–174.  
265.  Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R. The Alamar Blue assay to 
determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. 
gambiense) in vitro. Acta Trop. 1997;68: 139–147.  
266.  Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina 
sequence data. Bioinforma Oxf Engl. 2014;30: 2114–2120. 
doi:10.1093/bioinformatics/btu170 
267.  Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinforma Oxf Engl. 2009;25: 1754–1760. 
doi:10.1093/bioinformatics/btp324 
268.  Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence 
Alignment/Map format and SAMtools. Bioinforma Oxf Engl. 2009;25: 2078–2079. 
doi:10.1093/bioinformatics/btp352 
269.  Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinforma Oxf Engl. 2015;31: 166–169. 
doi:10.1093/bioinformatics/btu638 
270.  Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion 
for RNA-seq data with DESeq2. Genome Biol. 2014;15: 550. doi:10.1186/s13059-
014-0550-8 
271.  Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, et al. Full-
length transcriptome assembly from RNA-Seq data without a reference genome. Nat 
Biotechnol. 2011;29: 644–652. doi:10.1038/nbt.1883 
272.  Aline R, MacDonald G, Brown E, Allison J, Myler P, Rothwell V, et al. (TAA)n 
within sequences flanking several intrachromosomal variant surface glycoprotein 
genes in Trypanosoma brucei. Nucleic Acids Res. 1985;13: 3161–3177.  
273.  Brenndörfer M, Boshart M. Selection of reference genes for mRNA quantification in 
Trypanosoma brucei. Mol Biochem Parasitol. 2010;172: 52–55. 
doi:10.1016/j.molbiopara.2010.03.007 
274.  Cross GAM, Kim H-S, Wickstead B. Capturing the variant surface glycoprotein 
repertoire (the VSGnome) of Trypanosoma brucei Lister 427. Mol Biochem 
Parasitol. 2014;195: 59–73. doi:10.1016/j.molbiopara.2014.06.004 
275.  Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, et al. Anti-
trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev 
Microbiol. 2017;15: 217–231. doi:10.1038/nrmicro.2016.193 
276.  Pal A, Hall BS, Field MC. Evidence for a non-LDL-mediated entry route for the 
trypanocidal drug suramin in Trypanosoma brucei. Mol Biochem Parasitol. 
2002;122: 217–221.  
277.  Wiedemar N, Graf FE, Zwyer M, Ndomba E, Kunz Renggli C, Cal M, et al. Beyond 
immune escape: a variant surface glycoprotein causes suramin resistance in 




278.  Alsford S, Kawahara T, Glover L, Horn D. Tagging a T. brucei RRNA locus 
improves stable transfection efficiency and circumvents inducible expression position 
effects. Mol Biochem Parasitol. 2005;144: 142–148. 
doi:10.1016/j.molbiopara.2005.08.009 
279.  Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. 
Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9: 
676–682. doi:10.1038/nmeth.2019 
280.  Van der Ploeg LH, Schwartz DC, Cantor CR, Borst P. Antigenic variation in 
Trypanosoma brucei analyzed by electrophoretic separation of chromosome-sized 
DNA molecules. Cell. 1984;37: 77–84.  
281.  Harrisson F, Callebaut M, Vakaet L. Microspectrographic analysis of trypan blue-
induced fluorescence in oocytes of the Japanese quail. Histochemistry. 1981;72: 563–
578.  
282.  Steverding D. The transferrin receptor of Trypanosoma brucei. Parasitol Int. 2000;48: 
191–198.  
283.  Coppens I, Opperdoes FR, Courtoy PJ, Baudhuin P. Receptor-mediated endocytosis 
in the bloodstream form of Trypanosoma brucei. J Protozool. 1987;34: 465–473.  
284.  Koval A, Ahmed K, Katanaev VL. Inhibition of Wnt signalling and breast tumour 
growth by the multi-purpose drug suramin through suppression of heterotrimeric G 
proteins and Wnt endocytosis. Biochem J. 2016;473: 371–381. 
doi:10.1042/BJ20150913 
285.  Schwede A, Macleod OJS, MacGregor P, Carrington M. How Does the VSG Coat of 
Bloodstream Form African Trypanosomes Interact with External Proteins? PLoS 
Pathog. 2015;11: e1005259. doi:10.1371/journal.ppat.1005259 
286.  Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S. Characterization of a novel 
trypanosome lytic factor from human serum. Infect Immun. 1999;67: 1910–1916.  
287.  Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den 
Abbeele J, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. 
Nature. 2003;422: 83–87. doi:10.1038/nature01461 
288.  Lecordier L, Uzureau P, Tebabi P, Pérez-Morga D, Nolan D, Schumann Burkard G, 
et al. Identification of Trypanosoma brucei components involved in trypanolysis by 
normal human serum. Mol Microbiol. 2014;94: 625–636. doi:10.1111/mmi.12783 
289.  Vanhollebeke B, De Muylder G, Nielsen MJ, Pays A, Tebabi P, Dieu M, et al. A 
haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in 
humans. Science. 2008;320: 677–681. doi:10.1126/science.1156296 
290.  Pal A, Hall BS, Nesbeth DN, Field HI, Field MC. Differential endocytic functions of 
Trypanosoma brucei Rab5 isoforms reveal a glycosylphosphatidylinositol-specific 
endosomal pathway. J Biol Chem. 2002;277: 9529–9539. 
doi:10.1074/jbc.M110055200 
291.  Pal A, Hall BS, Jeffries TR, Field MC. Rab5 and Rab11 mediate transferrin and anti-
variant surface glycoprotein antibody recycling in Trypanosoma brucei. Biochem J. 




292.  Field MC, Allen CL, Dhir V, Goulding D, Hall BS, Morgan GW, et al. New 
approaches to the microscopic imaging of Trypanosoma brucei. Microsc Microanal 
Off J Microsc Soc Am Microbeam Anal Soc Microsc Soc Can. 2004;10: 621–636. 
doi:10.1017/S1431927604040942 
293.  Coppens I, Levade T, Courtoy PJ. Host plasma low density lipoprotein particles as an 
essential source of lipids for the bloodstream forms of Trypanosoma brucei. J Biol 
Chem. 1995;270: 5736–5741.  
294.  Schell D, Borowy NK, Overath P. Transferrin is a growth factor for the bloodstream 
form of Trypanosoma brucei. Parasitol Res. 1991;77: 558–560.  
295.  Kabiri M, Steverding D. Studies on the recycling of the transferrin receptor in 
Trypanosoma brucei using an inducible gene expression system. Eur J Biochem. 
2000;267: 3309–3314.  
296.  Coppens I, Baudhuin P, Opperdoes FR, Courtoy PJ. Receptors for the host low 
density lipoproteins on the hemoflagellate Trypanosoma brucei: purification and 
involvement in the growth of the parasite. Proc Natl Acad Sci U S A. 1988;85: 6753–
6757.  
297.  Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal 
for protein modeling, prediction and analysis. Nat Protoc. 2015;10: 845–858. 
doi:10.1038/nprot.2015.053 
298.  Torreira E, Jha S, López-Blanco JR, Arias-Palomo E, Chacón P, Cañas C, et al. 
Architecture of the pontin/reptin complex, essential in the assembly of several 
macromolecular complexes. Struct Lond Engl 1993. 2008;16: 1511–1520. 
doi:10.1016/j.str.2008.08.009 
299.  Jha S, Dutta A. RVB1/RVB2: running rings around molecular biology. Mol Cell. 
2009;34: 521–533. doi:10.1016/j.molcel.2009.05.016 
300.  Matias PM, Gorynia S, Donner P, Carrondo MA. Crystal structure of the human 
AAA+ protein RuvBL1. J Biol Chem. 2006;281: 38918–38929. 
doi:10.1074/jbc.M605625200 
301.  Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. 
SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic 
Acids Res. 2018;46: W296–W303. doi:10.1093/nar/gky427 
302.  Eustermann S, Schall K, Kostrewa D, Lakomek K, Strauss M, Moldt M, et al. 
Structural basis for ATP-dependent chromatin remodelling by the INO80 complex. 
Nature. 2018;556: 386–390. doi:10.1038/s41586-018-0029-y 
303.  Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, Berriman M, et al. 
High-throughput phenotyping using parallel sequencing of RNA interference targets 
in the African trypanosome. Genome Res. 2011;21: 915–924. 
doi:10.1101/gr.115089.110 
304.  Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput 
Sequence Data. 6 Apr 2017 [cited 6 Apr 2017]. Available: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 





306.  McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The 
Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation 
DNA sequencing data. Genome Res. 2010;20: 1297–1303. 
doi:10.1101/gr.107524.110 
307.  Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for 
annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: 
SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 
(Austin). 2012;6: 80–92. doi:10.4161/fly.19695 
308.  Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. 
Integrative genomics viewer. Nat Biotechnol. 2011;29: 24–26. doi:10.1038/nbt.1754 
309.  Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): 
high-performance genomics data visualization and exploration. Brief Bioinform. 
2013;14: 178–192. doi:10.1093/bib/bbs017 
310.  Cross GA. Identification, purification and properties of clone-specific glycoprotein 
antigens constituting the surface coat of Trypanosoma brucei. Parasitology. 1975;71: 
393–417.  
311.  Horn D. Antigenic variation in African trypanosomes. Mol Biochem Parasitol. 
2014;195: 123–129. doi:10.1016/j.molbiopara.2014.05.001 
312.  Günzl A, Bruderer T, Laufer G, Schimanski B, Tu L-C, Chung H-M, et al. RNA 
polymerase I transcribes procyclin genes and variant surface glycoprotein gene 
expression sites in Trypanosoma brucei. Eukaryot Cell. 2003;2: 542–551.  
313.  De Greef C, Hamers R. The serum resistance-associated (SRA) gene of Trypanosoma 
brucei rhodesiense encodes a variant surface glycoprotein-like protein. Mol Biochem 
Parasitol. 1994;68: 277–284.  
314.  Campillo N, Carrington M. The origin of the serum resistance associated (SRA) gene 
and a model of the structure of the SRA polypeptide from Trypanosoma brucei 
rhodesiense. Mol Biochem Parasitol. 2003;127: 79–84.  
315.  Faulkner SD, Oli MW, Kieft R, Cotlin L, Widener J, Shiflett A, et al. In vitro 
generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei. 
Eukaryot Cell. 2006;5: 1276–1286. doi:10.1128/EC.00116-06 
316.  Kieft R, Stephens NA, Capewell P, MacLeod A, Hajduk SL. Role of expression site 
switching in the development of resistance to human Trypanosome Lytic Factor-1 in 
Trypanosoma brucei brucei. Mol Biochem Parasitol. 2012;183: 8–14. 
doi:10.1016/j.molbiopara.2011.12.004 
317.  Salmon D, Geuskens M, Hanocq F, Hanocq-Quertier J, Nolan D, Ruben L, et al. A 
novel heterodimeric transferrin receptor encoded by a pair of VSG expression site-
associated genes in T. brucei. Cell. 1994;78: 75–86.  
318.  Mehlert A, Wormald MR, Ferguson MAJ. Modeling of the N-glycosylated 
transferrin receptor suggests how transferrin binding can occur within the surface 





319.  Kabiri M, Steverding D. Studies on the recycling of the transferrin receptor in 
Trypanosoma brucei using an inducible gene expression system. Eur J Biochem. 
2000;267: 3309–3314.  
320.  Lane-Serff H, MacGregor P, Lowe ED, Carrington M, Higgins MK. Structural basis 
for ligand and innate immunity factor uptake by the trypanosome haptoglobin-
haemoglobin receptor. eLife. 2014;3: e05553. doi:10.7554/eLife.05553 
321.  Hartel AJW, Glogger M, Guigas G, Jones NG, Fenz SF, Weiss M, et al. The 
molecular size of the extra-membrane domain influences the diffusion of the GPI-
anchored VSG on the trypanosome plasma membrane. Sci Rep. 2015;5: 10394. 
doi:10.1038/srep10394 
322.  Hartel AJW, Glogger M, Jones NG, Abuillan W, Batram C, Hermann A, et al. N-
glycosylation enables high lateral mobility of GPI-anchored proteins at a molecular 
crowding threshold. Nat Commun. 2016;7: 12870. doi:10.1038/ncomms12870 
323.  Bartossek T, Jones NG, Schäfer C, Cvitković M, Glogger M, Mott HR, et al. 
Structural basis for the shielding function of the dynamic trypanosome variant 
surface glycoprotein coat. Nat Microbiol. 2017;2: 1523–1532. doi:10.1038/s41564-
017-0013-6 
324.  Schwede A, Macleod OJS, MacGregor P, Carrington M. How Does the VSG Coat of 
Bloodstream Form African Trypanosomes Interact with External Proteins? PLoS 
Pathog. 2015;11: e1005259. doi:10.1371/journal.ppat.1005259 
325.  Koumandou VL, Boehm C, Horder KA, Field MC. Evidence for recycling of 
invariant surface transmembrane domain proteins in African trypanosomes. Eukaryot 
Cell. 2013;12: 330–342. doi:10.1128/EC.00273-12 
326.  Ziegelbauer K, Multhaup G, Overath P. Molecular characterization of two invariant 
surface glycoproteins specific for the bloodstream stage of Trypanosoma brucei. J 
Biol Chem. 1992;267: 10797–10803.  
327.  Grab DJ, Shaw MK, Wells CW, Verjee Y, Russo DC, Webster P, et al. The 
transferrin receptor in African trypanosomes: identification, partial characterization 
and subcellular localization. Eur J Cell Biol. 1993;62: 114–126.  
328.  Mussmann R, Engstler M, Gerrits H, Kieft R, Toaldo CB, Onderwater J, et al. 
Factors affecting the level and localization of the transferrin receptor in Trypanosoma 
brucei. J Biol Chem. 2004;279: 40690–40698. doi:10.1074/jbc.M404697200 
329.  Morgan GW, Hall BS, Denny PW, Carrington M, Field MC. The kinetoplastida 
endocytic apparatus. Part I: a dynamic system for nutrition and evasion of host 
defences. Trends Parasitol. 2002;18: 491–496.  
330.  Pal A, Hall BS, Nesbeth DN, Field HI, Field MC. Differential endocytic functions of 
Trypanosoma brucei Rab5 isoforms reveal a glycosylphosphatidylinositol-specific 
endosomal pathway. J Biol Chem. 2002;277: 9529–9539. 
doi:10.1074/jbc.M110055200 
331.  Auffret CA, Turner MJ. Variant specific antigens of Trypanosoma brucei exist in 




332.  Ferguson MA, Homans SW, Dwek RA, Rademacher TW. Glycosyl-
phosphatidylinositol moiety that anchors Trypanosoma brucei variant surface 
glycoprotein to the membrane. Science. 1988;239: 753–759.  
333.  Freymann DM, Metcalf P, Turner M, Wiley DC. 6 A-resolution X-ray structure of a 
variable surface glycoprotein from Trypanosoma brucei. Nature. 1984;311: 167–169.  
334.  Mehlert A, Zitzmann N, Richardson JM, Treumann A, Ferguson MA. The 
glycosylation of the variant surface glycoproteins and procyclic acidic repetitive 
proteins of Trypanosoma brucei. Mol Biochem Parasitol. 1998;91: 145–152.  
335.  Carrington M, Miller N, Blum M, Roditi I, Wiley D, Turner M. Variant specific 
glycoprotein of Trypanosoma brucei consists of two domains each having an 
independently conserved pattern of cysteine residues. J Mol Biol. 1991;221: 823–
835.  
336.  Pinger J, Nešić D, Ali L, Aresta-Branco F, Lilic M, Chowdhury S, et al. African 
trypanosomes evade immune clearance by O-glycosylation of the VSG surface coat. 
Nat Microbiol. 2018;3: 932–938. doi:10.1038/s41564-018-0187-6 
337.  Zoltner M, Horn D, de Koning HP, Field MC. Exploiting the Achilles’ heel of 
membrane trafficking in trypanosomes. Curr Opin Microbiol. 2016;34: 97–103. 
doi:10.1016/j.mib.2016.08.005 
338.  Gentili C, Castor D, Kaden S, Lauterbach D, Gysi M, Steigemann P, et al. 
Chromosome Missegregation Associated with RUVBL1 Deficiency. PloS One. 
2015;10: e0133576. doi:10.1371/journal.pone.0133576 
339.  Radovic S, Rapisarda VA, Tosato V, Bruschi CV. Functional and comparative 
characterization of Saccharomyces cerevisiae RVB1 and RVB2 genes with bacterial 
Ruv homologues. FEMS Yeast Res. 2007;7: 527–539. doi:10.1111/j.1567-
1364.2006.00205.x 
340.  Lilley DM. Homologous recombination. A ring for a warhead. Curr Biol CB. 1994;4: 
1152–1154.  
341.  Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of 
ATPases pontin and reptin as telomerase components essential for holoenzyme 
assembly. Cell. 2008;132: 945–957. doi:10.1016/j.cell.2008.01.019 
342.  Vaughan S, Gull K. The structural mechanics of cell division in Trypanosoma brucei. 
Biochem Soc Trans. 2008;36: 421–424. doi:10.1042/BST0360421 
343.  Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. 
Lancet Lond Engl. 2017;390: 2397–2409. doi:10.1016/S0140-6736(17)31510-6 
344.  Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, Kaminsky R. Melarsoprol 
refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 
TM IH. 2001;6: 407–411.  
345.  Robays J, Nyamowala G, Sese C, Betu Ku Mesu Kande V, Lutumba P, Van der 
Veken W, et al. High failure rates of melarsoprol for sleeping sickness, Democratic 
Republic of Congo. Emerg Infect Dis. 2008;14: 966–967. 
doi:10.3201/eid1406.071266 
346.  Berger BJ, Carter NS, Fairlamb AH. Characterisation of pentamidine-resistant 




347.  Baker N, Glover L, Munday JC, Aguinaga Andrés D, Barrett MP, de Koning HP, et 
al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in 
African trypanosomes. Proc Natl Acad Sci U S A. 2012;109: 10996–11001. 
doi:10.1073/pnas.1202885109 
348.  Bernhard SC, Nerima B, Mäser P, Brun R. Melarsoprol- and pentamidine-resistant 
Trypanosoma brucei rhodesiense populations and their cross-resistance. Int J 
Parasitol. 2007;37: 1443–1448. doi:10.1016/j.ijpara.2007.05.007 
349.  Volpon L, D’Orso I, Young CR, Frasch AC, Gehring K. NMR structural study of 
TcUBP1, a single RRM domain protein from Trypanosoma cruzi: contribution of a 
beta hairpin to RNA binding. Biochemistry (Mosc). 2005;44: 3708–3717. 
doi:10.1021/bi047450e 
350.  D’Orso I, Frasch AC. TcUBP-1, a developmentally regulated U-rich RNA-binding 
protein involved in selective mRNA destabilization in trypanosomes. J Biol Chem. 
2001;276: 34801–34809. doi:10.1074/jbc.M102120200 
351.  Cassola A, Frasch AC. An RNA recognition motif mediates the nucleocytoplasmic 
transport of a trypanosome RNA-binding protein. J Biol Chem. 2009;284: 35015–
35028. doi:10.1074/jbc.M109.031633 
352.  Richardson JB, Evans B, Pyana PP, Van Reet N, Sistrom M, Büscher P, et al. Whole 
genome sequencing shows sleeping sickness relapse is due to parasite regrowth and 





































































I have performed the drug sensitivity assays of the melarsoprol-pentamidine resistant 





Appendix 2. The enigmatic role of uridine-rich-binding 
protein 1 in melarsoprol/ pentamidine cross-resistance of 
Trypanosoma brucei 
 
Natalie Wiedemar1,2, Fabrice E. Graf1,2, Remo S. Schmidt1,2, Pascal Mäser1,2 
 
1 Swiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland 

















































Melarsoprol and pentamidine are drugs that have been used to treat human African 
trypanosomiasis (HAT) for decades. It has been known for a long time that resistance 
against one of the drugs confers cross-resistance to the other. This has been attributed to 
shared transporters: AT1 and AQP2, which both mediate cellular uptake of melarsoprol and 
pentamidine. In a previous study we have identified mutations in both genes in two in vitro 
selected melarsoprol and pentamidine resistant Trypanosoma brucei rhodesiense lines. 
Additionally, both lines carried a homozygous mutation in uridine-rich-binding protein 1 
(UBP1), follow-up on which was inconclusive. In the present study, we re-introduce the 
wildtype UBP1 sequence into one of the selected lines and investigate the effects on drug 
sensitivity. The transfected clones do not show a clear loss of resistance in presence of the 






UBP1 and MPXR 
Cure for human African trypanosomiasis (HAT) exclusively relies on successful drug 
treatment. HAT is caused by two subspecies of the protozoan parasite Trypanosoma brucei: 
T. b. gambiense and T. b. rhodesiense. During the first stage, when the trypanosomes have 
not yet invaded the central nervous system, the disease is treated with pentamidine for 
T. b. gambiense HAT or suramin for T. b. rhodesiense HAT [1]. The treatment of the 
second stage with involvement of the central nervous system relies on drugs that are able to 
cross the blood-brain barrier, for a long time melarsoprol was the only option. In the last 
decade a combination of eflornithine and nifurtimox have been used to treat T. b. gambiense 
HAT [1], and most recently fexinidazole [2] has been approved for treatment of all stages. 
Besides complicated administration and unacceptable side effects, especially in case of 
melarsoprol, increasing reports of treatment failures, possibly due to drug resistance, 
hamper treatment with the current drugs [3,4]. Shortly after the introduction of melarsoprol 
[5], laboratory induced melarsoprol resistance with cross-resistance to pentamidine was 
reported [6]. This melarsoprol-pentamidine cross-resistance (MPXR) was attributed to a 
defective drug transporter and consequently a reduced drug uptake [7,8]. The transporter 
itself was later on identified as an adenosine transporter [7,9] encoded by the gene TbAT1 
[10]. Mutations in TbAT1 were also identified in MPXR patient isolates [11]. A second 
transporter was identified in a genome-wide RNAi library screen: aquaglyceroporin 2, 
encoded by the gene TbAQP2, which also leads to MPXR under knockdown [12,13]. 
Aquaporin 2 mutations were also shown to be present in the field, as deletions and 
chimerism of TbAQP2/TbAQP3 were identified in drug-resistant field isolates [14].  
In a past study we selected the T. b. rhodesiense STIB900 line independently with 
melarsoprol (STIB900-M) and pentamidine (STIB900-P) over the course of two years [15]. 
Both lines showed MPXR and were subjected to mRNA and whole genome sequencing. 
STIB900-M carried a 25 kb deletion encompassing TbAT1 while STIB900-P had acquired a 
point mutation in TbAT1 that rendered the protein non-functional regarding drug transport 
[16]. Additionally, both lines contained a 1.8 kb deletion leading to a loss of AQP2. These 
findings were in agreement with the model of loss of drug import as the cause of MPXR. 
However, simultaneous knock-out of TbAQP2 and TbAT1 in T. b. brucei cells did not lead 
to such a strong MPXR phenotype as observed in the selected lines, which indicates that 




mutations were identified in STIB900-M and STIB900-P. Most noticeable, both lines had 
acquired the same point mutation, a G to T transversion at position 392 of the coding 
sequence in Tb927.11.500, the gene encoding the RNA-binding protein UBP1 (uridine-rich-
binding protein 1). UBP1 contains a well-conserved RNA-recognition motive (RRM) that 
binds to AU-rich instability elements in the 3’ UTR of certain mRNAs and decreases their 
half-life as shown in T. cruzi [17,18]. The identified mutation is located within the RRM 
and leads to the amino acid substitution arginine131 to leucine (R131L) [16]. UBP1 is an 
essential gene in T. brucei bloodstream forms [19]. 
Additional lines of evidence point towards a potential role for UBP1 in drug resistance: (i) 
the orthologue in T. cruzi, TcUBP1, relocalized from the cytoplasm to the nucleus during 
arsenite stress, and this process was inhibited by mutations that affected RNA-binding [20]. 
(ii) a paralogue in T. brucei, UBP2, was identified as a secondary hit for pentamidine 
resistance by genome-wide RNAi, and UBP1 showed a pentamidine signature as well [12]. 
(iii) Whole-genome sequencing of clinical isolates derived from T. b. gambiense relapse 
patients after melarsoprol treatment identified heterozygous single-nucleotide 
polymorphism in UBP1 [21]. 
Experimental investigation on the mutation R131L in T. b. brucei 2T1 was inconclusive: 
parasites overexpressing GFP-UBP1-R131L became slightly hypersensitive to pentamidine, 
while in situ introduction of the mutated allele did not alter melarsoprol and pentamidine 
sensitivity [16]. However, it was still possible that the UBP1 mutation would mediate drug 
resistance only in the STIB900-M and STIB900-P background, i.e. loss of function for 
TbAT1 and TbAQP2. 
To investigate this hypothesis we introduced the UBP1 wildtype allele in situ into the 
resistant STIB900-P and STIB900-M lines. Therefore parasites were transfected with a 
construct consisting of the intergenic region upstream of UBP1, a βα tubulin splice site, the 
blasticidine resistance gene, an αβ tubulin splice site, the 5’ untranslated region of UBP1 
and the first part of the UBP1 coding sequence (cds) including the site of the mutation 
(Fig. 1A). As the original construct [16] contained the mutant T allele at position 392, we 
used a primer that spanned the mutation but contained a G at the respective position to 
insert the wildtype allele into the amplified product. Transfection of trypanosomes was 
carried out [16] and pseudoclones were picked after one week. Subsequently DNA was 




the presence of the wildtype allele. In an initial round of transfection, only one out of six 
recovered clones was homozygous GG, the remaining clones had integrated parts of the 
construct including the blasticidine resistance gene but without the last part of the UBP1 
cds. Thus, the homologous recombination event in those clones must have happened further 
upstream of the mutated position, which is located at the very end of the construct in the last 
nine nucleotides. To increase chances of a correct replacement of the mutated with the 
wildtype allele in a second round of transfection we extended the construct by using a 
primer with a 49 nucleotide overhang. Of the 13 recovered clones, four were homozygous 
GG and nine remained homozygous TT. Clones that showed any additional mutations in the 
coding sequence were excluded from further experiments. Sequencing revealed that 
STIB900 as well as STIB900-M and STIB900-P had an additional AAC deletion when 
compared to the Tb927.11.500 reference sequence, leading to a loss of a glutamine at 
position 29. At the given position the transfectants were identical to the Tb927.11.500 
reference sequence on which the construct was based on.  
 
 
Figure 1: Reverse genetics of UBP1 and the effect on drug sensitivity (A) Construct used to replace the 
mutated UBP1 by the wildtype allele with the upstream intergenic region of UBP1 (upstr. inerg. region) as 
homologous region on the 5’ end of the construct, a βα tubulin splice site (βα tub), blasticidine resistance gene 
(BSD), αβ tubulin splice site (αβ tub), 5’UTR of UBP1 and the first 400 nucleotides of the UBP1 coding 




to transfection are shown as black arrows; the reverse primers (Rv) contained the wildtype G allele at position 
392 of the UBP1 coding sequence. (B) Drug sensitivities for melarsoprol and pentamidine are shown for the 
transfected STIB900-P clones. Two transfectants (TT) had retained the mutated T allele and three 
transfectants (GG) carried the wildtype G allele. Error bars represent standard deviations of five replicates, 
different letters indicate significant differences between the clones (Tukey multiple comparison test). 
Drug sensitivities of the parental STIB900-P, three homozygous GG, and two homozygous 
TT transfectants (as additional controls) were determined using Alamar Blue assays [22]. 
For melarsoprol, STIB900-P showed an IC50 of 95 nM, the transfectants with the retained 
TT mutation had an IC50 of 75 and 80 nM, and the transfectants reverted back to the 
wildtype allele GG had an IC50 of 58, 45 and 90 nM (Fig 1B). For pentamidine the IC50 
was at 183 nM in STIB900-P, 98 and 103 nM for the TT transfectants and 65, 82 and 216 
nM for the GG transfectants (Fig 1B). Comparison of the three GG clones with the lines 
carrying the TT genotype yielded an overall p-value of 0.91 for pentamidine and 0.29 for 
melarsoprol (Welch Two Sample t-test). 
In summary, neither did the introduction of the R131L mutation cause MPXR in sensitive 
T. b. brucei cells [16], nor did its reversion in abrogate resistance in MPXR T. b. 
rhodesiense cells (Tab 1). Interestingly, four out of five transfectants showed trend of 
decreased IC50 for melarsoprol and pentamidine irrespective of their genotype. In light of 
the faint observed signatures in the RNAi library screen [12], one could speculate that the 
resistance phenotype is rather influenced by gene dosage and that the introduction of the 
construct leads to alterations of mRNA abundance and thus generally decreases the 
melarsoprol and pentamidine sensitivity. Taken together these results do not support the 
hypothesis that UBP1 is involved in drug sensitivity and that the mutation R131L causes 
melarsoprol/pentamidine cross-resistance in T. brucei. Nevertheless, the role of UBP1 






Table 1: Melarsoprol and Pentamidine sensitivities of different cell lines carrying either 
wildtype arginine or the mutated leucine at position 131 of UBP1  
 
Line UBP1 IC50 ± standard deviation [nM] 
  Melarsoprol Pentamidine 
STIB900 Arg131 6.0 ± 3.4 2.8 ± 0.8 
STIB900_P Leu131 84 ± 52 130 ± 69 
STIB900_M Leu131 170 ± 63 210 ± 93 
2T1 Arg131 16 ± 3.3 2.1 ± 0.9 
2T1 _H Leu131 15 ± 4.0 2.6 ± 1.2 
2T1 _L Leu131 17 ± 4.2 2.5 ± 0.9 
STIB900_P Leu131 95 ± 18 183 ± 55 
900P_TT1 Leu131 75 ± 20 98 ± 28 
900P_TT2 Leu131 80 ± 13 103 ± 44 
900P_GG1 Arg131 58 ± 7.9 65 ± 28 
900P_GG2 Arg131 45 ± 12 82 ± 19 
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